Application of the SYNTAX score in interventional cardiology

A systematic review and meta-analysis

Pravesh Kumar Bundhun, MD^a, Yashna Sookharee, MBBS^b, Anita Bholee, MBBS^b, Feng Huang, MD^{a,*}

Abstract

Background: Should the SYNTAX score be integrated in Interventional Cardiology? Should it really be considered as a vital decision-making tool in percutaneous coronary intervention (PCI)? To confirm the importance of this score, we aimed to systematically compare the postinterventional adverse cardiovascular outcomes which were observed in patients who were allotted a low versus a high SYNTAX score.

Methods: Randomized controlled trials and observational studies which were published from January 2007 to January 2017 were identified from MEDLINE, EMBASE, and the Cochrane databases using the searched terms 'SYNTAX score and percutaneous coronary intervention.' Adverse cardiovascular outcomes were considered as the major endpoints. Risk ratios (RRs) with 95% confidence intervals (CIs) were used as the statistical parameters, and the main analysis was carried out by the RevMan 5.3 software.

Results: Sixteen studies with a total number of 19,751 participants (8589 participants with a low versus 11,162 participants with a high SYNTAX score) were included. Current results showed mortality to be significantly higher with a higher SYNTAX score (RR 2.09, 95% CI 1.78–2.46, P=.00001). Cardiac death also significantly favored a low SYNTAX score (RR 2.08, 95% CI 1.66–2.61, P=.00001. Similarly, myocardial infarction, major adverse cardiac events, repeated revascularization, and stent thrombosis were significantly higher following a high SYNTAX score (RR 1.71, 95% CI 1.45–2.03, P=.00001; RR 2.03, 95% CI 1.81–2.26, P=.00001; RR 1.96, 95% CI 1.69–2.28, P=.00001; and RR 3.16, 95% CI 2.17–4.59, P=.00001, respectively). Even when patients with ST-segment elevation myocardial infarction were separately analyzed, a low SYNTAX score was still significantly associated with lower adverse outcomes.

Conclusions: This analysis is a confirmatory piece of evidence to show that the application of the SYNTAX score in Interventional Cardiology is apparently relevant. The use of this scoring system to grade patients with coronary artery disease and to further guide for revascularization should be encouraged.

Abbreviations: CABG = coronary artery bypass surgery, CAD = coronary artery disease, MACEs = major adverse cardiac events, PCI = percutaneous coronary intervention, RR = risk ratios, STEMI = ST-segment elevation myocardial infarction.

Keywords: coronary artery disease, interventional cardiology, percutaneous coronary intervention, SYNTAX score

Editor: Jacek Bil.

Authors' contributions: P.K.B., Y.S., A.B., and F.H. were responsible for the conception and design, acquisition of data, analysis and interpretation of data, drafting the initial manuscript, and revising it critically for important intellectual content. P.K.B. wrote the final manuscript. All authors read and approved the final manuscript.

Funding: This research was supported by National Natural Science Foundation of China (No. 81560046), Scientific Project of Guangxi Higher Education (No. KY2015ZD028), and the Youth Science Foundation of Guangxi Medical University (No. GXMUYSF201308).

The authors declare no competing interests.

^a Institute of Cardiovascular Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, ^b Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei, P.R. China.

^{*} Correspondence: Dr Feng Huang, Institute of Cardiovascular Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530027, P.R. China (e-mail: huangfeng7925@163.com).

Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Medicine (2017) 96:28(e7410)

Received: 2 May 2017 / Received in final form: 7 June 2017 / Accepted: 12 June 2017

http://dx.doi.org/10.1097/MD.000000000007410

1. Introduction

What is Interventional Cardiology? It might be defined as a branch of cardiology which focuses specifically on the treatment and management of structural heart diseases in catheter-based laboratories. The current status, new updates, and future directions related to Interventional cardiology have recently been published.^[1-4] Interventional procedures are becoming increasingly common and they are now becoming the preferred modes of treatment among patients with specific cardiac disorders. Percutaneous coronary intervention (PCI), which is often associated with earlier hospital discharge,^[5] is 1 among the most common interventional procedures which are carried out in PCIcapable centers. Management of acute coronary syndrome (ACS) including ST-segment elevation myocardial infarction (STEMI) and non-STEMI,^[6] and also several types of nonsevere multivessel coronary artery diseases (MVCADs),^[7] and unprotected left main coronary artery diseases (ULMCAD) is nowadays possible with PCI.^[8] Even though PCI might be an acceptable choice in most of the patients, certain patients' conditions and the extent of coronary lesions might restrict its use, thereby shifting its place to coronary artery bypass surgery (CABG).^[9]

However, the question which has to be raised at this particular point concerns the identification of patients who might benefit from PCI. Recently, the Synergy Between PCI With Taxus and CABG (SYNTAX) score was developed.^[10] It is a tool which takes into consideration the anatomical features of the coronary lesions as a guide to assess patients who will be eligible for PCI.^[11]

Nevertheless, should the SYNTAX score be integrated in Interventional Cardiology? Should it really be considered as a vital decision-making tool in PCI? To confirm the importance of this score, we aimed to systematically compare the postinterventional adverse cardiovascular outcomes which were observed in patients who were allotted a low versus a high SYNTAX score.

2. Methods

2.1. Searched databases and strategies

Following the PRISMA guideline,^[12] randomized controlled trials and observational studies published from January 2007 to January 2017 were identified through MEDLINE, EMBASE, and the Cochrane databases using the searched terms or keywords which were listed below:

- 1. SYNTAX score
- 2. SYNTAX score and percutaneous coronary intervention
- 3. SYNTAX score and interventional cardiology
- 4. SYNTAX score and coronary angioplasty
- 5. SYNTAX score and PCI
- 6. SYNTAX score and coronary artery disease (CAD)
- 7. SYNTAX score and coronary stenting

It should be noted that the reference lists of suitable publications were also checked for relevant articles.

Our searched criteria were limited to English publications involving humans only.

2.2. Inclusion criteria

Studies were included if they met the following criteria:

Type of participants, reported outcomes, and follow-ups

1. They were randomized trials or observational cohorts comparing PCI in patients who were allotted a low versus a high SYNTAX score.

- 2. They reported adverse clinical outcomes as their major endpoints.
- 3. They included any type of participants with CAD.

2.3. Exclusion criteria

Studies were excluded based on the following criteria:

- 1. They were meta-analysis, case-control studies, or letters to editors.
- 2. They compared only CABG in patients who were allotted a low versus a high SYNTAX score.
- 3. They did not report adverse clinical outcomes as their major endpoints.
- 4. They were duplicated studies or they were different studies which involved the same trial.

2.4. Types of participants, outcomes, and follow-ups

This research article included several types of patients with CAD who were revascularized by PCI. The different types of participants (Table 1) were patients with any type of CAD; ST-segment elevation MI (STEMI); non-ST-segment elevation MI (NSTEMI); left main CAD (LMCAD); MVCAD; and three-vessel CAD.

The outcomes which were assessed included the following:

- 1. All-cause mortality.
- 2. Cardiac death.
- 3. Myocardial infarction (MI).
- 4. Major adverse cardiac events (MACEs), which were defined as the combination of death, MI, and revascularization. Major adverse cerebrovascular and cardiovascular events (MAC-CEs), which consisted of death, MI, stroke, and revascularization, were also included in the same category as MACEs and analyzed together.
- 5. Repeated revascularization which consisted of target vessel revascularization (TVR) and/or target lesion revascularization (TLR).
- 6. Stent thrombosis (ST), which was defined according to the Academic Research Consortium (ARC)^[29] and which was composed of definite and probable ST.

Table 1

Studies	Types of participants	Reported outcomes	Follow-up periods, y
Akgun et al, 2015 ^[13]	STEMI	Death, cardiac death, MI, TVR, any revascularization, stroke, overall MACEs	4.5
Capodanno et al, 2009 ^[14]	LMCAD	Death	2
Capodanno et al, 2009 ^[15]	ULMCAD	MACEs	1
Garg et al, 2011 ^[16]	STEMI	Death, MI, MACEs, TVR, definite ST, definite or probable ST	1
Garg et al, 2011 ^[17]	Any CAD	Death, cardiac death, MI, repeated revascularization, MACEs, ARC defined ST	1
Girasis et al, 2011 ^[18]	Any CAD	MACEs, death, cardiac death, TLR, ST, MI	5
He et al, 2011 ^[19]	Three-vessel CAD	MACEs, death, MI, repeated revascularization	1
lkeno et al, 2017 ^[20]	Any CAD	MACEs	5
Kim et al, 2010 ^[21]	ULMCAD	MACEs	3
Magro et al, 2011 ^[22]	STEMI	Death, MI, TVR, MACEs	1.5
Nozue et al, 2012 ^[23]	ULMCAD	MACEs	1
Park et al, 2013 ^[24]	Any CAD	Death, MI, cardiac death, revascularization, ARC defined ST, MACEs	1
Sinning et al, 2013 ^[25]	MVCAD	Death, cardiac death, MI, TLR, MACCEs	3
Valgimigli et al, 2007 ^[26]	Three-vessel CAD	MACCEs, death, MI, TVR	1
Wykrzykowska et al, 2010 ^[27]	Any CAD	Death, ST, MI, TVR, TLR, MACEs	1
Yadav et al, 2015 ^[28]	NSTEMI	Definite ST, definite or probable ST	1

ARC = Academic Research Consortium, CAD = coronary artery disease, LMCAD = left main coronary artery disease, MACCEs = major adverse cerebrovascular and cardiovascular events, MACEs = major adverse cardiac events, MVCAD = multivessel coronary artery disease, NSTEMI = non-ST-segment elevation myocardial infarction, ST = stent thrombosis, STEMI = ST-segment elevation myocardial infarction, TLR = target lesion revascularization, TVR = target vessel revascularization, ULMCAD = unprotected left main coronary artery disease.

The follow-up periods varied from study to study. Most of the studies had a follow-up period of 1 year, as shown in Table 1.

2.5. Definitions

The SYNTAX score was classified into 3 different categories known as tertiles, as given below:

- 1. Tertile I was defined as patients with the lowest SYNTAX score.
- 2. Tertile II was defined as patients with an intermediate/mid SYNTAX score.
- 3. Tertile III was defined as patients with the highest SYNTAX score.

This information has been represented in Table 2.

2.6. Data extraction and quality assessment

Studies which were considered eligible for this analysis were first of all carefully assessed by 3 independent reviewers (P.K.B., Y.S., and A.B.) to ensure that they satisfied the eligibility criteria of this research article.

The following data were extracted by the same 3 reviewers:

- 1. Names of the first author
- 2. Year of publication
- 3. Types of study which were reported
- 4. Periods of participants' enrollment
- 5. Types of participants which were included
- 6. Baseline characteristics of the participants (including the mean age, percentage of male participants, percentage of participants suffering from comorbidities such as hypertension, dyslipidemia, and diabetes mellitus)
- 7. Total number of participants who were allotted a low SYNTAX score
- 8. Total number of participants who were allotted a higher SYNTAX score
- 9. The different tertiles (tertiles I, II, and III)
- 10. The clinical outcomes and the number of events which were reported within the study and the control groups, respectively
- 11. The follow-up periods
- 12. The interventional procedures which were followed
- 13. Details about the quality of the trials and observational studies

Quality assessment was carried out separately for the trials and the observational cohorts using the Cochrane Handbook^[30] and the Newcastle Ottawa Scale (NOS),^[31] respectively. The trials were assessed for the 6 components which were recommended by the Cochrane Collaborations, whereby scores were given in accordance to a low, unclear and high risk of bias, and the total score which was obtained by each trial was graded from A to E, whereby A implied a very low risk of bias, B and C implied low to moderate risk of bias, and E indicated a very high risk of bias.

For the observational studies, a star system assessment was carried out whereby stars were allotted based on certain components which were required during quality assessment. A maximum total number of 9 stars were possible which implied a very low risk of bias.

Any disagreement which followed whether during the data extraction process or the quality assessment was discussed among the reviewers. However, if a consensus could not be reached, a decision was finalized by the fourth reviewer (F.H.).

2.7. Statistical analysis

This is a meta-analysis of several studies, including different types of patients who underwent revascularization by PCI. Therefore, inconsistency across the studies was possible. To obtain a more consistent result, heterogeneity^[32] across the studies was calculated/evaluated/assessed using the *Q* statistic test ($P \le .05$ was considered statistically significant) and the I^2 statistic test (high percentage=higher heterogeneity [whereby a random-effects model was used if a value greater than 50% was obtained] and low percentage=lower heterogeneity [whereby a fixed-effects model was used if a value equal to or less than 50% was obtained]).

The analysis was carried out whereby risk ratios (RRs) with 95% confidence intervals (CIs) were calculated by the RevMan version 5.3 software.

Sensitivity analysis was also carried out by excluding each study one by one and observing any significant difference in subgroup analysis in comparison to the main results.

In addition, publication bias,^[32] which was also possible across the studies, was visually estimated by assessing graphical plots through RevMan 5.3.

2.8. Ethical approval

Ethical or board review approval and patients' consents were not required for meta-analyses.

3. Results

3.1. Searched outcomes

A careful search through the electronic databases which was carried out by those 3 reviewers resulted in a total number of 1147 articles as listed below:

- 1. MEDLINE: 401 articles
- 2. EMBASE: 423 articles
- 3. Cochrane database: 234 articles
- 4. Reference lists of relevant articles: 89 articles

The 3 reviewers carefully assessed the titles and abstracts. Based on this assessment, 1004 articles were eliminated since they were not considered relevant to the scope of this research.

In all, 143 full-text articles were assessed for eligibility. Further articles were eliminated due to the following reasons:

- 1. They were meta-analysis, case-control studies, and letters to editors (n=4).
- 2. They only compared adverse outcomes in patients who were revascularized by PCI with a low SYNTAX score versus CABG with a high SYNTAX score (n=12).
- 3. They only compared CABG patients who were allotted a low versus a high SYNTAX score (n=8).
- 4. They were duplicated studies or they were different studies which were associated with similar trials (n = 103).

Finally, only 16 full-text articles^[13–28] (6 randomized trials and 10 observational studies) were selected for this analysis as shown in Fig. 1.

3.2. General features of the studies


Six randomized trials and 10 observational cohorts with a total number of 19,751 participants (8589 participants with a low SYNTAX score versus 11,162 participants with a high SYNTAX

Table 2

Definitions of low versus high SYNTAX score (the different tertiles).

Studies	Defining Iow SS	Defining high SS	Components of the high SS	Type of intervention
Akgun et al, 2015 ^[13]	SS < 20	SS≥20	Tertile III	PCI
Akgun et al, 2015 ^[13]	$SS \le 9$	9 < SS < 16	Tertile II	PCI
Akgun et al, 2015 ^[13]	$SS \le 9$	SS>9	Tertile II + III	PCI
Akgun et al, 2015 ^[13]	SS<16	$16 \leq$ SS < 20	Tertile II	PCI
Akgun et al, 2015 ^[13]	SS<16	$SS \ge 20$	Tertile III	PCI
Capodanno et al, 2009 ^[14]	$SS \leq 34$	SS>34	Tertile III	PCI
Capodanno et al, 2009 ^[15]	$SS \leq 18$	$18 > SS \le 27$	Tertile II	PCI
Capodanno et al, 2009 ^[15]	$SS \leq 27$	SS>27	Tertile III	PCI
Capodanno et al, 2009 ^[15]	$SS \le 18$	SS>27	Tertile III	PCI
Capodanno et al, 2009 ^[15]	$SS \leq 18$	SS>18	Tertile II + III	PCI
Garg et al, 2011 ^[16]	$SS \le 9$	$9 < SS \le 16$	Tertile II	PCI
Garg et al, 2011 ^[16]	$SS \le 16$	SS > 16	Tertile III	PCI
Garg et al, 2011 ^[16]	$SS \leq 9$	SS>16	Tertile III	PCI
Garg et al, 2011 ^[16]	$SS \leq 9$	SS>9	Tertile II + III	PCI
Garg et al, 2011 ^[17]	$SS \leq 9$	$9 < SS \le 17$	Tertile II	PCI
Garg et al, 2011 ^[17]	$SS \le 17$	SS>17	Tertile III	PCI
Garg et al, 2011 ^[17]	$SS \leq 9$	SS>17	Tertile III	PCI
Garg et al, 2011 ^[17]	$SS \le 9$	SS>9	Tertile II + III	PCI
Girasis et al, 2011 ^[18]	SS ≤ 7	$7 < SS \le 14$	Tertile II	PCI
Girasis et al, 2011 ^[18]	$SS \le 14$	SS > 14	Tertile III	PCI
Girasis et al, 2011 ^[18]	$SS \le 7$	SS > 14	Tertile III	PCI
Girasis et al, 2011 ^[18]	$SS \le 7$	SS>7	Tertile II + III	PCI
He et al, 2011 ^[19]	$SS \le 22$	$23 < SS \le 32$	Tertile II	PCI
He et al, 2011 ^[19]	$SS \le 32$	SS≥33	Tertile III	PCI
He et al, 2011 ^[19]	$SS \le 22$	SS≥33	Tertile III	PCI
He et al, $2011^{[19]}$	$SS \le 22$	SS > 22	Tertile II + III	PCI
keno et al, 2017 ^[20]	$SS \le 22$	SS≥23	Tertile II + III	PCI
Kim et al, $2010^{[21]}$	$SS \le 23$	23 < SS ≤ 36	Tertile II	PCI
Kim et al, $2010^{[21]}$	$SS \le 36$	SS > 36	Tertile III	PCI
Kim et al, $2010^{[21]}$	SS≤23	SS > 36	Tertile III	PCI
Kim et al, $2010^{[21]}$	SS≤23	SS>23	Tertile II + III	PCI
Magro et al, $2011^{[22]}$	SS < 10	$10 \le SS < 20$	Tertile II	PCI
Magro et al, $2011^{[22]}$	SS≤20	SS > 20	Tertile III	PCI
Magro et al, 2011 ^[22]	SS < 10	SS > 20	Tertile III	PCI
Magro et al, $2011^{[22]}$	SS < 10	SS≥10	Tertile II + III	PCI
Nozue et al, $2012^{[23]}$	SS≤22	$23 \le SS \le 32$	Tertile II	PCI
Nozue et al, 2012 ^[23]	$SS \leq 32$	SS≥33	Tertile III	PCI
Nozue et al, $2012^{[23]}$	SS≤22	SS≥33	Tertile III	PCI
Nozue et al, 2012 ^[23]	$SS \le 22$	SS>22	Tertile II + III	PCI
Park et al, $2013^{[24]}$	SS < 8	$8 \le SS \le 16$	Tertile II	PCI
Park et al, $2013^{[24]}$	SS < 16	SS > 16	Tertile III	PCI
Park et al, $2013^{[24]}$	SS < 8	SS > 16	Tertile III	PCI
Park et al, $2013^{[24]}$	SS < 8	SS>8	Tertile II + III	PCI
Sinning et al, 2013 ^[25]	SS≤22	$23 \le SS \le 32$	Tertile II	PCI
Sinning et al, 2013 ^[25]	$SS \le 22$ $SS \le 32$	23≤33≤32 SS≥33	Tertile III	PCI
Sinning et al, 2013 ^[25]			Tertile III	PCI
Sinning et al, 2013 ^[25]	$SS \le 22$	SS≥33 SS>22		PCI
Valgimigli et al, 2007 ^[26]	$SS \le 22$ $SS \le 18$		Tertile II + III Tertile II	PCI
Valgimigli et al, 2007 ^[26]		$18 < SS \le 26$		PCI
Valgiinigii et al. 2007 ²³	$SS \le 26$	SS > 26	Tertile III	
Valgimigli et al, 2007 ^[26] Valgimigli et al, 2007 ^[26]	$SS \le 18$	SS > 26	Tertile III	PCI
	$SS \le 18$	SS>18	Tertile II + III	PCI
Wykrzykowska et al, 2010 ^[27]	$SS \leq 8$	$8 < SS \le 16$	Tertile II	PCI
Nykrzykowska et al, 2010 ^[27]	$SS \le 16$	SS > 16		PCI
Mykrzykowska et al, 2010 ^[27]	$SS \leq 8$	SS > 16		PCI
Wykrzykowska et al, 2010 ^[27]	$SS \leq 8$	SS > 8	Tertile II + III	PCI
Yadav et al, 2015 ^[28]	SS < 23	23 < SS < 32	Tertile II	PCI
Yadav et al, 2015 ^[28]	SS < 23	SS > 32	Tertile III	PCI
Yadav et al, 2015 ^[28]	SS<23	SS≥23	Tertile II + III	PCI

PCI=percutaneous coronary intervention, SS=SYNTAX score, tertile II=intermediate score, tertile III=high score tertile.






Table 3

score) were included in the main analysis. Patients' enrollment periods varied from the years 2000 to 2010 as shown in Table 3.

After the quality assessment, a grade B was allotted to the trials, whereas number of stars allotted to the observational studies varied from 6 to 8 stars.

3.3. Baseline features of the participants

The baseline characteristics of the participants were summarized in Table 4. A mean age ranging from 50.0 to 71.0 years was noted among the participants. Most of the studies reported a majority of male compared with female participants as shown in Table 4. The percentage of participants with hypertension, dyslipidemia, current smoking, and those who suffered from type 2 diabetes mellitus were also listed in Table 4. According to the baseline features, almost no significant differences were observed among participants within the low SYNTAX and high SYNTAX groups, with the exception of a few studies.

3.4. Main results of this analysis

The results were subdivided into different categories, as described in the following subsections.

Studies	Type of study	No. of patients with low SS (n)	No. of patients with high SS (n)	Patients' enrollment period, y
Akgun et al, 2015 ^[13]	OS	819	2174	2006-2010
Capodanno et al, 2009 ^[14]	OS	257	85	2002-2008
Capodanno et al, 2009 ^[15]	OS	79	176	
Garg et al, 2011 ^[16]	RCT	311	496	
Garg et al, 2011 ^[17]	RCT	698	1335	
Girasis et al, 2011 ^[18]	RCT	293	555	
He et al, 2011 ^[19]	OS	71	132	2007-2008
lkeno et al, 2017 ^[20]	RCT	849	124	2001-2005
Kim et al, 2010 ^[21]	OS	435	384	2000-2006
Magro et al, 2011 ^[22]	OS	209	460	2006-2008
Nozue et al, 2012 ^[23]	OS	26	23	2002-2008
Park et al, 2013 ^[24]	OS	1608	3494	2008-2010
Sinning et al, 2013 ^[25]	OS	52	276	2005-2010
Valgimigli et al, 2007 ^[26]	OS	103	203	
Wykrzykowska et al, 2010 ^[27]	RCT	464	933	
Yadav et al, 2015 ^[28]	RCT	2315	312	
Total no. of participants (N)		8589	11,162	

OS = observational studies, RCT = randomized controlled trial, SS = SYNTAX score.

Table 4

Baseline features (for the participants with a low vs a higher SYNTAX score).

Studies	Mean age, y LSS/HSS	Males, % LSS/HSS	HT, % LSS/HSS	Ds, % LSS/HSS	Cs, % LSS/HSS	DM, % LSS/HSS
Akgun et al, 2015 ^[13]	57.6/58.9	79.2/77.8	40.9/43.8	37.1/40.6	52.9/53.6	21.4/23.5
Capodanno et al, 2009 ^[14]	66.1/70.2	75.9/80.0	68.1/68.2	56.4/55.3	45.1/43.5	30.7/36.1
Capodanno et al, 2009 ^[15]	63.0/67.0	81.0/76.0	72.0/66.5	62.0/60.5	57.0/38.5	27.0/36.0
Garg et al, 2011 ^[16]	61.8/64.7	75.2/72.2	54.8/57.5	41.8/38.7	42.1/36.0	10.3/15.6
Garg et al, 2011 ^[17]	63.0/64.3	71.2/77.9	70.6/69.8	65.6/62.0	25.5/29.2	19.3/24.0
Girasis et al, 2011 ^[18]	60.7/62.6	74.4/77.5	58.4/60.4	60.1/55.0	42.3/34.8	15.4/21.0
He et al, 2011 ^[19]	50.0/61.0	71.8/70.4	62.0/64.4	39.4/44.7	29.6/36.4	19.7/22.7
lkeno et al, 2017 ^[20]	62.0/63.3	68.7/78.9	81.8/80.6	_	64.1/64.2	49.7/48.9
Kim et al, 2010 ^[21]	58.5/66.9	66.2/51.4	42.5/59.5	28.7/36.1	26.9/18.5	22.1/40.8
Magro et al, 2011 ^[22]	63.0/66.0	64.0/72.5	29.0/35.5	19.0/21.5	48.0/39.0	8.00/11.0
Nozue et al, 2012 ^[23]	71.0/68.9	81.0/71.5	73.0/97.0	65.0/57.5	_	38.0/43.0
Park et al, 2013 ^[24]	63.0/64.5	68.1/66.8	63.5/65.4	34.0/36.2	32.8/32.7	32.0/40.3
Sinning et al, 2013 ^[25]	_	_	_	_	_	_
Valgimigli et al, 2007 ^[26]	61.0/65.0	79.0/75.5	65.0/72.0	81.0/72.5	20.0/18.0	18.0/33.0
Wykrzykowska et al, 2010 ^[27]	_	74.6/73.4	76.1/72.6	67.7/64.2	28.9/26.5	20.0/24.5
Yadav et al, 2015 ^[28]	59.3/61.3	63.9/69.2	64.5/66.1	56.6/56.0	38.2/34.2	25.4/30.0

Cs = current smokers, DM = diabetes mellitus, Ds = dyslipidemia, HSS = high SYNTAX score, HT = hypertension, LSS = low SYNTAX score.

Study or Subgroup 1.1.1 Mortality	High SYNTA: Events	C Score Total	Low SYNTA Events		Weight	Risk Ratio M-H, Fixed, 95% C	Risk Ratio M-H, Fixed, 95% Cl
1.1.1 Mortality Akgun2014	381	2174	73	819	8.2%	1.97 [1.55, 2.49]	
Akgun2014 Capodanno2009A	28	2174	21	257	8.2% 0.8%	4.03 [2.42, 6.71]	
							<u> </u>
Garg2011A	34	496	10	311	0.9%	2.13 [1.07, 4.25]	
Garg2011B	25	1335	13	698	1.3%	1.01 [0.52, 1.95]	
Girasis2011	55	555	18	293	1.8%	1.61 [0.97, 2.69]	
He2011	2	132	0	71	0.0%	2.71 [0.13, 55.62]	
Magro2011	63	460	18	209	1.9%	1.59 [0.97, 2.62]	
Park2013	82	3494	11	1608	1.2%	3.43 [1.83, 6.42]	
Sinning2013	44	276	1	52	0.1%	8.29 [1.17, 58.84]	· · · · · · · · · · · · · · · · · · ·
Valgimigli2007	0	203	0	103		Not estimable	
Wykrzykowska2010	36	933	7	464	0.7%	2.56 [1.15, 5.70]	
Subtotal (95% CI)		10143		4885	17.0%	2.09 [1.78, 2.46]	•
Total events	750		172				
Heterogeneity: Chi ² = Test for overall effect:	18.02, df = 9 (P						
1.1.2 Cardiac death	040		50	040	0.001	0.00 // 50.0.051	
Akgun2014	318	2174	59	819	6.6%	2.03 [1.56, 2.65]	
Garg2011B	17	1335	7	698	0.7%	1.27 [0.53, 3.05]	
Girasis2011	33	555	8	293	0.8%	2.18 [1.02, 4.65]	
Park2013	50	3494	10	1608	1.1%	2.30 [1.17, 4.53]	
Sinning2013	29	276	0	52	0.1%	11.29 [0.70, 181.91]	+
Subtotal (95% CI)		7834		3470	9.2%	2.08 [1.66, 2.61]	♦
Total events	447		84				.
Heterogeneity: Chi ² = ; Test for overall effect:	2.78, df = 4 (P =						
1.1.3 Myocardial Infa	rction						
Akgun2014	211	2174	60	819	6.7%	1.32 [1.01, 1.74]	<u>⊢</u>
Garg2011A	22	496	4	311	0.4%	3.45 [1.20, 9.91]	<u> </u>
Garg2011B	202	1335	56	698	5.7%	1.89 [1.42, 2.50]	-
Girasis2011	47	555	9	293	0.9%	2.76 [1.37, 5.55]	
	4/	555 132				3.79 [0.20, 72.35]	
He2011			0	71	0.0%		
Magro2011	12	460	3	209	0.3%	1.82 [0.52, 6.37]	
Park2013	21	3494	2	1608	0.2%	4.83 [1.13, 20.58]	
Sinning2013	29	276	3	52	0.4%	1.82 [0.58, 5.76]	
Valgimigli2007	4	203	0	103	0.1%	4.59 [0.25, 84.41]	
Wykrzykowska2010	50	933	20	464	2.1%	1.24 [0.75, 2.06]	
Subtotal (95% CI)		10058		4628	16.7%	1.71 [1.45, 2.03]	♦
Total events	601		157				
Heterogeneity: Chi ² = Test for overall effect:			22%				
		,					
1.1.4 Major adverse o							
	ardiac events 96	496	24	311	2.3%	2.51 [1.64, 3.83]	
Garg2011A	96						-
Garg2011A Garg2011B	96 208	1335	59	698	6.0%	1.84 [1.40, 2.42]	
Garg2011A Garg2011B Girasis2011	96 208 126	1335 555	59 37	698 293	6.0% 3.7%	1.84 [1.40, 2.42] 1.80 [1.28, 2.52]	
Garg2011A Garg2011B Girasis2011 He2011	96 208 126 16	1335 555 132	59 37 1	698 293 71	6.0% 3.7% 0.1%	1.84 [1.40, 2.42] 1.80 [1.28, 2.52] 8.61 [1.17, 63.56]	
Garg2011A Garg2011B Girasis2011 He2011 Ikeno2017	96 208 126 16 44	1335 555 132 124	59 37 1 151	698 293 71 849	6.0% 3.7% 0.1% 3.0%	1.84 [1.40, 2.42] 1.80 [1.28, 2.52] 8.61 [1.17, 63.56] 2.00 [1.51, 2.63]	
Garg2011A Garg2011B Girasis2011 He2011 Ikeno2017 Kim2010	96 208 126 16 44 80	1335 555 132 124 384	59 37 1 151 51	698 293 71 849 435	6.0% 3.7% 0.1% 3.0% 3.7%	1.84 [1.40, 2.42] 1.80 [1.28, 2.52] 8.61 [1.17, 63.56] 2.00 [1.51, 2.63] 1.78 [1.29, 2.46]	
Garg2011A Garg2011B Girasis2011 He2011 Ikeno2017 Kim2010 Magro2011	96 208 126 16 44 80 87	1335 555 132 124 384 460	59 37 1 151 51 23	698 293 71 849 435 209	6.0% 3.7% 0.1% 3.0% 3.7% 2.4%	1.84 [1.40, 2.42] 1.80 [1.28, 2.52] 8.61 [1.17, 63.56] 2.00 [1.51, 2.63] 1.78 [1.29, 2.46] 1.72 [1.12, 2.64]	
Garg2011A Garg2011B Girasis2011 He2011 Ikeno2017 Kim2010 Magro2011 Nozue2012	96 208 126 44 80 87 11	1335 555 132 124 384 460 23	59 37 151 51 23 1	698 293 71 849 435 209 26	6.0% 3.7% 0.1% 3.0% 3.7% 2.4% 0.1%	1.84 [1.40, 2.42] 1.80 [1.28, 2.52] 8.61 [1.17, 63.56] 2.00 [1.51, 2.63] 1.78 [1.29, 2.46] 1.72 [1.12, 2.64] 12.43 [1.74, 89.05]	
Garg2011A Garg2011B Girasis2011 He2011 Ikeno2017 Kim2010 Magro2011 Nozue2012 Park2013	96 208 126 44 80 87 11 344	1335 555 132 124 384 460 23 3494	59 37 151 51 23 1 68	698 293 71 849 435 209 26 1608	6.0% 3.7% 0.1% 3.0% 3.7% 2.4% 0.1% 7.2%	1.84 [1.40, 2.42] 1.80 [1.28, 2.52] 8.61 [1.17, 63.56] 2.00 [1.51, 2.63] 1.78 [1.29, 2.46] 1.72 [1.12, 2.64] 12.43 [1.74, 89.05] 2.33 [1.81, 3.00]	
Garg2011A Garg2011B Girasis2011 He2011 Kikeno2017 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013	96 208 126 16 44 80 87 11 344 152	1335 555 132 124 384 460 23 3494 276	59 37 151 51 23 1 68 12	698 293 71 849 435 209 26 1608 52	6.0% 3.7% 0.1% 3.0% 3.7% 2.4% 0.1% 7.2% 1.6%	1.84 [1.40, 2.42] 1.80 [1.28, 2.52] 8.61 [1.17, 63.56] 2.00 [1.51, 2.63] 1.78 [1.29, 2.46] 1.72 [1.12, 2.64] 12.43 [1.74, 89.05] 2.33 [1.81, 3.00] 2.39 [1.44, 3.96]	
Garg2011A Garg2011B Girasis2011 He2011 Ikeno2017 Kim2010 Magro2011 Nozue2012 Park2013	96 208 126 44 80 87 11 344	1335 555 132 124 384 460 23 3494	59 37 151 51 23 1 68	698 293 71 849 435 209 26 1608	6.0% 3.7% 0.1% 3.0% 3.7% 2.4% 0.1% 7.2%	1.84 [1.40, 2.42] 1.80 [1.28, 2.52] 8.61 [1.17, 63.56] 2.00 [1.51, 2.63] 1.78 [1.29, 2.46] 1.72 [1.12, 2.64] 12.43 [1.74, 89.05] 2.33 [1.81, 3.00]	
Garg2011A Garg2011B Girasis2011 He2011 Kikeno2017 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013	96 208 126 16 44 80 87 11 344 152	1335 555 132 124 384 460 23 3494 276	59 37 151 51 23 1 68 12	698 293 71 849 435 209 26 1608 52	6.0% 3.7% 0.1% 3.0% 3.7% 2.4% 0.1% 7.2% 1.6%	1.84 [1.40, 2.42] 1.80 [1.28, 2.52] 8.61 [1.17, 63.56] 2.00 [1.51, 2.63] 1.78 [1.29, 2.46] 1.72 [1.12, 2.64] 12.43 [1.74, 89.05] 2.33 [1.81, 3.00] 2.39 [1.44, 3.96]	
Garg2011A Garg2011B Girasis2011 He2011 Ikeno2017 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Valgimigil2007	96 208 126 44 80 87 11 344 152 16	1335 555 132 124 384 460 23 3494 276 203	59 37 1 151 23 1 68 12 3	698 293 71 849 435 209 26 1608 52 103	6.0% 3.7% 0.1% 3.0% 2.4% 0.1% 7.2% 1.6% 0.3%	1.84 [1.40, 2.42] 1.80 [1.28, 2.52] 8.61 [1.17, 63.56] 2.00 [1.51, 2.63] 1.78 [1.29, 2.46] 1.72 [1.12, 2.64] 12.43 [1.74, 89.05] 2.33 [1.81, 3.00] 2.39 [1.44, 3.96] 2.71 [0.81, 9.08]	
Garg2011A Garg2011B Girasis2011 He2011 Ikeno2017 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Valgimgli2007 Wykrzykowska2010 Subtotal (95% CI) Total events	96 208 126 16 44 80 87 11 344 152 16 113	1335 555 132 124 384 460 23 3494 276 203 933 8415	59 37 1 151 51 23 1 68 12 3 36 466	698 293 71 849 435 209 26 1608 52 103 464	6.0% 3.7% 0.1% 3.0% 2.4% 0.1% 7.2% 1.6% 0.3% 3.7%	1.84 [1.40, 2.42] 1.80 [1.28, 2.52] 8.61 [1.17, 63.56] 2.00 [1.51, 2.63] 1.78 [1.29, 2.46] 1.72 [1.12, 2.64] 2.43 [1.74, 89.05] 2.33 [1.81, 3.00] 2.39 [1.44, 3.96] 2.71 [0.81, 9.08] 1.56 [1.09, 2.23]	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Valgim[gl2007 Subtotal (95% CI) Total events Heterogeneity: Ch ² =	96 208 126 16 44 80 87 11 344 152 16 113 1293 12.21, df = 11 (F	1335 555 132 124 384 460 23 3494 276 203 933 8415 P = 0.35); I ²	59 37 1 151 51 23 1 68 12 3 36 466	698 293 71 849 435 209 26 1608 52 103 464	6.0% 3.7% 0.1% 3.0% 2.4% 0.1% 7.2% 1.6% 0.3% 3.7%	1.84 [1.40, 2.42] 1.80 [1.28, 2.52] 8.61 [1.17, 63.56] 2.00 [1.51, 2.63] 1.78 [1.29, 2.46] 1.72 [1.12, 2.64] 2.43 [1.74, 89.05] 2.33 [1.81, 3.00] 2.39 [1.44, 3.96] 2.71 [0.81, 9.08] 1.56 [1.09, 2.23]	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magrc2012 Park2013 Sinning2013 Valgimgl/2007 Vykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect:	96 208 126 16 44 80 87 11 344 152 16 113 1223 12.21, df = 11 (F Z = 12.48 (P < C	1335 555 132 124 384 460 23 3494 276 203 933 8415 P = 0.35); I ²	59 37 1 151 51 23 1 68 12 3 36 466	698 293 71 849 435 209 26 1608 52 103 464	6.0% 3.7% 0.1% 3.0% 2.4% 0.1% 7.2% 1.6% 0.3% 3.7%	1.84 [1.40, 2.42] 1.80 [1.28, 2.52] 8.61 [1.17, 63.56] 2.00 [1.51, 2.63] 1.78 [1.29, 2.46] 1.72 [1.12, 2.64] 2.43 [1.74, 89.05] 2.33 [1.81, 3.00] 2.39 [1.44, 3.96] 2.71 [0.81, 9.08] 1.56 [1.09, 2.23]	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.5 Repeated revas	96 208 126 14 80 87 11 344 152 16 113 1293 12.21, df = 11 (F Z = 12.48 (P < C	1335 555 132 124 384 460 23 3494 276 203 933 8415 2 = 0.35); ²	59 37 1 151 23 1 68 12 3 36 466 = 10%	698 293 71 849 435 209 26 1608 52 103 464 5119	6.0% 3.7% 0.1% 3.7% 2.4% 0.1% 7.2% 1.6% 0.3% 3.7% 34.0%	1 84 (1 40, 2.42) 1 80 (1 28, 252) 8.61 (1.17, 63.56) 2.00 (1.51, 2.63) 1.78 (1.29, 2.46) 1.72 (1.29, 2.46) 1.72 (1.12, 2.64) 2.33 (1.81, 3.00) 2.39 (1.44, 3.96) 2.33 (1.44, 3.96) 2.71 (0.81, 9.08) 1.56 (1.09, 2.23) 2.03 (1.81, 2.26)	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2012 Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Ch ² = Test for overall effect: 1.1.5 Repeated revas Garg2011A	$\begin{array}{r} 96\\ 208\\ 126\\ 16\\ 44\\ 80\\ 87\\ 11\\ 344\\ 152\\ 16\\ 113\\ 1221\\ df=11\\ (df=11\\ df=11\\ 2f=12.48 \ (P<0\\ cularization\\ 49\\ \end{array}$	1335 555 132 124 384 460 23 3494 276 203 933 8415 2 = 0.35); ²	59 37 1 151 51 23 1 68 12 3 36 466 = 10%	698 293 71 849 435 209 26 1608 52 103 464 5119 311	6.0% 3.7% 0.1% 3.0% 2.4% 0.1% 7.2% 1.6% 3.7% 34.0%	184 [140,242] 180 [128,252] 8.6[1117,635.6] 2.00 [1.51,263] 1.78 [1.29,246] 1.72 [1.29,246] 2.33 [1.41,300] 2.33 [1.41,300] 2.33 [1.41,300] 2.33 [1.44,356] 2.71 [0.81,908] 1.56 [1.09,223] 2.03 [1.81,226]	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2017 Kim2010 Park2013 Sinning2013 Valgimgli2007 Valgimgli2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.5 Repeated revass Garg2011B	96 208 126 16 44 80 87 11 344 152 16 113 12.21, df = 11 (f Z = 12.48 (P < (cularization 49 142	1335 555 132 124 384 460 23 3494 276 203 933 8415 2 = 0.35); ² 2 = 0.35); ² 496 1335	59 37 1 151 51 23 1 68 12 3 36 466 = 10%	698 293 71 849 435 209 26 1608 52 103 464 5119 311 698	6.0% 3.7% 0.1% 3.0% 2.4% 0.1% 7.2% 1.6% 3.7% 34.0%	1.84 (1,40, 2.42) 1.80 (128, 2.52) 8.61 (1.17, 63.56) 2.00 (1.51, 2.63) 1.78 (1.29, 2.46) 1.72 (1.12, 2.64) 2.33 (1.44, 306) 2.33 (1.44, 306) 2.33 (1.44, 306) 2.33 (1.44, 306) 1.56 (1.09, 2.23) 2.03 (1.81, 2.26) 2.79 (1.48, 5.29) 2.79 (1.48, 5.29) 2.12 (1.48, 5.29)	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magr02011 Nozue2012 Park2013 Sinning2013 Sinning2013 Sinning2013 Subt0a1 (95% CI) Total events Heterogeneity: Ch ² = Test for overall effect: 1.1.5. Repeated revas Garg2011A Garg2011B Girasis2011	96 208 126 44 80 87 11 344 152 16 113 1221.df = 11 (f Z = 12.48 (P < (f cularization 49 49 142 87	1335 555 132 124 384 460 23 3494 276 203 933 8415 2 = 0.35); l ² .00001) 496 1335 555	59 37 1 151 51 23 3 36 466 = 10%	698 293 71 849 435 209 26 1608 52 103 464 5119 311 698 293	6.0% 3.7% 0.1% 3.0% 2.4% 0.1% 7.2% 1.6% 0.3% 3.7% 34.0%	1.84 [1,40,2.42] 1.80 [1,28,2.52] 8.61 [1.17, 63.56] 2.00 [1.51,2.63] 1.78 [1,29,2.46] 1.72 [1,29,2.46] 1.72 [1,29,2.46] 1.72 [1,29,2.46] 1.73 [1,29,2.46] 1.74 [1,29,2.46] 1.74 [1,48,9.05] 1.56 [1,09,2.23] 2.03 [1.81,2.26] 2.79 [1.48,5.29] 2.12 [1.48,3.04] 1.64 [1.10,2.45]	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2017 Kim2010 Park2013 Sinning2013 Valgimgli2007 Valgimgli2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.5 Repeated revass Garg2011B	96 208 126 16 44 80 87 11 344 152 16 113 12.21, df = 11 (f Z = 12.48 (P < (cularization 49 142	1335 555 132 124 384 460 23 3494 276 203 8415 933 8415 9.00001) 496 1335 555 132	59 37 1 151 51 23 1 68 12 3 36 466 = 10%	698 293 71 849 435 209 26 1608 52 103 464 5119 311 698 293 71	6.0% 3.7% 0.1% 3.0% 2.4% 0.1% 7.2% 1.6% 0.3% 3.7% 34.0%	$\begin{array}{c} 1.84 \left(1.40, 2.42 \right) \\ 1.80 \left(1.28, 2.52 \right) \\ 8.61 \left(1.17, 63.56 \right) \\ 2.00 \left(1.51, 2.63 \right) \\ 1.78 \left(1.29, 2.46 \right) \\ 1.78 \left(1.29, 2.46 \right) \\ 2.33 \left(1.44, 3.86 \right) \\ 2.33 \left(1.44, 3.86 \right) \\ 2.33 \left(1.44, 3.86 \right) \\ 2.30 \left(1.44, 3.86 \right) \\ 2.30 \left(1.44, 3.86 \right) \\ 2.30 \left(1.48, 3.26 \right) \\ 2.30 \left(1.48, 5.29 \right) \\ 2.12 \left(1.48, 5.29 \right) $	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magr02011 Nozue2012 Park2013 Sinning2013 Sinning2013 Sinning2013 Subt0a1 (95% CI) Total events Heterogeneity: Ch ² = Test for overall effect: 1.1.5. Repeated revas Garg2011A Garg2011B Girasis2011	96 208 126 44 80 87 11 344 152 16 113 1221.df = 11 (f Z = 12.48 (P < (f cularization 49 49 142 87	1335 555 132 124 384 460 23 3494 276 203 933 8415 2 = 0.35); l ² .00001) 496 1335 555	59 37 1 151 51 23 3 36 466 = 10%	698 293 71 849 435 209 26 1608 52 103 464 5119 311 698 293	6.0% 3.7% 0.1% 3.0% 2.4% 0.1% 7.2% 1.6% 0.3% 3.7% 34.0%	1.84 [1,40,2.42] 1.80 [1,28,2.52] 8.61 [1.17, 63.56] 2.00 [1.51,2.63] 1.78 [1,29,2.46] 1.72 [1,29,2.46] 1.72 [1,29,2.46] 1.72 [1,29,2.46] 1.73 [1,29,2.46] 1.74 [1,29,2.46] 1.74 [1,48,9.05] 1.56 [1,09,2.23] 2.03 [1.81,2.26] 2.79 [1.48,5.29] 2.12 [1.48,3.04] 1.64 [1.10,2.45]	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magrc2012 Park2013 Sinning2013 Valgimgl/2007 Vykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011B Girasis2011 He2011	96 208 126 16 44 80 87 11 344 152 16 113 1221, df = 11 [f Z = 12,48 (P < (cularization 49 142 87 11	1335 555 132 124 384 460 23 3494 276 203 8415 933 8415 9.00001) 496 1335 555 132	59 37 1 151 51 23 1 68 12 3 36 466 = 10%	698 293 71 849 435 209 26 1608 52 103 464 5119 311 698 293 71	6.0% 3.7% 0.1% 3.0% 2.4% 0.1% 7.2% 1.6% 0.3% 3.7% 34.0%	$\begin{array}{c} 1.84 \left(1.40, 2.42 \right) \\ 1.80 \left(1.28, 2.52 \right) \\ 8.61 \left(1.17, 63.56 \right) \\ 2.00 \left(1.51, 2.63 \right) \\ 1.78 \left(1.29, 2.46 \right) \\ 1.78 \left(1.29, 2.46 \right) \\ 2.33 \left(1.44, 3.86 \right) \\ 2.33 \left(1.44, 3.86 \right) \\ 2.33 \left(1.44, 3.86 \right) \\ 2.30 \left(1.44, 3.86 \right) \\ 2.30 \left(1.44, 3.86 \right) \\ 2.30 \left(1.48, 3.26 \right) \\ 2.30 \left(1.48, 5.29 \right) \\ 2.12 \left(1.48, 5.29 \right) $	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2012 Park2013 Sinning2013 Valgimigli2007 Vykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Tost for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011A Garg2011B He2011 He2011 Magro2011B Park2013	96 208 126 16 44 80 87 7 11 344 152 16 113 1223 1221.df = 11 (f Z = 12.48 (P < (cularization 49 142 87 11 26 257	1335 555 132 124 384 460 23 3494 276 203 933 8415 2 = 0.35); l ² 2 = 0.35); l ² 100001) 496 1335 555 132 460 3494	59 37 1 151 51 23 1 68 12 3 36 466 = 10%	698 293 71 849 435 209 26 1608 522 103 464 5119 3111 698 293 71 209 1608	6.0% 3.7% 0.1% 3.0% 3.7% 2.4% 0.1% 0.3% 3.7% 3.7% 34.0%	$\begin{array}{c} 1.84 \left[1.40, 2.42 \right] \\ 1.80 \left[1.28, 2.52 \right] \\ 8.61 \left[1.17, 63.56 \right] \\ 2.00 \left[1.51, 2.63 \right] \\ 1.78 \left[1.29, 2.46 \right] \\ 1.78 \left[1.29, 2.46 \right] \\ 2.33 \left[1.41, 3.60 \right] \\ 2.31 \left[1.43, 3.61 \right] \\ 1.55 \left[1.09, 2.23 \right] \\ 2.10 \left[1.48, 5.29 \right] \\ 2.12 \left[1.48, 3.04 \right] \\ 1.64 \left[1.10, 2.45 \right] \\ 5.52 \left[0.78, 4.49 0 \right] \\ 2.36 \left[0.92, 6.07 \right] \\ 2.15 \left[1.62, 2.86 \right] \\ 2.16 \left[1.62, 2.86 \right] \\ \end{array}$	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2017 Kim2010 Magro2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ^a = Test for overall effect: 1.1.5 Repeated revas Garg2011A Girasis2011 He2011 Magro2011 Park2013 Sinning2013	96 208 126 16 44 80 87 11 344 152 16 6 113 1221, df = 11 (f 2 = 12.48 (P < c cularization 49 142 87 11 26 257 75	1335 555 132 124 384 460 23 3494 276 203 933 8415 2 = 0.35); ² 0.00001) 496 1335 555 132 460 3494 276	59 37 1 151 23 1 68 12 36 466 = 10%	698 293 71 849 435 209 26 1608 52 103 464 5119 311 698 293 71 209 1608 52	6.0% 3.7% 0.1% 3.0% 3.7% 2.4% 1.6% 0.3% 3.7% 3.7% 3.7% 3.7% 3.7% 3.7% 3.7% 3	$\begin{array}{c} 1.84 \left(1.40, 2.42 \right) \\ 1.80 \left(1.28, 2.52 \right) \\ 8.61 \left(1.17, 63.56 \right) \\ 2.00 \left(1.51, 2.63 \right) \\ 1.78 \left(1.29, 2.46 \right) \\ 1.72 \left(1.29, 2.46 \right) \\ 2.33 \left(1.43, 9.06 \right) \\ 2.33 \left(1.44, 3.96 \right) \\ 2.33 \left(1.44, 3.96 \right) \\ 2.71 \left(1.64, 3.96 \right) \\ 1.56 \left(1.09, 2.23 \right) \\ 2.03 \left(1.44, 3.96 \right) \\ 2.12 \left(1.48, 5.29 \right) $	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2012 Park2013 Sinning2013 Valgimgli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011A Garg2011 He2011 Park2013 Sinning2013 Valgimgli2007	$\begin{array}{c} 96\\ 208\\ 126\\ 126\\ 16\\ 44\\ 80\\ 87\\ 11\\ 152\\ 16\\ 113\\ 1223\\ 1221, df=11 (f\\ 2=12.48 (P < (c\\ cularization\\ 49\\ 237\\ 11\\ 122\\ 87\\ 75\\ 75\\ 6\end{array}$	1335 555 132 124 384 460 23 3494 276 203 933 8415 2 = 0.35); l ² 0.00001) 496 1335 555 132 460 3494 276 203	59 37 1 51 51 23 1 8 23 36 466 = 10% 111 35 28 28 1 55 55 8 0	698 293 71 849 435 209 26 1608 52 52 103 464 5119 311 698 293 71 1209 1608 52 201 311	6.0% 3.7% 0.1% 3.0% 3.7% 2.4% 0.1% 7.2% 1.0% 3.7% 3.7% 3.4.0% 1.0% 5.8% 0.5% 5.8% 1.0% 0.1%	$\begin{array}{c} 1.84 \left[1.40, 2.42 \right] \\ 1.80 \left[1.28, 2.52 \right] \\ 8.61 \left[1.17, 63.56 \right] \\ 2.00 \left[1.51, 2.63 \right] \\ 1.78 \left[1.29, 2.46 \right] \\ 1.72 \left[1.29, 2.46 \right] \\ 2.33 \left[1.41, 3.00 \right] \\ 2.33 \left[1.41, 3.00 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.31 \left[1.43, 9.23 \right] \\ 2.31 \left[1.44, 3.96 \right] \\ 2.37 \left[1.48, 5.29 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 1.48 \left[1.28 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 1.56$	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2017 Kim2010 Magro2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ^a = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011B Girasis2011 He2011 Magro2013 Sinning2013 Valgimigli2007	96 208 126 16 44 80 87 11 344 152 16 6 113 1221, df = 11 (f 2 = 12.48 (P < c cularization 49 142 87 11 26 257 75	1335 555 132 124 3494 276 203 8415 2= 0.35); l ² 0.00001) 496 1335 555 132 460 3494 276 203 933	59 37 1 151 23 1 68 12 36 466 = 10%	698 293 71 849 435 209 26 1608 52 103 464 5119 311 698 293 71 209 1608 52 103 464	6.0% 3.7% 0.1% 3.0% 3.7% 2.4% 0.1% 7.2% 3.4.0% 3.7% 3.4.0% 3.5% 2.8% 0.1% 0.5% 5.8% 1.0% 0.1% 5.2%	$\begin{array}{c} 1.84 \left(1.40, 2.42 \right) \\ 1.80 \left(1.28, 2.52 \right) \\ 8.61 \left(1.17, 63.56 \right) \\ 2.00 \left(1.51, 2.63 \right) \\ 1.78 \left(1.29, 2.46 \right) \\ 1.72 \left(1.29, 2.46 \right) \\ 2.33 \left(1.44, 3.96 \right) \\ 2.33 \left(1.44, 3.96 \right) \\ 2.33 \left(1.44, 3.96 \right) \\ 2.30 \left(1.48, 5.29 \right) \\ 2.12 \left(1.48, 3.04 \right) \\ 1.54 \left(1.10, 2.45 \right) \\ 2.15 \left(1.62, 2.86 \right) \\ 2.17 \left(1.09, 1.54 \right) \\ 1.54 \left(1.15, 2.07 \right) \\ 1.54 \left(1.15, 2.07 \right) \\ 1.54 \left(1.54, 2.07 \right) \\ 1.55 \left(1.54, 2.07 \right) $	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magr02011 Nozue2012 Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) 1.1.5 Repeated revas Garg2011A Garg2011A Garg2011B Garg32011 He2011 Magr02013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI)	$\begin{array}{c} 96\\ 208\\ 126\\ 16\\ 144\\ 80\\ 87\\ 11\\ 344\\ 152\\ 16\\ 113\\ 1223\\ 1221, df=11 (f\\ 2=12.48 (P < (c\\ cularization\\ 49\\ 11\\ 26\\ 87\\ 11\\ 26\\ 87\\ 75\\ 6\\ 6\\ 158\\ \end{array}$	1335 555 132 124 384 460 23 3494 276 203 933 8415 2 = 0.35); l ² 0.00001) 496 1335 555 132 460 3494 276 203	59 37 1 151 51 23 1 68 12 3 36 466 = 10% 11 35 28 1 5 55 8 0 51	698 293 71 849 435 209 26 1608 52 52 103 464 5119 311 698 293 71 1209 1608 52 201 311	6.0% 3.7% 0.1% 3.0% 3.7% 2.4% 0.1% 7.2% 1.0% 3.7% 3.7% 3.4.0% 1.0% 5.8% 0.5% 5.8% 1.0% 0.1%	$\begin{array}{c} 1.84 \left[1.40, 2.42 \right] \\ 1.80 \left[1.28, 2.52 \right] \\ 8.61 \left[1.17, 63.56 \right] \\ 2.00 \left[1.51, 2.63 \right] \\ 1.78 \left[1.29, 2.46 \right] \\ 1.72 \left[1.29, 2.46 \right] \\ 2.33 \left[1.41, 3.00 \right] \\ 2.33 \left[1.41, 3.00 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.31 \left[1.43, 9.23 \right] \\ 2.31 \left[1.44, 3.96 \right] \\ 2.37 \left[1.48, 5.29 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 1.48 \left[1.28 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 1.56$	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magrc2012 Park2013 Sinning2013 Valgimgl/2007 Vykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011B Girasis2011 Ha2r0211 Magrc20211 Park2013 Sinning2013 Valgimgl/2007 Wykrzykowska2010 Subtotal (95% CI) Total events	96 208 126 44 80 87 11 344 152 12 21 41 23 12 21 41 23 12 21 41 23 12 21 41 2 11 2 1	1335 555 132 124 384 460 23 3494 276 203 933 8415 2 = 0.35); I ² 0.00001) 496 1335 555 555 132 460 3494 276 203 33 484	59 37 1 151 51 23 68 12 3 3 36 = 10% 11 35 28 1 5 5 55 5 5 5 5 5 5 5 5 5 5 1 94	698 293 71 849 435 209 26 1608 52 103 464 5119 311 698 293 71 209 1608 52 103 464	6.0% 3.7% 0.1% 3.0% 3.7% 2.4% 0.1% 7.2% 3.4.0% 3.7% 3.4.0% 3.5% 2.8% 0.1% 0.5% 5.8% 1.0% 0.1% 5.2%	$\begin{array}{c} 1.84 \left(1.40, 2.42 \right) \\ 1.80 \left(1.28, 2.52 \right) \\ 8.61 \left(1.17, 63.56 \right) \\ 2.00 \left(1.51, 2.63 \right) \\ 1.78 \left(1.29, 2.46 \right) \\ 1.72 \left(1.29, 2.46 \right) \\ 2.33 \left(1.44, 3.96 \right) \\ 2.33 \left(1.44, 3.96 \right) \\ 2.33 \left(1.44, 3.96 \right) \\ 2.30 \left(1.48, 5.29 \right) \\ 2.12 \left(1.48, 3.04 \right) \\ 1.54 \left(1.10, 2.45 \right) \\ 2.15 \left(1.62, 2.86 \right) \\ 2.17 \left(1.09, 1.54 \right) \\ 1.54 \left(1.15, 2.07 \right) \\ 1.54 \left(1.15, 2.07 \right) \\ 1.54 \left(1.54, 2.07 \right) \\ 1.55 \left(1.54, 2.07 \right) $	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magr02011 Nozue2012 Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) 1.1.5 Repeated revas Garg2011A Garg2011A Garg2011B Garg32011 He2011 Magr02013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI)	96 208 126 16 44 80 87 11 152 16 113 223 1221, df = 11 (f 2 = 12.48 (P < C cularization 49 49 47 11 26 87 75 5 6 158 811 7.18, df = 8 (P =	1335 555 132 124 384 460 233 3494 276 203 933 8415 2 = 0.35); l ² = 0.35); l ² 0.00001) 4966 1335 555 132 460 3494 2766 203 3494 2768 203 3494 2768 203 3494 2768 203 3494 2768 203 3494 2768 203 3494 2768 203 3494 2768 203 3494 2768 2035; l ² 2 = 0.35; l ² 3495 3496 1325 132 124 203 3494 2055 132 124 205 132 124 205 132 124 205 132 132 132 132 132 132 132 132	59 37 1 151 51 23 68 12 3 3 36 = 10% 11 35 28 1 5 5 55 5 5 5 5 5 5 5 5 5 5 1 94	698 293 71 849 435 209 26 1608 52 103 464 5119 311 698 293 71 209 1608 52 103 464	6.0% 3.7% 0.1% 3.0% 3.7% 2.4% 0.1% 7.2% 3.4.0% 3.7% 3.4.0% 3.5% 2.8% 0.1% 0.5% 5.8% 1.0% 0.1% 5.2%	$\begin{array}{c} 1.84 \left(1.40, 2.42 \right) \\ 1.80 \left(1.28, 2.52 \right) \\ 8.61 \left(1.17, 63.56 \right) \\ 2.00 \left(1.51, 2.63 \right) \\ 1.78 \left(1.29, 2.46 \right) \\ 1.72 \left(1.29, 2.46 \right) \\ 2.33 \left(1.44, 3.96 \right) \\ 2.33 \left(1.44, 3.96 \right) \\ 2.33 \left(1.44, 3.96 \right) \\ 2.30 \left(1.48, 5.29 \right) \\ 2.12 \left(1.48, 3.04 \right) \\ 1.54 \left(1.10, 2.45 \right) \\ 2.15 \left(1.62, 2.86 \right) \\ 2.17 \left(1.09, 1.54 \right) \\ 1.54 \left(1.15, 2.07 \right) \\ 1.54 \left(1.15, 2.07 \right) \\ 1.54 \left(1.54, 2.07 \right) \\ 1.55 \left(1.54, 2.07 \right) $	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magr02011 Nozue2012 Park2013 Sinning2013 Sinning2013 Subt014 (95% CI) Total events Heterogeneity: Ch ² = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011B Girasis2011 He2011 Magr02011 Park2013 Subt041 (95% CI) Total events Heterogeneity: Ch ² = Test for overall effect:	96 208 126 16 44 80 87 11 152 16 113 1221, df = 11 (F Z = 12.48 (P < C cularization 49 47 11 26 87 75 5 6 158 81 7.18, df = 8 (P < 0.	1335 555 132 124 384 460 233 3494 276 203 933 8415 2 = 0.35); l ² .00001) 496 1335 555 132 460 3494 276 203 3494 276 203 3494 276 203 37884 0.52); l ² = (00001)	59 37 1 151 51 23 68 12 3 3 36 = 10% 11 35 28 1 5 5 55 5 5 5 5 5 5 5 5 5 5 1 94	698 293 71 849 435 209 26 1608 52 103 464 5119 311 698 293 71 209 1608 52 103 464	6.0% 3.7% 0.1% 3.0% 3.7% 2.4% 0.1% 7.2% 3.4.0% 3.7% 3.4.0% 3.5% 2.8% 0.1% 0.5% 5.8% 1.0% 0.1% 5.2%	$\begin{array}{c} 1.84 \left(1.40, 2.42 \right) \\ 1.80 \left(1.28, 2.52 \right) \\ 8.61 \left(1.17, 63.56 \right) \\ 2.00 \left(1.51, 2.63 \right) \\ 1.78 \left(1.29, 2.46 \right) \\ 1.72 \left(1.29, 2.46 \right) \\ 2.33 \left(1.44, 3.96 \right) \\ 2.33 \left(1.44, 3.96 \right) \\ 2.33 \left(1.44, 3.96 \right) \\ 2.30 \left(1.48, 5.29 \right) \\ 2.12 \left(1.48, 3.04 \right) \\ 1.54 \left(1.10, 2.45 \right) \\ 2.15 \left(1.62, 2.86 \right) \\ 2.17 \left(1.09, 1.54 \right) \\ 1.54 \left(1.15, 2.07 \right) \\ 1.54 \left(1.15, 2.07 \right) \\ 1.54 \left(1.54, 2.07 \right) \\ 1.55 \left(1.54, 2.07 \right) $	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2012 Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011A Garg2011A Magro2011 Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Wykrzykowska2010 Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.6 Definite or Prob	96 208 125 16 44 80 87 11 14 152 16 113 1223 1221, df = 11 (f z = 12.48 (P < (cularization 49 237 75 6 158 811 7.18, df = 8 (P < 0. 257 75 6 158	1335 555 132 124 384 460 23 3494 276 203 933 8415 2 = 0.35); l ² 00001) 496 1335 555 132 460 3494 276 203 3494 276 203 3494 276 203 3494 203 3494 276 203 3494 276 203 3494 276 203 3494 276 203 3494 276 203 3494 276 203 3494 276 203 3494 276 203 3494 276 203 3494 276 203 3494 276 203 3495 132 132 124 3494 135 132 124 3494 135 132 124 124 3494 135 132 132 132 132 132 132 132 132 132 132	59 37 1 151 51 23 466 = 10% 11 35 28 15 55 8 0 51 194	608 8293 711 8499 435 52099 26 62 1033 405 52 1033 404 5119 3111 608 52 233 711 2293 711 2393 608 52 233 711 404 43809	6.0% 3.7% 0.1% 3.0% 2.4% 0.1% 2.4% 0.1% 3.7% 3.7% 3.5% 3.4.0%	$\begin{array}{c} 1.84 \left[1.40, 2.42 \right] \\ 1.80 \left[1.28, 2.52 \right] \\ 8.61 \left[1.17, 63.56 \right] \\ 2.00 \left[1.51, 2.63 \right] \\ 1.78 \left[1.29, 2.46 \right] \\ 1.78 \left[1.29, 2.46 \right] \\ 2.43 \left[1.74, 89.05 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.31 \left[1.44, 3.96 \right] \\ 2.31 \left[1.44, 3.96 \right] \\ 2.30 \left[1.48, 2.26 \right] \\ 2.03 \left[1.81, 2.26 \right] \\ 2.12 \left[1.48, 3.04 \right] \\ 1.64 \left[1.10, 2.45 \right] \\ 5.52 \left[0.76, 44.90 \right] \\ 2.36 \left[0.92, 6.37 \right] \\ 2.15 \left[1.62, 2.86 \right] \\ 1.77 \left[0.91, 3.44 \right] \\ 3.16 \left[1.02, 2.85 \right] \\ 1.54 \left[1.15, 2.07 \right] \\ 1.54 \left[1.15, 2.07 \right] \\ 1.96 \left[1.69, 2.28 \right] \\ \end{array}$	
Garg2011A Garg2011B Garg2011B Garg2011B He2011 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Vulgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Total events Garg2011A Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Subtotal (95% CI) Total events Heterogeneity: Ch ² = 1 Total for overail effect: 1.1.6 Definite or Phase Heterogeneity: Ch ² = 1 Total for overail effect:	96 208 126 16 44 80 87 11 344 152 16 6 113 1293 1221, df = 11 (f 2 = 12.48 (P < c cularization 49 12 = 12.48 (P < c 2 = 12.48 (P < c 158 87 5 5 6 158 8 811 7.18, df = 8 (P = 0 2 = 8,78 (P < 0.0) 2 = 12,48 (P < 0.0)	1335 555 132 124 384 460 233 3494 276 203 933 8415 555 132 496 1335 555 132 496 203 933 8415 0,00001) 496 203 933 7884 0,0001 1,000 1,	59 37 1 151 23 466 = 10% 11 35 28 11 5 5 5 8 0 51 194 194	608 (2023) 711 8499 262 520 926 522 103 464 5119 3111 2099 1608 522 103 711 2099 1608 523 3809 3809	6.0% 3.7% 0.1% 3.7% 2.4% 0.1% 2.4% 0.1% 3.7% 3.7% 3.4.0% 0.3% 0.3% 0.3% 0.3% 0.3% 0.1% 0.5% 5.2% 20.2%	1 84 (1, 40, 2, 42) 1, 80 (1, 28, 2, 52) 8, 61 (1, 17, 63, 56) 2, 00 (1, 51, 2, 63) 1, 78 (1, 29, 2, 46) 1, 72 (1, 12, 2, 64) 2, 33 (1, 41, 306) 2, 33 (1, 44, 306) 2, 33 (1, 44, 306) 2, 71 (0, 84, 9, 08) 1, 56 (1, 09, 2, 23) 2, 03 (1, 44, 36) 2, 77 (1, 48, 5, 29) 2, 12 (1, 58, 58) 2,	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magro2012 Park2013 Sinning2013 Sinning2013 Valgimgil2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011A Garg2011 Park2013 Sinning2013 Valgimgil2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.6 Definite or Prob Garg2011B	96 208 126 16 144 80 87 11 344 152 16 113 1293 1221, df = 11 (f 2 = 12.48 (P < 0 cularization 49 287 75 6 811 748 871 158 811 75 6 811 75 6 811 75 6 811 75 6 811 75 6 811 75 6 811 75 6 811 75 88 811 75 6 811 75 6 811 75 88 811 75 75 88 811 75 88 811 75 88 811 75 88 811 75 75 88 811 75 75 88 811 75 75 75 75 75 75 75 88 811 75 75 75 75 75 75 75 75 75 75	1335 555 132 124 384 460 23 3494 276 203 933 8415 2 = 0.35); l ² 00001) 496 1335 555 132 460 3494 276 203 3784 276 203 3784 276 203 3784 276 203 3784 276 203 3784 276 203 3784 276 203 276 203 3784 276 203 3784 276 203 3784 276 203 3784 276 203 3784 276 203 3784 276 203 3784 276 203 3784 276 203 3784 276 203 3784 203 3786 203 3784 203 3786 203 3786 203 3786 203 203 3786 203 203 203 203 203 203 203 203 203 203	59 37 1 151 51 23 1 68 12 3 36 = 10% 466 = 10% 11 35 28 1 55 8 0 51 194 194 194	6080 2933 71 435 2099 26 6 52 5103 464 5119 3111 6080 2933 71 71 2090 52 3311 608 52 3309 3311 608 53 53 53 53 53 53 53 53 53 53 53 53 53	6.0% 3.7% 0.1% 3.7% 2.4% 0.1% 2.4% 0.3% 3.7% 3.7% 3.7% 3.7% 3.7% 3.7% 3.7% 3.4.0% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.3% 0.4%	$\begin{array}{c} 1.84 \left[1.40, 2.42 \right] \\ 1.80 \left[1.28, 2.52 \right] \\ 8.61 \left[1.17, 63.56 \right] \\ 2.00 \left[1.51, 2.63 \right] \\ 1.78 \left[1.29, 2.46 \right] \\ 1.72 \left[1.29, 2.46 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.31 \left[1.44, 3.96 \right] \\ 2.30 \left[1.44, 3.96 \right] \\ 2.30 \left[1.48, 5.29 \right] \\ 2.12 \left[1.48, 3.34 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.12 \left[1.48, 3.44 \right] \\ 2.59 \left[0.78, 44.90 \right] \\ 2.28 \left[0.92, 2.33 \right] \\ 1.21 \left[1.48, 3.44 \right] \\ 1.64 \left[1.10, 2.45 \right] \\ 5.92 \left[0.78, 44.90 \right] \\ 2.36 \left[1.69, 2.28 \right] \\ 1.77 \left[0.91, 3.44 \right] \\ 6.53 \left[0.38, 116.51 \right] \\ 1.54 \left[1.15, 2.07 \right] \\ 1.96 \left[1.69, 2.28 \right] \\ 5.96 \left[1.40, 25.40 \right] \\ 1.39 \left[0.55, 3.55 \right] \\ \end{array}$	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ^a = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011B Girasis2011 He2011 Magro2011 Park2013 Subtotal (95% CI) Total events Heterogeneity: Chi ^a = Test for overall effect: 1.1.6 Definite or Prob Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A	$\begin{array}{c} 96\\ 208\\ 208\\ 126\\ 16\\ 144\\ 80\\ 87\\ 11\\ 344\\ 152\\ 16\\ 6\\ 113\\ 1221, df = 11 (f \\ 21 \\ 22 \\ 12 \\ 24 \\ 12 \\ 24 \\ 12 \\ 24 \\ 12 \\ 12$	1335 555 132 124 384 460 233 3494 276 203 933 8415 1325 555 132 460 3494 276 203 933 7884 0.52); ² = (00001) 00001	59 37 1 151 23 466 = 10% 111 35 28 1 15 23 36 466 = 10% 11 35 28 1 5 5 5 5 5 5 8 0 51 1 1 1 1 1 1 1 1 1 1 1 1 1	698 8 293 3 71 1 849 9 26 2 52 9 26 2 52 103 3 464 5 5119 3 464 5 5119 3 698 2 93 3 11 209 1 608 3 52 2 103 3 11 209 3 608 3 52 3 3809 3 3111 6 98 3 293 3	6.0% 3.7% 0.1% 3.0% 7.2% 1.6% 3.7% 3.7% 3.37% 3.37% 3.37% 3.4.0%	1 84 (1,40, 2,42) 1,80 (1,28, 2,52) 8,61 (1,17, 63,56) 2,00 (1,51, 2,63) 1,78 (1,29, 2,46) 1,78 (1,29, 2,46) 1,78 (1,29, 2,46) 2,33 (1,44, 3,96) 2,33 (1,44, 3,96) 2,33 (1,44, 3,96) 2,39 (1,44, 3,96) 1,56 (1,09, 2,23) 2,03 (1,48, 5,29) 2,12 (1,48, 3,04) 1,56 (1,52,27) 2,15 (1,62, 2,86) 1,77 (0,91, 3,44) 6,63 (0,92, 6,07) 1,56 (1,52,27) 1,56 (1,52,27) 1,56 (1,52,27) 1,56 (1,40, 25,40) 1,39 (0,55, 3,55) 5,96 (1,40, 25,40) 1,39 (0,55, 3,55) 5,11 (0,93, 4,78)	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magr02011 Nozue2012 Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Ch ² = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011A Garg2011B Garg2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Ch ² = Test for overall effect: 1.1.6 Definite or Prob Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B	96 208 126 16 44 80 87 11 344 152 16 113 223 1221, df = 11 (f Z = 12.48 (P < C cularizative (P < C cularizative (P < C 87 11 26 87 158 811 7.18, df = 6 (P = 2 2 = 8.78 (P < 0. able Stem Through (P <	1335 555 132 124 384 460 23 3494 276 203 8415 2 = 0.35); l ² 00001) 496 1335 555 555 555 3494 276 203 3788 4 355 555 355 355 355 355 355 355 355 3	59 37 1 151 23 1 68 12 3 66 55 28 1 15 55 8 0 51 194 194 194 194	6080 2833 71 435 2099 26 6 52 52 53 464 5119 3111 6080 2833 71 209 1608 283 3809 1608 3311 6080 3311 6080 3111 6080 609 600 710 710 710 710 710 710 710 710 710 7	6.0% 0.1% 3.0% 2.4% 0.1% 2.4% 0.3% 3.7% 2.4% 0.3% 3.7% 3.%	$\begin{array}{c} 1.84 \left[1.40, 2.42 \right] \\ 1.80 \left[1.28, 2.52 \right] \\ 8.61 \left[1.17, 63.56 \right] \\ 2.00 \left[1.51, 2.63 \right] \\ 1.78 \left[1.29, 2.46 \right] \\ 1.72 \left[1.29, 2.46 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.37 \left[1.48, 5.29 \right] \\ 2.32 \left[1.48, 3.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.12 \left[1.48, 3.24 \right] \\ 2.23 \left[1.48, 2.26 \right] \\ 2.23 \left[1.48, 2.26 \right] \\ 2.23 \left[1.48, 2.26 \right] \\ 2.36 \left[1.40, 2.26 \right] \\ 2.36 \left[1.40, 2.26 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 1.56 \left[1.40, 2.54 \right] \\ 1.38 \left[0.55, 3.55 \right] \\ 2.11 \left[0.93, 4.78 \right] \\ 1.38 \left[0.55, 3.55 \right] \\ 2.11 \left[0.93, 4.78 \right] \\ 1.58 \left[1.40, 2.54 \right] \\ 1.38 \left[0.55, 3.55 \right] \\ 2.11 \left[0.93, 4.78 \right] \\ 1.58 \left[1.40, 2.54 \right] $	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Vulgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011B Girasis2011 He2011 Magro2013 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.6 Definite or Prob Garg2011A Garg2011A Garg2011A Garg2013 Valgimigli2007 Wykrzykowska2010 Girasis2011 Heterogeneity: Chi ² = Test for overall effect: 1.1.6 Definite or Prob Garg2011A Garg2011B Girasis2011 Park2013	$\begin{array}{c} 96\\ 208\\ 126\\ 16\\ 144\\ 80\\ 87\\ 7\\ 11\\ 344\\ 162\\ 123\\ 1223\\ 1221, df=11 (f\\ Z=12.48 (P < G\\ 113\\ 1223\\ 1221, df=11 (f\\ Z=12.48 (P < G\\ 113\\ 11\\ 26\\ 113\\ 1223\\ 123\\ 123\\ 123\\ 123\\ 123\\ 12$	1335 555 132 124 384 460 23 3494 276 203 933 8415 1335 555 132 460 3494 276 203 933 7884 0.52); l ² = (0.0001) 00001) 00001 00001 00001 00001	59 37 1 151 51 23 466 = 10% 11 35 28 11 5 55 55 55 55 8 0 51 194 0% 2 6 7 3 5 5 5 5 1 1 1 1 1 1 1 1 1 1 1 1 1	688 8233 711 8439 2093 2435 2090 25 5100 245 5100 245 5119 3111 6988 2033 711 2090 245 253 1034 645 3809 311608 523 3809 311608 2933 1608 2933 1608 2933 1608 2933 1608 2934 1608 2935 1608 2005 1608 2005 1608 2005 160	6.0% 3.7% 0.1% 3.0% 7.2% 1.0% 3.5% 3.7% 3.3% 3.3% 3.3% 5.2.8% 0.3% 5.2.8% 0.1% 0.5% 5.2% 0.2% 0.6% 0.7% 0.3%	$\begin{array}{c} 1.84 \left[1.40, 2.42 \right] \\ 1.80 \left[1.28, 2.52 \right] \\ 8.61 \left[1.17, 63.56 \right] \\ 2.00 \left[1.57, 2.63 \right] \\ 1.78 \left[1.29, 2.46 \right] \\ 1.78 \left[1.29, 2.46 \right] \\ 1.78 \left[1.29, 2.46 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.35 \left[1.44, 3.96 \right] \\ 2.35 \left[1.48, 5.29 \right] \\ 2.05 \left[1.9, 2.23 \right] \\ 2.05 \left[1.9, 2.23 \right] \\ 2.12 \left[1.48, 5.29 \right] \\ 2.12 \left[1.48, 5.29 \right] \\ 2.12 \left[1.48, 5.24 \right] \\ 2.12 \left[1.48, 3.04 \right] \\ 1.54 \left[1.10, 2.45 \right] \\ 1.54 \left[1.52, 2.65 \right] \\ 1.77 \left[0.91, 3.44 \right] \\ 6.63 \left[0.38, 11.65 \right] \\ 1.54 \left[1.52, 2.66 \right] \\ 1.77 \left[1.96 \left[1.69, 2.28 \right] \\ 1.39 \left[0.55, 3.55 \right] \\ 2.11 \left[0.93, 4.76 \right] \\ 4.45 \left[1.36, 1.45 \right] \\ 4.18 \left[1.66, 10.49 \right] \end{array}$	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Sinning2013 Sintotal (95% CI) Total events Heterogeneity: Ch ² = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011B Girasis2011 Park2013 Subtotal (95% CI) Total events Heterogeneity: Ch ² = Test for overall effect: 1.1.6 Definite or Prob Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2012B Garg2012B Garg2012B Garg2013 Garg2013 Garg2013 Garg2013 Garg2014 Garg2013 Garg2014 Garg2014 Garg2015	96 208 126 16 44 80 87 11 344 152 16 113 223 1221, df = 11 (f Z = 12.48 (P < C cularizative (P < C cularizative (P < C 87 11 26 87 158 811 7.18, df = 6 (P = 2 2 = 8.78 (P < 0. able Stem Through (P <	1335 555 132 124 384 460 23 3494 276 203 8415 2 = 0.35); l ² 00001) 496 1335 555 355 355 3494 276 203 3493 3788 444 276 203 3494 276 203 3788 444 276 203 3788 444 276 203 3788 444 276 203 3788 444 276 203 3788 444 276 203 3788 449 276 203 3788 449 276 203 3788 449 276 203 3788 449 276 203 3788 449 276 203 3788 449 203 3788 449 203 3788 449 203 3788 44 203 3788 44 203 3788 44 203 3788 44 203 3788 44 3788 3788 44 3788 3788 44 3788 3788	59 37 1 151 23 1 68 12 3 66 55 28 1 15 55 8 0 51 194 194 194 194	6080 2833 71 435 2099 26 6 52 52 52 53 464 5119 3111 6080 2233 3111 6080 464 454 3809 3111 6080 464 464 4223 3609	6.0% 0.1% 3.0% 2.4% 0.1% 2.4% 0.3% 3.7% 2.4% 0.3% 3.7% 3.4.0% 1.0% 3.5% 3.4.0% 0.5% 0.2% 0.6% 0.5%	$\begin{array}{c} 1.84 \left[1.40, 2.42 \right] \\ 1.80 \left[1.28, 2.52 \right] \\ 8.61 \left[1.17, 63.56 \right] \\ 2.00 \left[1.51, 2.63 \right] \\ 1.76 \left[1.29, 2.46 \right] \\ 1.72 \left[1.29, 2.46 \right] \\ 1.72 \left[1.29, 2.46 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.31 \left[1.48, 5.29 \right] \\ 2.12 \left[1.48, 3.04 \right] \\ 2.12 \left[1.48, 3.04 \right] \\ 2.36 \left[1.40, 2.23 \right] \\ 2.36 \left[1.40, 2.24 \right] \\ 2.36 \left[1.40, 2.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.36 \left[1.40, 2.26 \right] \\ 2.36 \left[0.29, 2.67 \right] \\ 1.56 \left[1.62, 2.86 \right] \\ 1.77 \left[0.91, 3.44 \right] \\ 1.54 \left[1.5, 2.07 \right] \\ 1.56 \left[1.40, 2.5.40 \right] \\ 1.59 \left[1.69, 2.28 \right] \\ 2.596 \left[1.40, 2.5.40 \right] \\ 1.59 \left[1.69, 2.28 \right] \\ 3.596 \left[1.40, 2.5.40 \right] \\ 3.58 \left[2.40, 7.26 \right] \\ 3.58 \left$	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Vulgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011B Girasis2011 He2011 Magro2013 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.6 Definite or Prob Garg2011A Garg2011A Garg2011A Garg2013 Valgimigli2007 Wykrzykowska2010 Girasis2011 Heterogeneity: Chi ² = Test for overall effect: 1.1.6 Definite or Prob Garg2011A Garg2011B Girasis2011 Park2013	$\begin{array}{c} 96\\ 208\\ 126\\ 16\\ 144\\ 80\\ 87\\ 7\\ 11\\ 344\\ 162\\ 123\\ 1223\\ 1221, df=11 (f\\ Z=12.48 (P < G\\ 113\\ 1223\\ 1221, df=11 (f\\ Z=12.48 (P < G\\ 113\\ 11\\ 26\\ 113\\ 1223\\ 123\\ 123\\ 123\\ 123\\ 123\\ 12$	1335 555 132 124 384 460 23 3494 276 203 933 8415 1335 555 132 460 3494 276 203 933 7884 0.52); l ² = (0.0001) 00001) 00001 00001 00001 00001	59 37 1 151 51 23 466 = 10% 11 35 28 11 5 55 55 55 55 8 0 51 194 0% 2 6 7 3 5 5 5 5 8 8 0 51 51 51 51 51 51 51 51 51 51	608 0 203 3 71 1 849 2 1 435 2 209 3 1 435 2 209 2 6 2 5 2 1 1 608 5 2 5 1 1 3 3 4 6 4 5 1 1 9 5 1 1 1 9 5 1 1 9 5 1 1 1 9 5 1 1 1 9 5 1 1 1 1	6.0% 3.7% 0.1% 3.0% 7.2% 1.0% 3.5% 3.7% 3.3% 3.3% 3.3% 5.2.8% 0.3% 5.2.8% 0.1% 0.5% 5.2% 0.2% 0.6% 0.7% 0.3%	$\begin{array}{c} 1.84 \left[1.40, 2.42 \right] \\ 1.80 \left[1.28, 2.52 \right] \\ 8.61 \left[1.17, 63.56 \right] \\ 2.00 \left[1.57, 2.63 \right] \\ 1.78 \left[1.29, 2.46 \right] \\ 1.78 \left[1.29, 2.46 \right] \\ 1.78 \left[1.29, 2.46 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.35 \left[1.44, 3.96 \right] \\ 2.35 \left[1.48, 5.29 \right] \\ 2.05 \left[1.9, 2.23 \right] \\ 2.05 \left[1.9, 2.23 \right] \\ 2.12 \left[1.48, 5.29 \right] \\ 2.12 \left[1.48, 5.29 \right] \\ 2.12 \left[1.48, 5.24 \right] \\ 2.12 \left[1.48, 3.04 \right] \\ 1.54 \left[1.10, 2.45 \right] \\ 1.54 \left[1.52, 2.65 \right] \\ 1.77 \left[0.91, 3.44 \right] \\ 6.63 \left[0.38, 11.65 \right] \\ 1.54 \left[1.52, 2.66 \right] \\ 1.77 \left[1.96 \left[1.69, 2.28 \right] \\ 1.39 \left[0.55, 3.55 \right] \\ 2.11 \left[0.93, 4.76 \right] \\ 4.45 \left[1.36, 1.45 \right] \\ 4.18 \left[1.66, 10.49 \right] \end{array}$	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2012 Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011A Garg2011A Garg2011A Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Yulgimigli2007 Wykrzykowska2010 Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2012B	$\begin{array}{c} 96\\ 208\\ 126\\ 126\\ 16\\ 44\\ 80\\ 87\\ 11\\ 14\\ 152\\ 16\\ 113\\ 1223\\ 1221, df=11 (f\\ 2=12.48 (P < (f\\ 2=12.48 (P < (f\\ 113\\ 2=12.48 (P < (f\\ 113\\ 2=12, 12) (P < (f\\ 113\\ 112\\ 112\\ 112\\ 112\\ 112\\ 112\\ 112$	1335 555 132 124 384 460 23 3494 276 203 8415 2 = 0.35); l ² 00001) 496 1335 555 355 355 3494 276 203 3493 3788 444 276 203 3494 276 203 3788 444 276 203 3788 444 276 203 3788 444 276 203 3788 444 276 203 3788 444 276 203 3788 449 276 203 3788 449 276 203 3788 449 276 203 3788 449 276 203 3788 449 276 203 3788 449 203 3788 449 203 3788 449 203 3788 44 203 3788 44 203 3788 44 203 3788 44 203 3788 44 3788 3788 44 3788 3788 44 3788 3788	59 37 1 151 51 23 466 = 10% 11 35 28 11 55 55 8 0 51 194 194 2 6 7 3 5 27	6080 2833 71 435 2099 26 6 52 52 52 53 464 5119 3111 6080 2233 3111 6080 464 454 3809 3111 6080 464 464 4223 3609	6.0% 0.1% 3.0% 2.4% 0.1% 2.4% 0.3% 3.7% 2.4% 0.3% 3.7% 3.4.0% 1.0% 3.5% 3.4.0% 0.5% 0.2% 0.6% 0.7% 0.5%	$\begin{array}{c} 1.84 \left[1.40, 2.42 \right] \\ 1.80 \left[1.28, 2.52 \right] \\ 8.61 \left[1.17, 63.56 \right] \\ 2.00 \left[1.51, 2.63 \right] \\ 1.76 \left[1.29, 2.46 \right] \\ 1.72 \left[1.29, 2.46 \right] \\ 1.72 \left[1.29, 2.46 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.31 \left[1.48, 5.29 \right] \\ 2.12 \left[1.48, 3.04 \right] \\ 2.12 \left[1.48, 3.04 \right] \\ 2.36 \left[1.40, 2.23 \right] \\ 2.36 \left[1.40, 2.24 \right] \\ 2.36 \left[1.40, 2.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.36 \left[1.40, 2.26 \right] \\ 2.36 \left[0.29, 2.67 \right] \\ 1.56 \left[1.62, 2.86 \right] \\ 1.77 \left[0.91, 3.44 \right] \\ 1.54 \left[1.5, 2.07 \right] \\ 1.56 \left[1.40, 2.5.40 \right] \\ 1.59 \left[1.69, 2.28 \right] \\ 2.596 \left[1.40, 2.5.40 \right] \\ 1.59 \left[1.69, 2.28 \right] \\ 3.596 \left[1.40, 2.5.40 \right] \\ 3.58 \left[2.40, 7.26 \right] \\ 3.58 \left$	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Sinning2013 Sintotal (95% CI) Total events Heterogeneity: Chi ² = Test for overail effect: 1.1.5 Repeated revas Garg2011A Garg2011B Garga52011 Heatorganeity: Chi ² = Test for overail effect: 1.1.6 Repeated revas Garg2011A Garg2011B Garg2011B Garg2011B Garg2011C Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overail effect: 1.1.6 Definite or Prob Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011B Garg2011A Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011A Garg2011B Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg201B Garg201B Garg201B Garg201B Garg201B Garg201B Garg201B Garg201B Garg201B G	96 208 126 16 44 80 87 11 344 152 16 113 229 Z = 12.48 (P < Ccularization49494949492 = 12.48 (P < Ccularization587.18, df = 8 (P = C2 = 8.78 (P < 0.387.18, df = 8 (P = C)165881126587.18, df = 8 (P = C)165881126587.18, df = 8 (P = C)165881126587.18, df = 8 (P = C)1658811165881117265877555618811919275755561910101010101010101010101010	1335 555 132 124 384 460 233 3494 276 203 933 8415 0.00001) 496 1335 555 132 460 3494 276 203 933 7884 0.52); [² = (0.0001) 933 7884 0.555 3494 933 312 7725	59 37 1 151 23 1 68 12 3 36 = 10% 11 35 28 28 1 55 8 0 51 194 9% 2 6 7 3 5 5 5 5 5 5 5 8 0 5 1 1 1 1 1 2 3 3 6 2 5 2 8 2 5 2 8 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 5 5 5 5 5 5 5 5 5 5 5 5	6080 2833 71 435 2099 26 6 52 52 52 53 464 5119 3111 6080 2233 3111 6080 464 454 3809 3111 6080 464 464 4223 3609	6.0% 0.1% 3.0% 2.4% 0.1% 2.4% 0.3% 3.7% 2.4% 0.3% 3.7% 3.4.0% 1.0% 3.5% 3.4.0% 0.5% 0.2% 0.6% 0.7% 0.5%	$\begin{array}{c} 1.84 \left[1.40, 2.42 \right] \\ 1.80 \left[1.28, 2.52 \right] \\ 8.61 \left[1.17, 63.56 \right] \\ 2.00 \left[1.51, 2.63 \right] \\ 1.76 \left[1.29, 2.46 \right] \\ 1.72 \left[1.29, 2.46 \right] \\ 1.72 \left[1.29, 2.46 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.31 \left[1.48, 5.29 \right] \\ 2.12 \left[1.48, 3.04 \right] \\ 2.12 \left[1.48, 3.04 \right] \\ 2.36 \left[1.40, 2.23 \right] \\ 2.36 \left[1.40, 2.24 \right] \\ 2.36 \left[1.40, 2.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.36 \left[1.40, 2.26 \right] \\ 2.36 \left[0.29, 2.67 \right] \\ 1.56 \left[1.62, 2.86 \right] \\ 1.77 \left[0.91, 3.44 \right] \\ 1.54 \left[1.5, 2.07 \right] \\ 1.56 \left[1.40, 2.5.40 \right] \\ 1.59 \left[1.69, 2.28 \right] \\ 2.596 \left[1.40, 2.5.40 \right] \\ 1.59 \left[1.69, 2.28 \right] \\ 3.596 \left[1.40, 2.5.40 \right] \\ 3.58 \left[2.40, 7.26 \right] \\ 3.58 \left$	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magro2012 Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011A Garg2011A Garg2011A Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Yubitotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.6 Definite or Prob Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2012B	96 208 125 16 44 80 87 11 14 152 16 113 1223 1221, df = 11 (f 2 = 12.48 (P < (cularization 49 2 = 12.48 (P < (cularization 49 40 2 = 12.48 (P < (cularization 49 40 42 42 42 42 44 44 5.66 (df = 5 (P = (cularization 40 40 40 40 40 40 40 40 40 40 40 40 40	1335 555 132 124 384 460 23 3494 276 203 38415 2 = 0.35); l ² 00001) 496 1335 555 132 460 3494 276 203 3412 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 342 277 277 277 277 277 2777 2777 2777	59 37 1 151 23 1 68 12 3 36 = 10% 11 35 28 28 1 55 8 0 51 194 9% 2 6 7 3 5 5 5 5 5 5 5 8 0 5 1 1 1 1 1 2 3 3 6 2 5 2 8 2 5 2 8 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 5 5 5 5 5 5 5 5 5 5 5 5	6080 2833 71 435 2099 26 6 52 52 52 53 464 5119 3111 6080 2233 3111 6080 464 454 3809 3111 6080 464 464 4223 3609	6.0% 0.1% 3.0% 2.4% 0.1% 2.4% 0.3% 3.7% 2.4% 0.3% 3.7% 3.4.0% 1.0% 3.5% 3.4.0% 0.5% 0.2% 0.6% 0.7% 0.5%	$\begin{array}{c} 1.84 \left[1.40, 2.42 \right] \\ 1.80 \left[1.28, 2.52 \right] \\ 8.61 \left[1.17, 63.56 \right] \\ 2.00 \left[1.51, 2.63 \right] \\ 1.76 \left[1.29, 2.46 \right] \\ 1.72 \left[1.29, 2.46 \right] \\ 1.72 \left[1.29, 2.46 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.31 \left[1.48, 5.29 \right] \\ 2.12 \left[1.48, 3.04 \right] \\ 2.12 \left[1.48, 3.04 \right] \\ 2.36 \left[1.40, 2.23 \right] \\ 2.36 \left[1.40, 2.24 \right] \\ 2.36 \left[1.40, 2.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.36 \left[1.40, 2.26 \right] \\ 2.36 \left[0.29, 2.67 \right] \\ 1.56 \left[1.62, 2.86 \right] \\ 1.77 \left[0.91, 3.44 \right] \\ 1.54 \left[1.5, 2.07 \right] \\ 1.56 \left[1.40, 2.5.40 \right] \\ 1.59 \left[1.69, 2.28 \right] \\ 2.596 \left[1.40, 2.5.40 \right] \\ 1.59 \left[1.69, 2.28 \right] \\ 3.596 \left[1.40, 2.5.40 \right] \\ 3.58 \left[2.40, 7.26 \right] \\ 3.58 \left$	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magro2012 Park2013 Sinning2013 Sinning2013 Sinning2013 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Park2013 Sinning2013 Valgimigil2007 Wykrzykowska2010 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.6 Definite or Prob Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2013 Valgimigil2007 Wykrzykowska2010 Wykr	96 208 125 16 44 80 87 11 14 152 16 113 1223 1221, df = 11 (f 2 = 12.48 (P < (cularization 49 2 = 12.48 (P < (cularization 49 40 2 = 12.48 (P < (cularization 49 40 42 42 42 42 44 44 5.66 (df = 5 (P = (cularization 40 40 40 40 40 40 40 40 40 40 40 40 40	1335 555 132 124 384 460 23 3494 276 203 933 8415 2 = 0.35); l ² 00001) 496 1335 555 132 460 3494 276 203 933 7884 0.52); l ² = (00001) ombosis 496 1335 555 555 3494 496 1335 555 555 3494 496 1335 555 555 3494 496 1335 555 555 3494 496 1335 555 555 3494 496 1335 555 555 3494 496 1335 555 555 555 534 93 312 27125	59 37 1 151 23 1 68 12 3 36 = 10% 11 35 28 28 1 55 8 0 51 194 9% 2 6 7 3 5 5 5 5 5 5 5 8 0 5 1 1 1 1 1 2 3 3 6 2 5 2 8 2 5 2 8 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 5 5 5 5 5 5 5 5 5 5 5 5	608 (200) 711 8493 2090 26 522 1033 464 551 951 9 5119 3111 608 523 5119 3111 608 523 5119 3111 608 523 510 809 464 464 2335 5669	6.0% 3.7% 0.1% 3.0% 2.4% 0.3% 3.7% 2.4% 0.3% 3.7% 3.7% 3.7% 3.4.0% 1.0% 5.2% 20.2% 0.2% 0.5% 0.5% 0.5% 0.5%	$1 \\ \begin{array}{l} 184 (1, 40, 2, 42) \\ 180 (1, 28, 2, 52) \\ 8, 61 (1, 17, 63, 66) \\ 2.00 (1, 51, 2, 63) \\ 1.78 (1, 29, 2, 46) \\ 1.72 (1, 22, 2, 64) \\ 1.73 (1, 29, 2, 46) \\ 2.33 (1, 44, 3, 96) \\ 2.33 (1, 44, 3, 96) \\ 2.33 (1, 44, 3, 96) \\ 2.33 (1, 44, 3, 96) \\ 2.33 (1, 44, 3, 96) \\ 2.33 (1, 44, 3, 96) \\ 2.33 (1, 44, 3, 96) \\ 2.33 (1, 44, 3, 96) \\ 2.33 (1, 44, 3, 96) \\ 2.33 (1, 44, 3, 96) \\ 2.33 (1, 43, 2, 26) \\ 2.33 (1, 43, 2, 26) \\ 2.33 (1, 43, 2, 26) \\ 2.33 (1, 43, 2, 26) \\ 2.33 (1, 43, 2, 26) \\ 2.33 (1, 43, 2, 26) \\ 2.33 (1, 43, 2, 26) \\ 2.33 (1, 43, 2, 26) \\ 2.33 (1, 43, 2, 26) \\ 3.43 (1, 26, 26) \\ 3.44 (1, 26, 26) \\ 3.44 (1, 26, 3, 14, 86) \\ 3.45 (1, 26, 4, 726$	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011B Girasis2011 He2011 Magro2011 Park2013 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.6 Definite or Prob Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2012A Garg2012A Garg2012A Garg2012A Garg2012A Garg2013 Total events Heterogeneity: Chi ² = 1 Test for overall effect: Total overall effect:	$\begin{array}{c} 96\\ 2008\\ 126\\ 126\\ 16\\ 44\\ 80\\ 87\\ 11\\ 1344\\ 152\\ 16\\ 6\\ 113\\ 1223\\ 1221, df = 11 (f\\ 212, 1df = 11 (f\\ 212, 1df = 11 (f\\ 212, 1df = 11 (f\\ 223, 1df = 11 (f\\ 223, 1df = 11 (f\\ 134, 1df = 11 (f\\ 122, 1df = 11 (f_{1}), 1df$	1335 555 132 124 384 460 23 3494 276 203 38415 2 = 0.35); l ² 00001) 496 1335 555 132 460 3494 276 203 3412 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 344 276 203 342 277 277 277 277 277 2777 2777 2777	59 37 1 151 23 1 68 12 3 36 = 10% 11 35 28 28 1 55 8 0 51 194 9% 2 6 7 3 5 5 5 5 5 5 5 8 0 5 1 1 1 1 1 2 3 3 6 2 5 2 8 2 5 2 8 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 2 5 5 5 5 5 5 5 5 5 5 5 5 5	608 (200) 711 8493 2090 26 522 1033 464 551 951 9 5119 3111 608 523 5119 3111 608 523 5119 3111 608 523 510 809 464 464 2335 5669	6.0% 0.1% 3.0% 2.4% 0.1% 2.4% 0.3% 3.7% 2.4% 0.3% 3.7% 3.4.0% 1.0% 3.5% 3.4.0% 0.5% 0.2% 0.6% 0.7% 0.5%	$\begin{array}{c} 1.84 \left[1.40, 2.42 \right] \\ 1.80 \left[1.28, 2.52 \right] \\ 8.61 \left[1.17, 63.56 \right] \\ 2.00 \left[1.51, 2.63 \right] \\ 1.76 \left[1.29, 2.46 \right] \\ 1.72 \left[1.29, 2.46 \right] \\ 1.72 \left[1.29, 2.46 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.33 \left[1.44, 3.96 \right] \\ 2.31 \left[1.48, 5.29 \right] \\ 2.12 \left[1.48, 3.04 \right] \\ 2.12 \left[1.48, 3.04 \right] \\ 2.36 \left[1.40, 2.23 \right] \\ 2.36 \left[1.40, 2.24 \right] \\ 2.36 \left[1.40, 2.24 \right] \\ 1.56 \left[1.09, 2.23 \right] \\ 2.36 \left[1.40, 2.26 \right] \\ 2.36 \left[0.29, 2.67 \right] \\ 1.56 \left[1.62, 2.86 \right] \\ 1.77 \left[0.91, 3.44 \right] \\ 1.54 \left[1.5, 2.07 \right] \\ 1.56 \left[1.40, 2.5.40 \right] \\ 1.59 \left[1.69, 2.28 \right] \\ 2.596 \left[1.40, 2.5.40 \right] \\ 1.59 \left[1.69, 2.28 \right] \\ 3.596 \left[1.40, 2.5.40 \right] \\ 3.58 \left[2.40, 7.26 \right] \\ 3.58 \left$	
Garg2011A Garg2011B Garg2011B Garg2011B He2011 Ikeno2017 Kim2010 Magro2013 Sinning2013 Sinning2013 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011A Garg2011A Garg2011A Garg2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.5 Definite or Prob Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2015 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: <	96 208 126 16 44 80 87 11 142 1293 1221, df = 11 (f 2 = 12.48 (P < (c cularization (P < 0. 49 11 26 257 75 6 158 8111 26 871 158 811 7.18, df = 6 (P < 0. able Stent Thro 19 16 28 29 42 42 42 42 42 42 42 44 5.66, df = 5 (P = 0. 40 28 28 28 28 28 28 28 28 28 28	1335 555 132 124 384 460 23 3494 276 203 8415 2 = 0.35); l ² 00001) 496 1335 555 132 460 3494 276 203 3494 276 203 3494 276 203 3494 400 1335 555 555 3494 496 1335 555 555 3494 496 1335 555 555 3494 496 1335 555 555 3494 496 1335 555 555 3494 496 1335 555 555 534 24 933 312 7125	59 37 1 151 23 1 68 12 3 68 12 3 66 11 35 28 10 55 8 0 51 194 2 6 7 3 5 27 104 2 2 6 5 27 1 1 1 1 1 1 1 1 1 1 1 1 1	608 (200) 711 8493 2090 26 522 1033 464 551 951 9 5119 3111 608 523 5119 3111 608 523 5119 3111 608 523 510 809 464 464 2335 5669	6.0% 3.7% 0.1% 3.0% 2.4% 0.3% 3.7% 2.4% 0.3% 3.7% 3.7% 3.7% 3.4.0% 1.0% 5.2% 20.2% 0.2% 0.5% 0.5% 0.5% 0.5%	$1 \\ \begin{array}{l} 184 (1, 40, 2, 42) \\ 180 (1, 28, 2, 52) \\ 8, 61 (1, 17, 63, 66) \\ 200 (1, 51, 2, 63) \\ 1, 78 (1, 29, 2, 46) \\ 1, 72 (1, 12, 2, 64) \\ 2, 33 (1, 41, 300) \\ 2, 33 (1, 44, 3, 96) \\ 2, 33 (1, 44, 3, 96) \\ 2, 71 (0, 81, 9, 08) \\ 1, 55 (1, 09, 2, 23) \\ 2, 12 (1, 48, 3, 64) \\ 1, 55 (1, 09, 2, 23) \\ 2, 12 (1, 48, 3, 64) \\ 2, 12 (1, 48, 3, 64) \\ 1, 55 (1, 09, 2, 23) \\ 1, 10, 2, 25 \\ 2, 10 (2, 1, 26) \\ 1, 10, 2, 45 \\ 1, 10, 2, 10, 2, 10 \\ 1, 10, 2, 10, 2, 10 \\ 1, 10, 2, 10, 2, 10 \\ 1, 10, 2, 10, 2, 10, 2, 10, 2, 10, 2, 10, 2, 10, 2, 10, 10, 10, 10, 10, 10, 10, 10, 10, 1$	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.5 Repeated revas Garg2011A Garg2011B Girasis2011 He2011 Magro2011 Park2013 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.1.6 Definite or Prob Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2012A Garg2012A Garg2012A Garg2012A Garg2012A Garg2013 Total events Heterogeneity: Chi ² = 1 Test for overall effect: Total overall effect:	96 208 126 16 44 80 87 11 142 1293 1221, df = 11 (f 2 = 12.48 (P < (c cularizative (P < c) 6 13 2 = 12.48 (P < (c cularizative (P < c) 8 811 2 = 6, 78 (P < 0. able Stent Thro 19 16 28 29 42 42 42 42 44 148 5.66, df = 5 (P = 2. 4050	1335 555 132 124 384 460 23 3494 276 203 8415 2 = 0.35); l ² 00001) 496 1335 555 132 460 3494 276 203 3494 276 203 3494 276 203 3494 400 1335 555 555 3494 496 1335 555 555 3494 496 1335 555 555 3494 496 1335 555 555 3494 496 1335 555 555 3494 496 1335 555 555 534 24 933 312 7125	59 37 1 151 23 1 68 12 3 68 12 3 66 11 35 28 10 55 8 0 51 194 2 6 7 3 5 27 104 2 2 6 5 27 1 1 1 1 1 1 1 1 1 1 1 1 1	608 (200) 711 8493 2090 26 522 1033 464 551 951 9 5119 3111 608 523 5119 3111 608 523 5119 3111 608 523 510 809 464 464 2335 5669	6.0% 3.7% 0.1% 3.0% 2.4% 0.3% 3.7% 2.4% 0.3% 3.7% 3.7% 3.7% 3.4.0% 1.0% 5.2% 20.2% 0.2% 0.5% 0.5% 0.5% 0.5%	$1 \\ \begin{array}{l} 184 (1, 40, 2, 42) \\ 180 (1, 28, 2, 52) \\ 8, 61 (1, 17, 63, 66) \\ 200 (1, 51, 2, 63) \\ 1, 78 (1, 29, 2, 46) \\ 1, 72 (1, 12, 2, 64) \\ 2, 33 (1, 41, 300) \\ 2, 33 (1, 44, 3, 96) \\ 2, 33 (1, 44, 3, 96) \\ 2, 71 (0, 81, 9, 08) \\ 1, 55 (1, 09, 2, 23) \\ 2, 12 (1, 48, 3, 64) \\ 1, 55 (1, 09, 2, 23) \\ 2, 12 (1, 48, 3, 64) \\ 2, 12 (1, 48, 3, 64) \\ 1, 55 (1, 09, 2, 23) \\ 1, 10, 2, 25 \\ 2, 10 (2, 1, 26) \\ 1, 10, 2, 45 \\ 1, 10, 2, 10, 2, 10 \\ 1, 10, 2, 10, 2, 10 \\ 1, 10, 2, 10, 2, 10 \\ 1, 10, 2, 10, 2, 10, 2, 10, 2, 10, 2, 10, 2, 10, 2, 10, 10, 10, 10, 10, 10, 10, 10, 10, 1$	

Figure 2. Postinterventional adverse cardiovascular outcomes which were observed between a low versus a higher (tertiles II and III) SYNTAX score.

3.4.1. Low SYNTAX score versus higher SYNTAX score (tertile II+III). First of all, after PCI, adverse cardiovascular outcomes associated with a low SYNTAX score was compared with adverse outcomes associated with a higher SYNTAX score (tertile II+III).

The current results showed mortality to be significantly higher with the higher SYNTAX score (RR 2.09, 95% CI 1.78-2.46, P=.00001, as shown in Fig. 2). Cardiac death also

significantly favored a low SYNTAX score (RR 2.08, 95% CI 1.66–2.61, P=.00001). Similarly, MI, MACEs, repeated revascularization, and stent thrombosis were significantly higher with a high SYNTAX score (RR 1.71, 95% CI 1.45–2.03, P=.00001; RR 2.03, 95% CI 1.81–2.26, P=.00001; RR 1.96, 95% CI 1.69–2.28, P=.00001; and RR 3.16, 95% CI 2.17–4.59, P=.00001, respectively, as shown in Fig. 2).

It should be noted that while carrying out this analysis, data which were obtained from observational studies were combined with data which were obtained from randomized controlled trials. Therefore, another analysis was separately carried out involving only data which were obtained from randomized trials to observe any change in the results. However, similar to the previous results, this separate analysis also showed that significantly higher mortality, cardiac death, MI, MACEs, repeated revascularization, and stent thrombosis were observed with a high SYNTAX score (RR 1.69, 95% CI 1.23–2.32, P=.001; RR 1.75, 95% CI 0.99–3.10, P=.05; RR 1.89, 95% CI 1.51–2.37, P=.00001; RR 1.88, 95% CI 1.63–2.18, P=.00001; RR 1.83, 95% CI 1.63–2.18, P=.00001; RR 1.83, 95% CI 1.51–2.21, P=.00001; and RR 2.99, 95% CI 2.02–4.43, P=.00001, respectively, as shown in Fig. 3).

01 1 0 .	High SYNTA)		ow SYNTA		147.1.1.1	Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% Cl
1.1.1 Mortality							
Garg2011A	34	496	10	311	1.9%	2.13 [1.07, 4.25]	
Garg2011B	25	1335	13	698	2.7%	1.01 [0.52, 1.95]	
Girasis2011	55	555	18	293	3.7%	1.61 [0.97, 2.69]	
Wykrzykowska2010	36	933	7	464	1.5%	2.56 [1.15, 5.70]	
Subtotal (95% CI)		3319		1766	9.8%	1.69 [1.23, 2.32]	◆
Total events	150		48				
Heterogeneity: Chi ² = 3. Test for overall effect: Z			22%				
1.1.2 Cardiac death							
Garg2011B	17	1335	7	698	1.4%	1.27 [0.53, 3.05]	
Girasis2011	33	555	8	293	1.6%	2.18 [1.02, 4.65]	
Subtotal (95% CI)		1890		991	3.1%	1.75 [0.99, 3.10]	◆
Total events	50		15				
Heterogeneity: Chi ² = 0. Test for overall effect: Z)%				
1.1.3 Myocardial Infard							
Garg2011A	22	496	4	311	0.8%	3.45 [1.20, 9.91]	
Garg2011B	202	1335	56	698	11.5%	1.89 [1.42, 2.50]	-
Girasis2011	47	555	9	293	1.8%	2.76 [1.37, 5.55]	
Wykrzykowska2010 Subtotal (95% CI)	50	933 3319	20	464 1766	4.2% 18.3%	1.24 [0.75, 2.06] 1.89 [1.51, 2.37]	↓
Total events Heterogeneity: Chi ² = 5. Test for overall effect: Z			89 10%				
1.1.4 Major adverse ca	rdiac events						
Garg2011A	96	496	24	311	4.6%	2.51 [1.64, 3.83]	
Garg2011B	208	1335	59	698	12.2%	1.84 [1.40, 2.42]	
Girasis2011	126	555	37	293	7.6%	1.80 [1.28, 2.52]	
Ikeno2017	44	124	151	849	6.0%	2.00 [1.51, 2.63]	-
Wykrzykowska2010	113	933	36	464	7.5%	1.56 [1.09, 2.23]	
Subtotal (95% CI)		3443		2615	37.9%	1.88 [1.63, 2.18]	•
Total events	587		307				
Heterogeneity: Chi ² = 3. Test for overall effect: Z)%				
1.1.5 Repeated revasc	ularization						
Garg2011A	49	496	11	311	2.1%	2.79 [1.48, 5.29]	—
Garg2011B	142	1335	35	698	7.2%	2.12 [1.48, 3.04]	· · · ·
Girasis2011	87	555	28	293	5.7%	1.64 [1.10, 2.45]	
Wykrzykowska2010	158	933	51	464	10.7%	1.54 [1.15, 2.07]	
Subtotal (95% CI)		3319		1766	25.8%	1.83 [1.51, 2.21]	•
Total events Heterogeneity: Chi ² = 3.	436 .92, df = 3 (P =	0.27); l ² = 2	125 24%				
Test for overall effect: Z	= 6.26 (P < 0.0	00001)					
1.1.6 Definite or Proba	ble Stent Thro	ombosis					
Garg2011A	19	496	2	311	0.4%	5.96 [1.40, 25.40]	———
Garg2011B	16	1335	6	698	1.2%	1.39 [0.55, 3.55]	- -
Girasis2011	28	555	7	293	1.4%	2.11 [0.93, 4.78]	<u>├</u>
Wykrzykowska2010	42	933	5	464	1.0%	4.18 [1.66, 10.49]	—
Yadav2015	14	312	27	2315	1.0%	3.85 [2.04, 7.26]	
Subtotal (95% CI)		3631		4081	5.1%	2.99 [2.02, 4.43]	•
Total events	119		47			•	
Heterogeneity: Chi ² = 5. Test for overall effect: Z	.24, df = 4 (P =						
Total (95% CI)		18921		12985	100.0%	1.90 [1.73, 2.09]	♦
Total events	1663		631			-	
	8.24, df = 23 (F	P = 0.21): I ²					
neterogeneity. Chi – Zo							0.01 0.1 1 10 100

Figure 3. Postinterventional adverse cardiovascular outcomes which were observed between a low versus a higher (tertiles II and III) SYNTAX score using data which were obtained only from randomized controlled trials.

3.4.2. Low SYNTAX score versus higher SYNTAX score (tertile II+III) with specific limits/ranges of score. The score range was completely omitted in the above-shown analysis. A low SYNTAX score with any range was compared with the corresponding higher score. However, the analysis was further divided into several subsets with different score limits.

When the adverse outcomes were compared in patients who were allotted a low SYNTAX score of ≤ 10 versus a higher score,

significantly higher mortality, MI, MACEs, repeated revascularization, and stent thrombosis were still associated with the higher score (RR 1.78, 95% CI 1.50–2.12, *P*=.00001; RR 1.96, 95% CI 1.57–2.43, *P*=.00001; RR 1.98, 95% CI 1.73–2.26, *P*=.00001; RR 1.94, 95% CI 1.66–2.27, *P*=.00001; and RR 3.01, 95% CI 1.94–4.67, *P*=.00001, respectively, as shown in Fig. 4).

When a lower SYNTAX score 10 > SYNTAX score ≤ 20 was considered as the lower score range, mortality, MI and MACEs

	High SYNTA	X Score	Low SYNTA	(Score		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
1.2.1 Mortality							
Akgun2014	311	2174	73	819	11.3%	1.60 [1.26, 2.04]	-
Garg2011A	34	496	10	371	1.2%	2.54 [1.27, 5.08]	
Garg2011B	25	1335	13	698	1.8%	1.01 [0.52, 1.95]	
Girasis2011	55	555	18	293	2.5%	1.61 [0.97, 2.69]	—
Magro2011	63	460	18	209	2.6%	1.59 [0.97, 2.62]	—
Park2013	82	3494	11	1608	1.6%	3.43 [1.83, 6.42]	
Wykrzykowska2010	36	933	7	464	1.0%	2.56 [1.15, 5.70]	
Subtotal (95% CI)		9447		4462	22.1%	1.78 [1.50, 2.12]	•
Total events	606		150				
Heterogeneity: Chi ² = 9 Test for overall effect: Z			39%				
1.2.2 Myocardial Infar	ction						
Garg2011A	22	496	4	311	0.5%	3.45 [1.20, 9.91]	
Garg2011B	202	1335	56	698	7.9%	1.89 [1.42, 2.50]	-
Girasis2011	47	555	9	293	1.3%	2.76 [1.37, 5.55]	
Magro2011	12	460	3	209	0.4%	1.82 [0.52, 6.37]	- <u> </u>
Park2013	21	3494	2	1608	0.3%	4.83 [1.13, 20.58]	
Wykrzykowska2010 Subtotal (95% CI)	50	933 7273	20	464 3583	2.9% 13.2%	1.24 [0.75, 2.06] 1.96 [1.57, 2.43]	•
Total events	354		94				
Heterogeneity: Chi ² = 6 Test for overall effect: Z			25%				
1.2.3 Major Adverse C	ardiac Events						
Garg2011A	96	496	24	311	3.2%	2.51 [1.64, 3.83]	
Garg2011B	208	1335	59	698	8.3%	1.84 [1.40, 2.42]	-
Girasis2011	126	555	37	293	5.2%	1.80 [1.28, 2.52]	
Magro2011	87	460	23	209	3.4%	1.72 [1.12, 2.64]	
Park2013	344	3494	68	1608	9.9%	2.33 [1.81, 3.00]	-
Wykrzykowska2010	113	933	36	464	5.1%	1.56 [1.09, 2.23]	
Subtotal (95% CI)		7273		3583	35.1%	1.98 [1.73, 2.26]	♦
Total events Heterogeneity: Chi ² = 5	974 45 df - 5 (P -	: 0.36); l ² = 8	247 3%				
Test for overall effect: Z		0.00001)					
	Z = 10.06 (P < 0	0.00001)					
Test for overall effect: Z	Z = 10.06 (P < 0	0.00001) 496	11	311	1.4%	2.79 [1.48, 5.29]	
Test for overall effect: Z	Z = 10.06 (P < 0		11 35	311 698	1.4% 4.9%	2.79 [1.48, 5.29] 2.12 [1.48, 3.04]	=
Test for overall effect: Z 1.2.4 Repeated Revas Garg2011A	Z = 10.06 (P < 0 cularization 49	496					
Test for overall effect: Z 1.2.4 Repeated Revase Garg2011A Garg2011B	Z = 10.06 (P < 0 cularization 49 142	496 1335	35	698	4.9%	2.12 [1.48, 3.04]	
Test for overall effect: Z 1.2.4 Repeated Revase Garg2011A Garg2011B Girasis2011	z = 10.06 (P < 0 cularization 49 142 87	496 1335 555	35 28	698 293	4.9% 3.9%	2.12 [1.48, 3.04] 1.64 [1.10, 2.45]	
Test for overall effect: Z 1.2.4 Repeated Revase Garg2011A Garg2011B Girasis2011 Magro2011	Z = 10.06 (P < 0 cularization 49 142 87 26	496 1335 555 460 3494 933	35 28 5	698 293 209 1608 464	4.9% 3.9% 0.7%	2.12 [1.48, 3.04] 1.64 [1.10, 2.45] 2.36 [0.92, 6.07]	
Test for overall effect: Z 1.2.4 Repeated Revase Garg2011A Garg2011B Girasis2011 Magro2011 Park2013	Z = 10.06 (P < 0 cularization 49 142 87 26 257	496 1335 555 460 3494	35 28 5 55	698 293 209 1608	4.9% 3.9% 0.7% 8.0%	2.12 [1.48, 3.04] 1.64 [1.10, 2.45] 2.36 [0.92, 6.07] 2.15 [1.62, 2.86]	
Test for overall effect: Z 1.2.4 Repeated Revas Garg2011A Garg2011B Girasis2011 Magro2011 Park2013 Wykrzykowska2010	Z = 10.06 (P < 0 cularization 49 142 87 26 257	496 1335 555 460 3494 933	35 28 5 55	698 293 209 1608 464	4.9% 3.9% 0.7% 8.0% 7.3%	2.12 [1.48, 3.04] 1.64 [1.10, 2.45] 2.36 [0.92, 6.07] 2.15 [1.62, 2.86] 1.54 [1.15, 2.07]	
Test for overall effect: Z 1.2.4 Repeated Revase Garg2011A Garg2011B Girasis2011 Magro2011 Park2013 Wykrzykowska2010 Subtotal (95% CI)	z = 10.06 (P < (cularization 49 142 87 26 257 158 719 .17, df = 5 (P =	496 1335 555 460 3494 933 7273 0.40); ² = 3	35 28 55 51 185	698 293 209 1608 464	4.9% 3.9% 0.7% 8.0% 7.3%	2.12 [1.48, 3.04] 1.64 [1.10, 2.45] 2.36 [0.92, 6.07] 2.15 [1.62, 2.86] 1.54 [1.15, 2.07]	
Test for overall effect: 2 1.2.4 Repeated Revas: Garg2011A Garg2011B Girasis2011 Magro2011 Park2013 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5 Test for overall effect: 2 1.2.5 Stent Thrombosi	z = 10.06 (P < (cularization 49 142 87 26 257 158 719 1.17, df = 5 (P = z = 8.36 (P < 0.	496 1335 555 460 3494 933 7273 0.40); ² = 3	35 28 55 51 185	698 293 209 1608 464	4.9% 3.9% 0.7% 8.0% 7.3%	2.12 [1.48, 3.04] 1.64 [1.10, 2.45] 2.36 [0.92, 6.07] 2.15 [1.62, 2.86] 1.54 [1.15, 2.07]	
Test for overall effect: Z 1.2.4 Repeated Revas: Garg2011A Garg2011B Girasis2011 Magro2011 Park2013 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5 Test for overall effect: Z 1.2.5 Stent Thrombosi Garg2011A	z = 10.06 (P < (cularization 49 142 87 26 257 158 719 .17, df = 5 (P = z = 8.36 (P < 0. is 19	496 1335 555 460 3494 933 7273 0.040); l ² = 3 00001) 496	35 28 5 55 51 185 3% 2	698 293 209 1608 464 3583 311	4.9% 3.9% 0.7% 8.0% 7.3% 26.3%	2.12 [1.48, 3.04] 1.64 [1.10, 2.45] 2.36 [0.92, 6.07] 2.15 [1.62, 2.86] 1.54 [1.15, 2.07] 1.94 [1.66, 2.27]	
Test for overall effect: Z 1.2.4 Repeated Revas: Garg2011A Garg2011B Girasis2011 Magro2011 Park2013 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5 Test for overall effect: Z 1.2.5 Stent Thrombosi Garg2011A Garg2011B	z = 10.06 (P < 0 cularization 49 142 87 26 257 158 719 17, df = 5 (P = 2 z = 8.36 (P < 0. is 19 16	496 1335 555 460 3494 933 7273 * 0.40); l ² = 3 00001) 496 1335	35 28 5 55 51 185 3% 2 6	698 293 209 1608 464 3583 311 698	4.9% 3.9% 0.7% 8.0% 7.3% 26.3% 0.3% 0.8%	2.12 [1.48, 3.04] 1.64 [1.10, 2.45] 2.36 [0.92, 6.07] 2.15 [1.62, 2.86] 1.54 [1.15, 2.07] 1.94 [1.66, 2.27] 5.96 [1.40, 25.40] 1.39 [0.55, 3.55]	
Test for overall effect: Z 1.2.4 Repeated Revas: Garg2011A Girasis2011 Magro2011 Park2013 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5 Test for overall effect: Z 1.2.5 Stent Thrombosi Garg2011A Garg2011B Girasis2011	z = 10.06 (P < (cularization 49 142 87 26 257 158 719 .17, df = 5 (P = z = 8.36 (P < 0. is 19 16 28	496 1335 555 460 3494 933 7273 7273 00001); l ² = 3 00001) 496 1335 555	35 28 5 55 51 185 3% 2 6 7	698 293 209 1608 464 3583 311 698 293	4.9% 3.9% 0.7% 8.0% 7.3% 26.3% 0.3% 0.8% 1.0%	2.12 [1.48, 3.04] 1.64 [1.10, 2.45] 2.36 [0.92, 6.07] 2.15 [1.62, 2.86] 1.54 [1.15, 2.07] 1.94 [1.66, 2.27] 5.96 [1.40, 25.40] 1.39 [0.55, 3.55] 2.11 [0.93, 4.78]	
Test for overall effect: Z 1.2.4 Repeated Revas : Garg2011A Garg2011B Girasis2011 Magro2011 Park2013 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5 Test for overall effect: Z 1.2.5 Stent Thrombosi Garg2011A Garg2011B Girasis2011 Park2013	z = 10.06 (P < 0 cularization 49 142 87 26 257 158 719 17, df = 5 (P = 0 z = 8.36 (P < 0. 19 16 28 29	496 1335 555 460 3494 933 7273 0.40); l ² = 3 00001) 496 1335 555 3494	35 28 5 55 51 185 3% 2 6 7 3	698 293 209 1608 464 3583 311 698 293 1608	4.9% 3.9% 0.7% 8.0% 7.3% 26.3% 0.3% 0.8% 1.0% 0.4%	2.12 [1.48, 3.04] 1.64 [1.10, 2.45] 2.36 [0.92, 6.07] 2.15 [1.62, 2.86] 1.54 [1.15, 2.07] 1.94 [1.66, 2.27] 5.96 [1.40, 25.40] 1.39 [0.55, 3.55] 2.11 [0.93, 4.78] 4.45 [1.36, 14.58]	
Test for overall effect: 2 1.2.4 Repeated Revas : Garg2011A Girasis2011 Magro2011 Park2013 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5 Test for overall effect: 2 1.2.5 Stent Thrombosi Garg2011A Garg2011B Girasis2011	z = 10.06 (P < (cularization 49 142 87 26 257 158 719 .17, df = 5 (P = z = 8.36 (P < 0. is 19 16 28	496 1335 555 460 3494 933 7273 7273 00001); l ² = 3 00001) 496 1335 555	35 28 5 55 51 185 3% 2 6 7	698 293 209 1608 464 3583 311 698 293	4.9% 3.9% 0.7% 8.0% 7.3% 26.3% 0.3% 0.8% 1.0%	2.12 [1.48, 3.04] 1.64 [1.10, 2.45] 2.36 [0.92, 6.07] 2.15 [1.62, 2.86] 1.54 [1.15, 2.07] 1.94 [1.66, 2.27] 5.96 [1.40, 25.40] 1.39 [0.55, 3.55] 2.11 [0.93, 4.78]	
Test for overall effect: 2 1.2.4 Repeated Revas: Garg2011A Garg2011B Girasis2011 Park2013 Wykrzykowska2010 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = 5 Test for overall effect: 2 1.2.5 Stent Thrombosi Garg2011A Garg2011B Girasis2011 Park2013 Wykrzykowska2010	z = 10.06 (P < 0 cularization 49 142 87 26 257 158 719 17, df = 5 (P = 0 z = 8.36 (P < 0. 19 16 28 29	496 1335 555 460 3494 933 7273 0.40); l ² = 3 00001) 496 1335 555 3494 933	35 28 5 55 51 185 3% 2 6 7 3	698 293 209 1608 464 3583 311 698 293 1608 464	4.9% 3.9% 0.7% 8.0% 7.3% 26.3% 0.3% 0.8% 1.0% 0.4% 0.7%	2.12 [1.48, 3.04] 1.64 [1.10, 2.45] 2.36 [0.92, 6.07] 2.15 [1.62, 2.86] 1.54 [1.15, 2.07] 1.94 [1.66, 2.27] 5.96 [1.40, 25.40] 1.39 [0.55, 3.55] 2.11 [0.93, 4.78] 4.45 [1.36, 14.58] 4.18 [1.66, 10.49]	
Test for overall effect: 2 1.2.4 Repeated Revas: Garg2011A Garg2011B Girasis2011 Magro2011 Park2013 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5 Test for overall effect: 2 1.2.5 Stent Thrombosi Garg2011A Garg2011B Girasis2011 Park2013 Wykrzykowska2010 Subtotal (95% CI)	z = 10.06 (P < (cularization 49 142 87 26 257 158 719 .17, df = 5 (P = z = 8.36 (P < 0. is 19 16 28 29 42 134 .09, df = 4 (P =	496 1335 555 460 3494 933 7273 00001); l ² = 3 00001) 496 1335 555 3494 933 6813	35 28 5 55 51 185 3% 2 6 7 3 5 23	698 293 209 1608 464 3583 311 698 293 1608 464	4.9% 3.9% 0.7% 8.0% 7.3% 26.3% 0.3% 0.8% 1.0% 0.4% 0.7%	2.12 [1.48, 3.04] 1.64 [1.10, 2.45] 2.36 [0.92, 6.07] 2.15 [1.62, 2.86] 1.54 [1.15, 2.07] 1.94 [1.66, 2.27] 5.96 [1.40, 25.40] 1.39 [0.55, 3.55] 2.11 [0.93, 4.78] 4.45 [1.36, 14.58] 4.18 [1.66, 10.49]	
Test for overall effect: 2 1.2.4 Repeated Revas: Garg2011A Garg2011B Girasis2011 Park2013 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5 Test for overall effect: 2 1.2.5 Stent Thrombosi Garg2011A Garg2011B Girasis2011 Park2013 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5 Test for overall effect: 2	z = 10.06 (P < (cularization 49 142 87 26 257 158 719 .17, df = 5 (P = z = 8.36 (P < 0. is 19 16 28 29 42 134 .09, df = 4 (P =	496 1335 555 460 3494 933 7273 00001); l ² = 3 00001) 496 1335 555 3494 933 6813	35 28 5 55 51 185 3% 2 6 7 3 5 23	698 293 209 1608 464 3583 3111 698 293 1608 464 337 4	4.9% 3.9% 0.7% 8.0% 7.3% 26.3% 0.3% 0.8% 1.0% 0.4% 0.7%	2.12 [1.48, 3.04] 1.64 [1.10, 2.45] 2.36 [0.92, 6.07] 2.15 [1.62, 2.86] 1.54 [1.15, 2.07] 1.94 [1.66, 2.27] 5.96 [1.40, 25.40] 1.39 [0.55, 3.55] 2.11 [0.93, 4.78] 4.45 [1.36, 14.58] 4.18 [1.66, 10.49] 3.01 [1.94, 4.67]	
Test for overall effect: 2 1.2.4 Repeated Revas Garg2011A Garg2011B Girasis2011 Magro2011 Park2013 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5 Test for overall effect: 2 1.2.5 Stent Thrombosi Garg2011A Garg2011B Girasis2011 Park2013 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 5	z = 10.06 (P < (cularization 49 142 87 26 257 158 719 .17, df = 5 (P = z = 8.36 (P < 0. is 19 16 28 29 42 134 .09, df = 4 (P =	496 1335 555 460 3494 933 7273 00001); l ² = 3 00001) 496 1335 555 3494 933 6813 0.28); l ² = 3	35 28 5 55 51 185 3% 2 6 7 3 5 23	698 293 209 1608 464 3583 3111 698 293 1608 464 337 4	4.9% 3.9% 0.7% 8.0% 7.3% 26.3% 0.3% 0.8% 1.0% 0.4% 0.4% 0.7% 3.2%	2.12 [1.48, 3.04] 1.64 [1.10, 2.45] 2.36 [0.92, 6.07] 2.15 [1.62, 2.86] 1.54 [1.15, 2.07] 1.94 [1.66, 2.27] 5.96 [1.40, 25.40] 1.39 [0.55, 3.55] 2.11 [0.93, 4.78] 4.45 [1.36, 14.58] 4.18 [1.66, 10.49]	

Figure 4. Postinterventional adverse cardiovascular outcomes which were observed between a low (SS < 10) versus a higher (tertiles II and III) SYNTAX score.

	High SYNTA	X Score	Low SYNTA	X Score		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI
1.3.1 Mortality							
Akgun2014	303	1459	151	1534	15.7%	2.11 [1.76, 2.53]	+
Garg2011A	24	262	20	545	1.4%	2.50 [1.40, 4.44]	
Garg2011B	18	659	20	1374	1.4%	1.88 [1.00, 3.52]	———
Girasis2011	32	268	42	580	2.8%	1.65 [1.07, 2.55]	
Magro2011	39	223	42	446	3.0%	1.86 [1.24, 2.78]	
Park2013	48	633	45	1422	3.0%	2.40 [1.61, 3.56]	
Valgimigli2007	0	203	0	103		Not estimable	
Wykrzykowska2010 Subtotal (95% CI)	26	461 4168	17	936 6940	1.2% 28.5%	3.11 [1.70, 5.66] 2.12 [1.85, 2.42]	→
Total events	490		337			. / .	
Heterogeneity: Chi ² = 4		$(0.67) \cdot 1^2 =$					
Test for overall effect: 2			0,0				
1.3.2 Myocardial Infar	ction						
Akgun2014	161	1459	110	1534	11.5%	1.54 [1.22, 1.94]	
Garg2011A	16	262	10	545	0.7%	3.33 [1.53, 7.23]	
Garg2011B	120	659	138	1374	9.6%	1.81 [1.45, 2.27]	+
Girasis2011	22	268	34	580	2.3%	1.40 [0.84, 2.35]	+
Magro2011	8	223	7	446	0.5%	2.29 [0.84, 6.22]	+
Park2013	12	633	11	1422	0.7%	2.45 [1.09, 5.52]	
Valgimigli2007	4	203	0	103	0.1%	4.59 [0.25, 84.41]	
Wykrzykowska2010	27	461	43	936	3.0%	1.27 [0.80, 2.04]	+
Subtotal (95% CI)		4168		6940	28.3%	1.68 [1.46, 1.93]	♦
Total events	370		353				
Heterogeneity: Chi ² = 7	.43, df = 7 (P =	0.39); l ² =	6%				
Test for overall effect: 2	Z = 7.26 (P < 0.	00001)					
1.3.3 Major Adverse C	ardiac Events						
Garg2011A	65	262	55	545	3.8%	2.46 [1.77, 3.41]	
Garg2011B	132	659	135	1374	9.3%	2.04 [1.63, 2.54]	+
Girasis2011	65	268	97	580	6.5%	1.45 [1.10, 1.92]	
Magro2011	57	223	53	446	3.8%	2.15 [1.53, 3.01]	
Park2013	202	633	210	1422	13.8%	2.16 [1.82, 2.56]	+
Valgimigli2007	16	203	3	103	0.4%	2.71 [0.81, 9.08]	+
Wykrzykowska2010	71	461	78	936	5.5%	1.85 [1.37, 2.50]	
Subtotal (95% CI)		2709	-	5406	43.2%	2.02 [1.82, 2.23]	♦
Total events	608		631			•	
Heterogeneity: Chi ² = 8	.12, df = 6 (P =	0.23); l ² =	26%				
Test for overall effect: 2		,.					
Total (95% CI)		11045		19286	100.0%	1.95 [1.82, 2.09]	•
Total events	1468		1321				
Heterogeneity: Chi ² = 2		P = 0.22): I					
Test for overall effect: 2							0.01 0.1 1 10 100
	•	,	$(P = 0.04), I^2$				Favours [High SS] Favours [Low SS]

Figure 5. Postinterventional adverse cardiovascular outcomes which were observed between a low ($10 > SS \le 20$) versus a higher (tertiles II and III) SYNTAX score. SS = SYNTAX score.

still significantly favored the lower score (RR 2.12, 95% CI 1.85–2.42, P=.00001; RR 1.68, 95% CI 1.46–1.93, P=.00001; and RR 2.02, 95% CI 1.82–2.23, P=.00001, respectively, as shown in Fig. 5). In addition, repeated revascularization and stent thrombosis were also significantly in favor of a lower SYNTAX score (RR 2.03, 95% CI 1.57–2.64, P=.00001 and RR 2.56, 95% CI 1.46–4.48, P=.001, respectively, as shown in Fig. 6).

When a score range 20 > SYNTAX score < 30 was considered for a low SYNTAX score, mortality, MI, MACEs, and repeated revascularization were still significantly higher (RR 6.74, 95% CI 1.28–35.33, P=.02; RR 2.63, 95% CI 1.42–4.85, P=.002; RR 2.18, 95% CI 1.80–2.65, P=.00001; and RR 2.50, 95% CI 1.39–4.49, P=.002, respectively, as shown in Fig. 7).

When a score range 30 > SYNTAX score < 40 was considered in the lower SYNTAX range, mortality and MI were still significantly higher with a high SYNTAX score (RR 3.34, 95% CI 2.26–4.93, P=.00001 and RR 2.03, 95% CI 1.06–3.89, P=.03, respectively; Fig. 8). In addition, MACEs were also significantly higher with a high SYNTAX score (RR 1.72, 95% CI 1.07–2.77, P=.02; Fig. 9).

3.4.3. Low versus intermediate SYNTAX score (tertile I vs tertile II). When a low SYNTAX score was compared with an intermediate SYNTAX score, mortality, MI, MACEs, repeated revascularization, and stent thrombosis were still significantly lower with a lower SYNTAX score (RR 1.36, 95% CI 1.10–1.67, P=.004; RR 1.40, 95% CI 1.15–1.71, P=.0009; RR 1.52, 95% CI 1.34–1.72, P=.00001; RR 1.57, 95% CI 1.32–1.86, P=.00001; and RR 2.12, 95% CI 1.30–3.47, P=.003, respectively, as shown in Fig. 10).

3.4.4. Low versus high SYNTAX score (tertile I vs tertile III). When a low SYNTAX score was compared with a high SYNTAX score, mortality, cardiac death, MI, MACEs, repeated revascularization, and stent thrombosis significantly favored a lower score (RR 2.86, 95% CI 2.42–3.39, *P*=.00001; RR 2.91, 95% CI 2.29–3.70, *P*=.00001; RR 2.18, 95% CI 1.82–2.61, *P*=.00001; RR 2.34, 95% CI 2.09–2.61, *P*=.00001; RR

	High SYNTA)	(Score	Low SYNTA	(Score		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% CI
1.3.1 Repeated Reva	scularization						
Garg2011A	32	262	28	545	9.8%	2.38 [1.46, 3.86]	
Garg2011B	90	659	87	1374	13.2%	2.16 [1.63, 2.85]	
Girasis2011	42	268	73	580	12.0%	1.25 [0.88, 1.77]	+
Magro2011	20	223	11	446	6.7%	3.64 [1.77, 7.46]	
Park2013	51	633	43	1422	11.3%	2.66 [1.80, 3.95]	
Valgimigli2007	6	203	0	103	0.7%	6.63 [0.38, 116.51]	
Wykrzykowska2010 Subtotal (95% CI)	92	461 2709	117	936 5406	13.7% 67.4%	1.60 [1.24, 2.05] 2.03 [1.57, 2.64]	-
Total events	333		359				
Test for overall effect: 1.3.2 Stent Thrombo		00001)					
			-		= +0/		
Garg2011A	14 11	262 659	7 11	545 1374	5.1%	4.16 [1.70, 10.18]	
Garg2011B Girasis2011	11	268	24	580	5.6% 6.9%	2.08 [0.91, 4.78]	
Park2013	22	200 633	24 10	1422	6.5%	0.99 [0.49, 2.00] 4.94 [2.35, 10.38]	
	22	461	10	936	6.5% 8.4%		
Wykrzykowska2010 Subtotal (95% Cl)	20	2283	19	4857	8.4% 32.6%	2.78 [1.55, 4.97] 2.56 [1.46, 4.48]	•
Total events	84		71				
Heterogeneity: Tau ² = Test for overall effect:			(P = 0.02); I ² =	65%			
Total (95% CI)		4992		10263	100.0%	2.20 [1.73, 2.82]	•
	417		430				
Total events	417						

Figure 6. Postinterventional adverse cardiovascular outcomes which were observed between a low ($10 > SS \le 20$) versus a higher (tertiles II and III) SYNTAX score. SS = SYNTAX score.

Study or Subgroup	High SYNTA) Events	Total	Low SYNTA) Events		Weight	Risk Ratio M-H, Fixed, 95% C	Risk Ratio M-H, Fixed, 95% Cl
1.4.1 Mortality	Eventa	Total	Lventa	Total	weight	W-11, 1 1Xed, 5576 0	
He2011	2	132	0	71	0.5%	2.71 [0.13, 55.62]	
Sinning2013	44	276	1	52	1.2%	8.29 [1.17, 58.84]	
Valgimigli2007	44	93	0	213	1.2 /0	Not estimable	
Subtotal (95% CI)	0	501	0	336	1.6%	6.74 [1.28, 35.33]	
Total events	46		1				
Heterogeneity: Chi ² = ($(0.53) \cdot 1^2 =$					
Test for overall effect: 2			0,0				
1.4.2 Myocardial Infan	rction						
He2011	3	132	0	71	0.5%	3.79 [0.20, 72.35]	
Sinning2013	29	276	3	52	3.5%	1.82 [0.58, 5.76]	
Valgimigli2007	15	93	11	213	4.7%	3.12 [1.49, 6.54]	
Subtotal (95% CI)		501		336	8.6%	2.63 [1.42, 4.85]	
Total events	47		14				
Heterogeneity: Chi ² = (0%				
Test for overall effect:	Z = 3.09 (P = 0.0	002)					
1.4.3 Major Adverse 0							
He2011	16	132	1	71	0.9%	8.61 [1.17, 63.56]	•
Ikeno2017	44	124	151	849	26.8%	2.00 [1.51, 2.63]	
Kim2010	80	384	51	435	33.3%	1.78 [1.29, 2.46]	-
Nozue2012	11	23	1	26	0.7%	12.43 [1.74, 89.05]	
Sinning2013	152	276	12	52	14.1%	2.39 [1.44, 3.96]	
Valgimigli2007 Subtotal (95% Cl)	11	93 1032	8	213 1646	3.4% 79.1%	3.15 [1.31, 7.57] 2.18 [1.80, 2.65]	•
Total events	314		224				
Heterogeneity: Chi ² = 7 Test for overall effect: 7	· ·	· · ·	34%				
1.4.4 Repeated Revas	scularization						
He2011	11	132	1	71	0.9%	5.92 [0.78, 44.90]	+
Sinning2013	75	276	8	52	9.4%	1.77 [0.91, 3.44]	—
Valgimigli2007 Subtotal (95% CI)	5	93 501	1	213 336	0.4% 10.7%	11.45 [1.36, 96.67] 2.50 [1.39, 4.49]	•
Total events	91		10				-
Heterogeneity: Chi ² = 3 Test for overall effect: 2			46%				
Total (95% CI)		2535		2654	100.0%	2.33 [1.95, 2.78]	•
Total events	498		249				
Heterogeneity: Chi ² = 1							

Figure 7. Postinterventional adverse cardiovascular outcomes which were observed between a low (20 > SS < 30) versus a higher (tertiles II and III) SYNTAX score. SS = SYNTAX score.

	High SYNTAX	Score	Low SYNTAX	Score		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	I M-H, Fixed, 95% CI
1.5.1 Mortality							
Capodanno2009A	28	85	21	257	29.8%	4.03 [2.42, 6.71]	
He2011	1	67	1	136	1.9%	2.03 [0.13, 31.95]	
Sinning2013 Subtotal (95% CI)	32	153 305	13	175 568	34.6% 66.2%	2.82 [1.53, 5.17] 3.34 [2.26, 4.93]	
Total events	61	505	35	500	00.2 /0	3.34 [2.20, 4.33]	
Heterogeneity: Chi ² = 0 Test for overall effect:	,	,	: 0%				
1.5.2 Myocardial Infa	rction						
He2011	2	67	1	136	1.9%	4.06 [0.37, 43.98]	
Sinning2013 Subtotal (95% CI)	20	153 220	12	175 311	31.9% 33.8%	1.91 [0.96, 3.77] 2.03 [1.06, 3.89]	•
Total events	22		13				
Heterogeneity: Chi ² = 0 Test for overall effect:		<i>,</i> .	: 0%				
Total (95% CI)		525		879	100.0%	2.90 [2.08, 4.04]	•
Total events Heterogeneity: Chi ² = 3 Test for overall effect: Test for subgroup diffe	Z = 6.26 (P < 0.0	00001)		39.8%			0.01 0.1 1 10 100 Favours [High SS] Favours [Low SS]

Figure 8. Postinterventional adverse cardiovascular outcomes which were observed between a low (30 > SS < 40) versus a higher (tertiles II and III) SYNTAX score.

2.37, 95% CI 2.02–2.78, *P*=.00001; and RR 4.09, 95% CI 2.67–6.27, *P*=.00001, respectively, as shown in Fig. 11).

involved in assessing the relevant cardiovascular outcomes (Figs. 14 and 15).

3.4.5. Low versus higher SYNTAX score (tertile II+III) in a subset of patients with STEMI. A separate analysis was carried out involving only patients with STEMI. The results were still in favor of a low SYNTAX score, whereby mortality and MI were significantly lower in STEMI patients with a low SYNTAX score (RR 1.92, 95% CI 1.56–2.35, *P*=.00001 and RR 1.45, 95% CI 1.12–1.88, *P*=.005, respectively; Fig. 12). In addition, MACEs also significantly favored a low SYNTAX score in these patients with STEMI (RR 1.73, 95% CI 1.18–2.53, *P*=.005; Fig. 13).

3.5. Publication bias

Sensitivity analysis did not show any deviation from these main results. Moreover, based on a visual evaluation of the funnel plots, there has been very little evidence for the existence of publication bias across all the eligible studies which were 4. Discussion

Even if the SYNTAX score is not among the newest angiographic tools which have been used in clinical practice, it was the most common one to be used to stratify patients who would benefit from either PCI or CABG until recently, newer scientific reports showed its application in Interventional cardiology, whereby it could potentially stratify those patients who would most probably benefit from PCI alone.

In this analysis, we demonstrated the potential benefits of the SYNTAX score and its potential application in Interventional cardiology. These current results showed that when a low SYNTAX score was compared with an intermediate or higher SYNTAX score, significantly lower adverse cardiovascular outcomes were associated with the lower score. A consistent result was obtained among all the subgroups. This analysis included patients with STEMI, NSTEMI, ULMCAD, and




Figure 9. Postinterventional adverse cardiovascular outcomes which were observed between a low (30 > SS < 40) versus a higher (tertiles II and III) SYNTAX score.

In	termediate SYNTA	X Score	Low SYNTA	X Score		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events		Weight	M-H, Fixed, 95% C	
1.6.1 Mortality							
Akgun2014	78	715	73	819	7.8%	1.22 [0.90, 1.66]	
Garg2011A	10	234	10	311	1.0%	1.33 [0.56, 3.14]	
Garg2011B	7	676	13	698	1.5%	0.56 [0.22, 1.39]	
Girasis2011	23	287	18	293	2.0%		
						1.30 [0.72, 2.36]	
He2011	1	65	0	71	0.1%	3.27 [0.14, 78.95]	
Magro2011	26	241	18	209	2.2%	1.25 [0.71, 2.22]	
Park2013	34	1838	11	1608	1.3%	2.70 [1.37, 5.32]	
Sinning2013	12	123	1	52	0.2%	5.07 [0.68, 38.02]	
Valgimigli2007	0	110	0	103		Not estimable	
Wykrzykowska2010	10	472	7	464	0.8%	1.40 [0.54, 3.66]	
Subtotal (95% CI)		4761		4628	16.8%	1.36 [1.10, 1.67]	◆
Total events	201		151				
Heterogeneity: Chi ² = 10.1 Test for overall effect: Z =		l² = 21%					
1.6.2 Myocardial Infarction	on						
Akgun2014	50	715	60	819	6.4%	0.95 [0.66, 1.37]	· →
Garg2011A	6	234	4	311	0.4%	1.99 [0.57, 6.98]	
Garg2011B	82	676	56	698	6.3%	1.51 [1.09, 2.09]	
Girasis2011	25	287	9	293	1.0%	2.84 [1.35, 5.97]	
He2011	1	65	ő	71	0.1%	3.27 [0.14, 78.95]	
Magro2011 Bark2012	4	241	3	209	0.4%	1.16 [0.26, 5.11]	
Park2013	9	1838	2	1608	0.2%	3.94 [0.85, 18.19]	
Sinning2013	9	123	3	52	0.5%	1.27 [0.36, 4.50]	
Valgimigli2007	5	110	0	103		10.31 [0.58, 184.09]	
Wykrzykowska2010	23	472	20	464	2.3%	1.13 [0.63, 2.03]	
Subtotal (95% CI)		4761		4628	17.6%	1.40 [1.15, 1.71]	
Total events Heterogeneity: Chi ² = 12.7 Test for overall effect: Z =		l² = 29%	157				
1.6.3 Major Adverse Care	tiac Events						
•		04	20	70	4 00/	1 00 10 74 4 003	
Capodanno2009B	45	91	39	79	4.8%	1.00 [0.74, 1.36]	
Garg2011A	31	234	24	311	2.4%	1.72 [1.04, 2.85]	
Garg2011B	76	676	59	698	6.6%	1.33 [0.96, 1.84]	
Girasis2011	61	287	37	293	4.2%	1.68 [1.16, 2.45]	
He2011	4	65	1	71	0.1%	4.37 [0.50, 38.09]	
Kim2010	44	268	51	435	4.4%	1.40 [0.96, 2.03]	
Magro2011	37	241	23	209	2.8%	1.40 [0.86, 2.27]	
	8	17		203	0.1%		
Nozue2012			1			12.24 [1.68, 89.23]	
Park2013	142	1838	68	1608	8.3%	1.83 [1.38, 2.42]	
Sinning2013	58	123	12	52	1.9%	2.04 [1.20, 3.47]	
Valgimigli2007	5	110	3	103	0.4%	1.56 [0.38, 6.37]	
Wykrzykowska2010	42	472	36	464	4.1%	1.15 [0.75, 1.76]	
Subtotal (95% CI)		4422		4349	40.1%	1.52 [1.34, 1.72]	•
Total events	553		354				
Heterogeneity: Chi ² = 18.2 Test for overall effect: Z =	5, df = 11 (P = 0.08)); I² = 40%					
1.6.4 Repeated Revascul	arization						
Garg2011A	17	234	11	311	1.1%	2.05 [0.98, 4.30]	
Garg2011B	52	676	35	698	3.9%	1.53 [1.01, 2.32]	
Girasis2011	45	287	28	293	3.9%		
						1.64 [1.05, 2.55]	
He2011	2	65	1	71	0.1%	2.18 [0.20, 23.53]	
Magro2011	12	241	5	209	0.6%	2.08 [0.75, 5.81]	
Park2013	107	1838	55	1608	6.7%	1.70 [1.24, 2.34]	
Sinning2013	27	123	8	52	1.3%	1.43 [0.70, 2.93]	
Valgimigli2007	1	110	0	103	0.1%	2.81 [0.12, 68.23]	· · · · · · · · · · · · · · · · · · ·
Wykrzykowska2010	66	472	51	464	5.9%	1.27 [0.90, 1.79]	
Subtotal (95% CI)		4046		3809	22.8%	1.57 [1.32, 1.86]	
Total events	329		194				
Heterogeneity: Chi ² = 2.82		² = 0%	104				
Test for overall effect: Z =		0 %					
1.6.5 Stent Thrombosis							
Garg2011A	5	234	2	311	0.2%	3.32 [0.65, 16.98]	· · · · · · · · · · · · · · · · · · ·
Garg2011B	5	676	6	698	0.7%	0.86 [0.26, 2.81]	
Girasis2011	17	287	7	293	0.8%	2.48 [1.04, 5.89]	
Park2013	7	1838	3	1608	0.4%	2.04 [0.53, 7.88]	
Wykrzykowska2010	14	472	5	464	0.6%	2.75 [1.00, 7.58]	
Yadav2015	0	0	27	2315		Not estimable	
Subtotal (95% CI)		3507		5689	2.6%	2.12 [1.30, 3.47]	-
Total events	48		50				
Heterogeneity: Chi ² = 2.91 Test for overall effect: Z =	, df = 4 (P = 0.57); l ²	² = 0%					
Total (95% CI)		21497		23103	100.0%	1.50 [1.38, 1.62]	•
Total events	1345		906	_5.00			
		12 - 100/	900				
Heterogeneity: Chi ² = 50.7 Test for overall effect: Z = Test for subgroup differen	9.73 (P < 0.00001)		-7), I² = 0%				0.01 0.1 1 10 100 Favours [Intermediate SS] Favours [Low SS]

Figure 10. Postinterventional adverse cardiovascular outcomes which were observed between a low versus an intermediate (tertile II) SYNTAX score.

MVCAD. However, even when patients with STEMI were separately analyzed, a low SYNTAX score was still significantly associated with lower adverse outcomes.

A subanalysis of the shinshu prospective multicenter study of elderly patients with coronary artery disease undergoing percutaneous coronary intervention registry also supported the results of this current analysis showing that a lower SYNTAX score predicted a lower incidence of MACEs.^[33] The authors also stated that the SYNTAX score should be considered an important parameter to improve risk stratification in similar patients. Even if the study satisfied most of the eligibility criteria for this analysis, it was not included among the eligible studies because the patients also suffered from heart failure.

The gene polymorphism, platelet reactivity, and the syntax score study,^[34] which was a prospective, multicentered cohort including 1053 patients with NSTEMI who underwent coronary

1.7.1 Mortality	Events	X Score I Total	Low SYNTA) Events		Weight	Risk Ratio M-H, Fixed, 95% Cl	Risk Ratio M-H, Fixed, 95% Cl
Akgun2014	195	749	73	819	7.1%	2.92 [2.27, 3.75]	
Capodanno2009A	28	749 85	21	257	1.1%	4.03 [2.42, 6.71]	
Garg2011A	20	262	10	311	0.9%	2.85 [1.39, 5.85]	<u> </u>
Garg2011B	24 18	659	10	698	1.3%	2.65 [1.39, 5.65] 1.47 [0.72, 2.97]	<u> </u>
Girasis2011	32	268	18	293	1.3%	1.94 [1.12, 3.38]	
He2011	32	200	0	293	0.0%	3.18 [0.13, 76.64]	
Magro2011	37	219	18	209	1.9%	1.96 [1.15, 3.33]	
Park2013	48	1656	11	1608	1.1%	4.24 [2.21, 8.13]	
Sinning2013	32	153	1	52	0.2%	10.88 [1.52, 77.62]	
Valgimigli2007	1	93	0	103	0.0%	3.32 [0.14, 80.49]	
Wykrzykowska2010	26	461	7	464	0.7%	3.74 [1.64, 8.53]	
Subtotal (95% CI)		4672		4885	16.1%	2.86 [2.42, 3.39]	•
Total events	442		172				
Heterogeneity: Chi ² = 1 Test for overall effect: 2	l2.62, df = 10 (P = Z = 12.14 (P < 0.0	0.25); l ² = 2' 0001)	1%				
1.7.2 Cardiac death							
Akgun2014	156	749	59	819	5.7%	2.89 [2.18, 3.84]	-
Garg2011B	14	659	7	698	0.7%	2.12 [0.86, 5.22]	
Girasis2011	20	268	8	293	0.8%	2.73 [1.22, 6.10]	
Park2013	29	1656	10	1608	1.0%	2.82 [1.38, 5.76]	
Sinning2013	21	153	0	52	0.1%	14.80 [0.91, 240.08]	· · · · ·
Subtotal (95% CI)		3485	-	3470	8.3%	2.91 [2.29, 3.70]	◆
Total events	240		84				
Heterogeneity: Chi ² = 1 Test for overall effect: 2							
1.7.3 Myocardial Infar Akgup2014		740	20	040	E 00/	1 60 11 04 0.047	_
Akgun2014	93	749	60	819	5.8%	1.69 [1.24, 2.31]	
Garg2011A	16	262	4	311	0.4%	4.75 [1.61, 14.03]	
Garg2011B	120	659	56	698	5.5%	2.27 [1.68, 3.06]	-
Girasis2011	22	268	9	293	0.9%	2.67 [1.25, 5.70]	
He2011	2	67	0	71	0.0%	5.29 [0.26, 108.29]	
Magro2011	8	219	3	209	0.3%	2.54 [0.68, 9.46]	
Park2013	12	1656	2	1608	0.2%	5.83 [1.31, 25.99]	
Sinning2013	20	153	3	52	0.5%	2.27 [0.70, 7.31]	+
Valgimigli2007	15	93	0	103	0.0%	34.30 [2.08, 565.32]	
Wykrzykowska2010	27	461	20	464	2.0%	1.36 [0.77, 2.39]	+
Subtotal (95% CI)		4587		4628	15.7%	2.18 [1.82, 2.61]	•
Total events	335		157				
Heterogeneity: Chi ² = 1 Test for overall effect: 2			%				
1.7.4 Major Adverse C Garg2011A Garg2011B	65	262 659	24 59	311 698	2.2% 5.8%	3.21 [2.07, 4.98] 2.37 [1.78, 3.16]	
Garg2011A Garg2011B	65 132	659	59	698	5.8%	2.37 [1.78, 3.16]	-
Garg2011A Garg2011B Girasis2011	65 132 65				5.8% 3.6%	2.37 [1.78, 3.16] 1.92 [1.33, 2.78]	
Garg2011A Garg2011B Girasis2011 He2011	65 132 65 12	659 268 67	59 37 1	698 293 71	5.8% 3.6% 0.1%	2.37 [1.78, 3.16] 1.92 [1.33, 2.78] 12.72 [1.70, 95.14]	
Garg2011A Garg2011B Girasis2011 He2011 Ikeno2017	65 132 65 12 118	659 268 67 331	59 37 1 151	698 293 71 849	5.8% 3.6% 0.1% 8.6%	2.37 [1.78, 3.16] 1.92 [1.33, 2.78] 12.72 [1.70, 95.14] 2.00 [1.63, 2.46]	
Garg2011A Garg2011B Girasis2011 He2011 Ikeno2017 Kim2010	65 132 65 12 118 18	659 268 67 331 116	59 37 1 151 51	698 293 71 849 435	5.8% 3.6% 0.1% 8.6% 2.2%	2.37 [1.78, 3.16] 1.92 [1.33, 2.78] 12.72 [1.70, 95.14] 2.00 [1.63, 2.46] 1.32 [0.81, 2.18]	
Garg2011A Garg2011B Girasis2011 He2011 Ikeno2017 Kim2010 Magro2011	65 132 65 12 118 18 50	659 268 67 331 116 219	59 37 1 151 51 23	698 293 71 849 435 209	5.8% 3.6% 0.1% 8.6% 2.2% 2.4%	2.37 [1.78, 3.16] 1.92 [1.33, 2.78] 12.72 [1.70, 95.14] 2.00 [1.63, 2.46] 1.32 [0.81, 2.18] 2.07 [1.31, 3.27]	
Garg2011A Garg2011B Girasis2011 He2011 Ikeno2017 Kim2010 Magro2011 Nozue2012	65 132 65 12 118 18 50 3	659 268 67 331 116 219 6	59 37 151 51 23 1	698 293 71 849 435 209 26	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0%	2.37 [1.78, 3.16] 1.92 [1.33, 2.78] 12.72 [1.70, 95.14] 2.00 [1.63, 2.46] 1.32 [0.81, 2.18] 2.07 [1.31, 3.27] 13.00 [1.62, 104.25]	
Garg2011A Garg2011B Girasis2011 He2011 Ikeno2017 Kim2010 Magro2011 Nozue2012 Park2013	65 132 65 12 118 18 50 3 202	659 268 67 331 116 219 6 1656	59 37 151 51 23 1 68	698 293 71 849 435 209 26 1608	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 7.0%	2.37 [1.78, 3.16] 1.92 [1.33, 2.78] 12.72 [1.70, 95.14] 2.00 [1.63, 2.46] 1.32 [0.81, 2.18] 2.07 [1.31, 3.27] 13.00 [1.62, 104.25] 2.88 [2.21, 3.76]	
Garg2011A Garg2011B Girasis2011 He2011 Ikeno2017 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013	65 132 65 12 118 18 50 3 202 94	659 268 67 331 116 219 6 1656 153	59 37 1 151 51 23 1 68 12	698 293 71 849 435 209 26 1608 52	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 7.0% 1.8%	2.37 [1.78, 3.16] 1.92 [1.33, 2.78] 12.72 [1.70, 95.14] 2.00 [1.63, 2.46] 1.32 [0.81, 2.18] 2.07 [1.31, 3.27] 13.00 [1.62, 104.25] 2.88 [2.21, 3.76] 2.66 [1.60, 4.44]	
Garg2011A Garg2011B Girasis2011 Hea2011 Ikeno2017 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Valgimigli2007	65 132 65 12 118 18 50 3 202 94 11	659 268 67 331 116 219 6 1656 153 93	59 37 1 151 51 23 1 68 12 3	698 293 71 849 435 209 26 1608 52 103	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 7.0% 1.8% 0.3%	2.37 [1.78, 3.16] 1.92 [1.33, 2.78] 12.72 [1.70, 95.14] 2.00 [1.63, 2.46] 1.32 [0.81, 2.18] 2.07 [1.31, 3.27] 13.00 [1.62, 104.25] 2.88 [2.21, 3.76] 2.66 [1.60, 4.44] 4.06 [1.17, 14.11]	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Valgimgli2007 Wykrzykowska2010	65 132 65 12 118 18 50 3 202 94	659 268 67 331 116 219 6 1656 153 93 461	59 37 1 151 51 23 1 68 12	698 293 71 849 435 209 26 1608 52 103 464	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 7.0% 1.8% 0.3% 3.6%	2.37 [1.78, 3.16] 1.92 [1.33, 2.78] 12.72 [1.70, 95.14] 2.00 [1.63, 2.46] 1.32 [0.81, 2.18] 1.32 [0.81, 2.18] 1.300 [1.62, 104.25] 2.88 [2.21, 3.76] 2.66 [1.60, 4.44] 4.06 [1.17, 14.11] 1.99 [1.36, 2.90]	
Garg2011A Garg2011B Garg352011 He2011 Ikeno2017 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Valgimgli2007 Wykrzykowska2010 Subtotal (95% CI) Total events	65 132 65 12 118 50 3 202 94 11 71 841	659 268 67 331 116 219 6 1656 153 93 461 4291	59 37 1 151 23 1 68 12 3 36 466	698 293 71 849 435 209 26 1608 52 103	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 7.0% 1.8% 0.3%	2.37 [1.78, 3.16] 1.92 [1.33, 2.78] 12.72 [1.70, 95.14] 2.00 [1.63, 2.46] 1.32 [0.81, 2.18] 2.07 [1.31, 3.27] 13.00 [1.62, 104.25] 2.88 [2.21, 3.76] 2.66 [1.60, 4.44] 4.06 [1.17, 14.11]	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2017 Kim2010 Park2013 Sinning2013 Valgimigli2007 Valgimigli2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2	65 132 65 12 18 18 50 3 202 94 41 71 71 841 20.05, df = 11 (P =	659 268 67 331 116 219 6 1656 153 93 461 4291 0.04); l ² = 45	59 37 1 151 23 1 68 12 3 36 466	698 293 71 849 435 209 26 1608 52 103 464	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 7.0% 1.8% 0.3% 3.6%	2.37 [1.78, 3.16] 1.92 [1.33, 2.78] 12.72 [1.70, 95.14] 2.00 [1.63, 2.46] 1.32 [0.81, 2.18] 1.32 [0.81, 2.18] 1.300 [1.62, 104.25] 2.88 [2.21, 3.76] 2.66 [1.60, 4.44] 4.06 [1.17, 14.11] 1.99 [1.36, 2.90]	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (65% CI) Total events Heterogeneity: Chi ² = 2 Test for overall effect: 2	65 132 65 12 118 18 50 3 202 94 94 11 71 71 20.05, df = 11 (P = Z = 15.07 (P < 0.0) cularization	659 268 67 331 116 219 6 1556 1553 93 461 4291 4291 0.004); l² = 45 0001)	59 37 1 151 23 1 8 12 3 36 466 5%	698 293 71 849 435 209 26 1608 52 103 464 5119	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 7.0% 1.8% 0.3% 3.6% 37.7%	2.37 (7.8.3.16) 1.92 (13.3.278) 1.272 (17.0.95.14) 2.00 (16.3.246) 1.32 (0.81,2.18) 2.07 (1.31,3.27) 13.00 (16.2.104.25) 2.88 (2.21,3.76) 2.86	
Garg2011A Garg2011B Girasis2011 He2011 Ikeno2017 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2 Test for overall effect: 2 1.7.5 Repeated Revas Garg2011A	65 132 65 12 118 18 50 3 202 94 11 71 20, 6f = 11 (P = Z = 15.07 (P < 0.0 ccularization 32	659 268 67 331 116 219 6 1656 1656 1656 1656 1656 1656 4291 0.04); l ² = 4! 0001)	59 37 1 151 23 1 68 12 3 3 6 466 5%	698 293 71 849 435 209 26 1608 52 103 464 5119 311	5.8% 3.6% 0.1% 8.6% 2.2% 0.0% 7.0% 1.8% 0.3% 3.6% 37.7%	$\begin{array}{c} 2.3^{\circ}(7.8,3.6)\\ 1.92(13.3,2.78)\\ 1.27(217.0,95.14)\\ 2.00(16.3,2.46)\\ 1.32(0.81,2.16)\\ 2.07(1.31,3.27)\\ 2.86(2.21,3.76)\\ 2.86(2.21,3.76)\\ 2.66(1.60,4.44)\\ 4.06(1.71,41.11)\\ 1.99(1.36,2.90)\\ 2.34(2.09,2.61)\\ 3.45(1.78,6.71)\\ \end{array}$	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2017 Kim2010 Park2013 Sinning2013 Valgimgil2007 Valgimgil2007 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2 Test for overall effect: 2 1.7.5 Repeated Revas Garg2011B Garg2011B	65 132 65 12 118 18 50 3 202 94 411 71 20.05, df = 11 (P = Z = 15.07 (P < 0.0 ccularization 32 90	659 268 67 331 116 219 6 1556 1555 93 461 4291 0.04); l ² = 4; 0001) 262 659	59 37 1 151 23 1 68 12 3 36 466 5%	698 293 71 849 435 209 26 1608 52 103 464 5119 311	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 7.0% 1.8% 3.6% 37.7%	2.37 (7.8. 3.16) 1.92 (13.3. 2.78) 1.272 (1.70, 95.14) 2.00 (16.3, 2.46) 2.01 (16.3, 2.46) 2.07 (1.31, 3.27) 2.00 (16.2, 104.25) 2.86 (2.61, 2.16) 2.66 (1.60, 4.44) 4.66 (1.17, 14.11) 1.99 (1.36, 2.90) 2.34 (2.09, 2.61) 3.45 (1.78, 6.71) 2.72 (1.87, 3.97)	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magr02011 Nozue2012 Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Ch ² = <i>z</i> Test for overall effect: <i>z</i> 17.5 Repeated Revas Garg2011A Garg3011B Girasis2011	65 132 65 12 18 18 50 3 202 90 41 71 841 71 841 20.05, df = 11 (P = 2 = 15.07 (P < 0.0 ccularization 32 90 42	659 268 67 331 116 219 6 1656 1556 1553 93 461 4291 0.04); l ² = 4 0001) 262 659 268	59 37 1 151 51 23 1 68 12 3 36 466 5%	698 293 71 849 435 209 26 1608 52 103 464 5119 311 698 293	5.8% 3.6% 0.1% 2.2% 2.4% 0.0% 7.0% 1.8% 3.6% 37.7%	2.37 (7.8.3.16) 1.92 (13.3.2.76) 1.272 (17.0.95.14) 2.00 (16.3.2.46) 1.32 (0.81,2.18) 2.07 (13.1.327) 13.00 (16.2.104.25) 2.68 (2.21,3.76) 2.68 (2.21,3.76) 2.68 (2.21,3.76) 2.68 (2.21,3.76) 2.68 (2.21,3.76) 2.64 (1.06,2.87) 3.45 (1.76,6.71) 2.72 (1.87,3.97) 1.64 (1.05,2.57)	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2017 Kim2010 Magro2012 Park2013 Subtoal (95% CI) Total events Heterogeneity: Chi ² = 2 Test for overall effect: : 1.7.5 Repeated Revas Garg2011B Girasis2011 Birasis2011 He2011	65 132 65 12 118 18 50 3 202 94 11 71 20.05, df = 11 (P = Z = 15.07 (P < 0.0 32 cucularization 32 9 9 42 9	659 268 67 331 116 219 6 1656 153 93 461 4291 0.04); I ² = 4 0001) 262 659 268 67	59 37 1 151 51 23 1 68 12 3 36 466 5% 11 35 28 1	698 293 71 849 435 209 26 1608 52 103 464 5119 311 698 293 71	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 7.0% 3.6% 37.7% 1.0% 3.6% 37.7%	$\begin{array}{c} 2.3^{\circ}(7.76, 3.16)\\ 1.92(133, 2.76)\\ 1.22(170, 95.14)\\ 2.00(163, 2.46)\\ 2.00(163, 2.46)\\ 2.01(131, 3.27)\\ 2.00(163, 2.16)\\ 2.06(160, 4.44)\\ 4.06[1.17, 14.11]\\ 1.99(1.36, 2.90)\\ 2.34(2.09, 2.61)\\ 2.34(2.09, 2.61)\\ 3.45[1.76, 6.71]\\ 2.72(1.67, 3.97)\\ 1.64(105, 2.57)\\ 1.64(105, 2.57)\\ 3.64(1.05, 2.57)\\ 3.64(1.05, 2.57)\\ 3.64(1.24, 7.326)\\ 3.64(1.24$	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magro2017 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Vulgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2 Test for overall effect: ; 1.7.5 Repeated Revas Garg2011B Garasis2011 He2011 Magro2011	65 132 65 12 18 18 50 3 202 94 11 71 841 20.05, df = 11 (P = Z = 15.07 (P < 0.0 52 90 42 90 42 9 14	659 268 67 331 116 219 6 1556 153 93 461 4291 0.04); I ² = 4{ 0001) 262 659 268 67 219	59 37 151 51 23 1 68 12 3 3 6 466 5% 11 35 28 1 5 5	698 293 71 849 435 209 266 1608 52 103 464 5119 311 698 293 71 1 209	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 7.0% 3.6% 3.6% 3.6% 3.6% 3.4% 2.7% 0.1% 0.5%	$\begin{array}{c} 2.3^{\circ}(7,8,3,16)\\ 1.92(13,3,278)\\ 1.27(17,0,95,14)\\ 2.00(163,246)\\ 1.32(081,2.18)\\ 2.07(131,327)\\ 13.00(162,104,25)\\ 2.88(221,376)\\ 2.88(221,376)\\ 2.86(160,444)\\ 4.06(1.17,14.11)\\ 1.99(1,36,290)\\ 2.34(2,09,2.61)\\ 2.34(2,09,2.61)\\ 2.72(1,87,397)\\ 1.64(1,05,257)\\ 9.54(1,24,73,26)\\ 2.67(1,09,8,729)\end{array}$	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2017 Aim2010 Park2013 Subtot13 Subtot13 Subtot1 (95% CI) Total events Heterogeneity: Ch ² = 2 Test for overall effect: 1 1.7.5 Repeated Revas Garg2011A Garg2011B Garg2011 He2011 Magro2011 Park2013	65 132 65 12 118 18 50 3 202 94 11 71 20.05, df = 11 (P = Z = 15.07 (P < 0.0 icularization 32 90 42 14 150	659 268 67 331 116 219 6 1656 153 93 461 4291 0.04); l² = 4! 0001) 262 658 67 219 268 67 219 1656	59 37 151 51 23 1 68 12 36 466 5% 11 35 28 1 5 5	698 293 711 849 435 2099 266 1608 52 103 464 5119 3111 698 293 71 2099 1608	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 1.8% 0.3% 3.6% 37.7% 1.0% 3.4% 2.7% 0.1% 0.5%	$\begin{array}{c} 2.3^{*}(7.8, 3.16)\\ 1.92(13.3, 2.78)\\ 1.27(21,70, 95.14)\\ 2.00(1.63, 2.46)\\ 1.32(0.81, 2.18)\\ 2.07(1.31, 3.27)\\ 2.86(2.21, 3.76)\\ 2.66(1.60, 4.44)\\ 4.06(1.17, 1.41, 1.27)\\ 2.34(2.09, 2.61)\\ 2.34(2.09, 2.$	
Garg2011A Garg2011B Grasis2011 He2011 Keno2017 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Vulgimigli2007 Wykrzykowska2010 Subtotal (95% C1) Total events Heterogeneity: Chi ² = 2 Test for overall effect: ; 1.7.5 Repeated Revas Garg2011A Garg2011B Garasis2011 He2011 Magro2011 Park2013 Sinning2013	65 132 65 12 12 18 18 50 3 202 94 11 71 841 841 20.05, df = 11 (P = 2 = 15.07 (P < 0.0 52 2 = 15.07 (P < 0.0 60 42 90 42 90 14 150 48	669 268 67 331 116 219 6 1556 155 155 4291 0.04); l ² = 45 0001) 2659 268 67 219 1656 153	59 37 151 51 23 1 68 68 12 3 3 6 466 5% 11 35 28 1 5 55 8	698 293 711 849 435 209 26 1608 52 103 464 5119 311 698 293 71 209 1608 52	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 7.0% 7.0% 7.0% 3.6% 37.7% 1.0% 3.4% 2.7% 0.1% 0.5% 5.7% 1.2%	$\begin{array}{c} 2.3^{\circ}(7,8,3,6)\\ 1.92(13,3,278)\\ 1.22(17,0,95,14)\\ 2.00(163,2.46)\\ 1.32(081,2.18)\\ 2.07(131,327)\\ 2.88(221,376)\\ 2.88($	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magro2012 Park2013 Sinning2013 Valgimgil2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1.7.5 Repeated Revas Garg2011A Garg2011A Garg2011A Magro2011 Park2013 Sinning2013 Valgimgil2007	$\begin{array}{c} 65\\ 132\\ 65\\ 12\\ 118\\ 18\\ 50\\ 3\\ 202\\ 94\\ 11\\ 71\\ 205, df=11 (P=2\\ 2=15.07 (P<0.0\\ cluarization\\ 32\\ 90\\ 42\\ 9\\ 14\\ 150\\ 48\\ 5\\ \end{array}$	659 268 67 331 116 219 6 1656 153 93 461 4291 0.04); l² = 4{ 0001) 262 659 268 67 219 1656 153 93 3	59 37 151 551 23 1 68 12 3 36 466 5% 111 35 28 28 1 55 55 8 0	698 293 711 849 435 209 26 1608 52 103 464 5119 3111 698 293 711 209 1608 52 103	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 1.8% 0.3% 3.6% 3.7.7% 1.0% 3.4% 2.7% 0.1% 0.5% 5.7% 1.2%	$\begin{array}{c} 2.3^{\circ}(7.8, 3.16)\\ 1.92(13.3, 2.78)\\ 1.27(17.0, 95.14)\\ 2.00(1.63, 2.46)\\ 1.32(0.81, 2.18)\\ 2.07(1.31, 3.27)\\ 2.88(2.21, 3.76)\\ 2.68(1.60, 4.44)\\ 4.06(1.71, 14.11)\\ 1.99(1.36, 2.10)\\ 2.34(2.09, 2.61)\\ 2.34(2.09, 2.61)\\ 3.45(1.78, 6.71)\\ 2.7(1.87, 3.97)\\ 1.64(1.05, 2.57)\\ 9.54(1.24, 73.26)\\ 2.67(1.09, 7.29)\\ 2.66(1.96, 5.88)\\ 2.04(1.03, 4.02)\\ 2.67(1.96, 5.88)\\ 2.04(1.03, 4.02)\\ 2.17(10.68, 2.17.15)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17$	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magro2017 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Valgimigil2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Ch ² = 2 Totsf or overall effect: 2 1.7.5 Repeated Revas Garg2011A Girasis2011 He2011 Magro2011 Park2013 Sinning2013 Valgimigil2007	65 132 65 12 12 18 18 50 3 202 94 11 71 841 841 20.05, df = 11 (P = 2 = 15.07 (P < 0.0 52 2 = 15.07 (P < 0.0 60 42 90 42 90 14 150 48	659 268 67 331 116 219 6 1656 1553 93 461 4291 0.004); l² = 45 0001) 2669 268 67 219 1656 153 93 461	59 37 151 51 23 1 68 68 12 3 3 6 466 5% 11 35 28 1 5 55 8	698 293 711 849 435 209 26 1608 52 103 464 5119 3111 698 293 71 209 1608 52 103 464	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 3.6% 3.6% 3.6% 3.7.7% 1.0% 5.7% 1.2% 0.0% 5.2%	$\begin{array}{c} 2.3^{\circ}(1.76, 3.16]\\ 1.92(13.3, 2.76]\\ 1.92(13.3, 2.76]\\ 1.2(21,70, 95.14]\\ 2.00(16.3, 2.46]\\ 2.01(16.3, 2.46]\\ 2.01(1.31, 2.01)\\ 2.00(16.2, 104.25)\\ 2.86(2.21, 3.76]\\ 2.66(16.0, 4.44]\\ 4.06(1.17, 14.11)\\ 1.99(1.36, 2.90)\\ 2.34(2.09, 2.61)$	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magro2017 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Valgimigil2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Ch ² = 2 Totsf or overall effect: 2 1.7.5 Repeated Revas Garg2011A Girasis2011 He2011 Magro2011 Park2013 Sinning2013 Valgimigil2007	$\begin{array}{c} 65\\ 132\\ 65\\ 12\\ 118\\ 18\\ 50\\ 3\\ 202\\ 94\\ 11\\ 71\\ 205, df=11 (P=2\\ 2=15.07 (P<0.0\\ cluarization\\ 32\\ 90\\ 42\\ 9\\ 14\\ 150\\ 48\\ 5\\ \end{array}$	659 268 67 331 116 219 6 1656 153 93 461 4291 0.04); l² = 4{ 0001) 262 659 268 67 219 1656 153 93 3	59 37 151 551 23 1 68 12 3 36 466 5% 111 35 28 28 1 55 55 8 0	698 293 711 849 435 209 26 1608 52 103 464 5119 3111 698 293 711 209 1608 52 103	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 1.8% 0.3% 3.6% 3.7.7% 1.0% 3.4% 2.7% 0.1% 0.5% 5.7% 1.2%	$\begin{array}{c} 2.3^{\circ}(7.8, 3.16)\\ 1.92(13.3, 2.78)\\ 1.27(17.0, 95.14)\\ 2.00(1.63, 2.46)\\ 1.32(0.81, 2.18)\\ 2.07(1.31, 3.27)\\ 2.88(2.21, 3.76)\\ 2.68(1.60, 4.44)\\ 4.06(1.71, 14.11)\\ 1.99(1.36, 2.10)\\ 2.34(2.09, 2.61)\\ 2.34(2.09, 2.61)\\ 3.45(1.78, 6.71)\\ 2.7(1.87, 3.97)\\ 1.64(1.05, 2.57)\\ 9.54(1.24, 73.26)\\ 2.67(1.09, 7.29)\\ 2.66(1.96, 5.88)\\ 2.04(1.03, 4.02)\\ 2.67(1.96, 5.88)\\ 2.04(1.03, 4.02)\\ 2.17(10.68, 2.17.15)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17, 1.07, 3.07)\\ 1.07(2.17$	
Garg2011A Garg2011B Girasis2011 He2011 Kim2010 Magro2017 Nozue2012 Park2013 Sinning2013 Valgimgil2007 Vykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Ch ² = 2 Test for overall effect: : 1.7.5 Repeated Revas Garg2011A Garg2011B Girasis2011 He2011 Magro2011 Park2013 Sinning2013 Sinning2013 Sinning2013 Sinning2013 Sinning2013 Sinning2013 Sinning2013 Sinning2013 Sinning2013 Sinning2013 Sinning2013 Sinning2013 Sinning2013 Sinning2013 Sinning2013 Sinning2013 Sinning2013 Sinning2013 Sinning2014 Sinning2013 Sinning2014 Sinning2015 Sinning2014 S	65 132 65 12 118 18 50 50 202 94 11 71 20.05, df = 11 (P = Z = 15.07 (P < 0.0 42 90 42 9 14 150 48 92 482	659 268 67 331 116 219 6 1656 1553 93 461 4291 0.04); l² = 4(0001) 2659 268 67 219 1566 1553 93 3461 3838	59 37 1 151 23 1 68 12 3 36 466 5% 11 35 28 1 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 1 94	698 293 711 849 435 209 26 1608 52 103 464 5119 3111 698 293 71 209 1608 52 103 464	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 3.6% 3.6% 3.6% 3.7.7% 1.0% 5.7% 1.2% 0.0% 5.2%	$\begin{array}{c} 2.3^{\circ}(1.76, 3.16]\\ 1.92(13.3, 2.76]\\ 1.92(13.3, 2.76]\\ 1.2(21,70, 95.14]\\ 2.00(16.3, 2.46]\\ 2.01(16.3, 2.46]\\ 2.01(1.31, 2.01)\\ 2.00(16.2, 104.25)\\ 2.86(2.21, 3.76]\\ 2.66(16.0, 4.44]\\ 4.06(1.17, 14.11)\\ 1.99(1.36, 2.90)\\ 2.34(2.09, 2.61)$	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magr02011 Nozue2012 Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 2 Test for overall effect: 2 1.7.5 Repeated Revas Garg2011A Garg2011B Garga52011 He2011 Magr02011 Park2013 Sunning2013 Valgimigli2007 Valgiwigli2007 Total events Heterogeneity: Chi ² = 1 Test for overall effect: 2	$\begin{array}{c} 65\\ 132\\ 65\\ 12\\ 18\\ 18\\ 50\\ 3\\ 202\\ 94\\ 11\\ 71\\ 20.05, df = 11 (P = 2\\ 2 = 15.07 (P < 0.0\\ 42\\ 9\\ 14\\ 150\\ 42\\ 9\\ 14\\ 150\\ 42\\ 9\\ 14\\ 150\\ 42\\ 9\\ 14\\ 150\\ 42\\ 9\\ 14\\ 150\\ 62\\ 2 = 10.59 (P < 0.0\\ 2 =$	659 268 67 331 116 219 6 1556 153 93 461 4291 0.04); I ² = 4{ 0001) 262 659 268 67 219 1666 153 93 461 1566 153 93 93 461 3838	59 37 1 151 23 1 68 12 3 36 466 5% 11 35 28 1 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 1 94	698 293 711 849 435 209 26 1608 52 103 464 5119 3111 698 293 71 209 1608 52 103 464	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 3.6% 3.6% 3.6% 3.7.7% 1.0% 5.7% 1.2% 0.0% 5.2%	$\begin{array}{c} 2.3^{\circ}(1.76, 3.16]\\ 1.92(13.3, 2.76]\\ 1.92(13.3, 2.76]\\ 1.2(21,70, 95.14]\\ 2.00(16.3, 2.46]\\ 2.01(16.3, 2.46]\\ 2.01(1.31, 2.01)\\ 2.00(16.2, 104.25)\\ 2.86(2.21, 3.76]\\ 2.66(16.0, 4.44]\\ 4.06(1.17, 14.11)\\ 1.99(1.36, 2.90)\\ 2.34(2.09, 2.61)$	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magro2012 Park2013 Sinning2013 Valgimgil2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = <i>1</i> Test for overall effect: <i>2</i> 1.7.5 Repeated Revas Garg2011A Garg2011A Garg2011 Magro2011 Park2013 Sinning2013 Valgimgil2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = <i>1</i> Test for overall effect: <i>2</i> 1.7.6 Stent Thrombos	65 132 65 12 18 18 50 3 202 94 11 71 2005, df = 11 (P = Z = 15.07 (P < 0.0 scularization 32 90 42 9 14 15 5 92 2 2 2 2 2 32 92 42 9 2 2 42 9 2 2 42 9 2 42 9 2 2 42 9 2 42 42 9 2 2 42 9 2 42 9 2 44 14 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	659 268 67 331 116 219 6 1556 153 93 461 4291 0.04); l² = 4{ 0001) 262 659 268 67 219 153 93 461 3838 0.21); l² = 26{ 0001}	59 37 1 151 23 1 68 12 3 36 466 5% 11 35 28 1 35 55 8 0 51 194	608 8293 711 8499 435 209 52 210 608 522 52 1068 52 21 52 1068 52 21 52 1068 52 21 52 5	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 1.8% 0.3% 3.7.7% 0.3% 3.7.7% 0.3% 5.7% 0.5% 5.2% 0.0% 5.2%	$\begin{array}{c} 2.3^{*}(7.8, 3.16)\\ 1.92(13.3, 2.78)\\ 1.27(21,70, 95.14)\\ 2.00(1.63, 2.46)\\ 1.32(0.81, 2.18)\\ 2.07(1.31, 3.27)\\ 2.88(2.21, 3.76)\\ 2.68(1.60, 4.44)\\ 4.06(1.17, 14.11)\\ 1.99(13.6, 2.10)\\ 2.34(2.09, 2.61)\\ $	
Garg2011A Garg2011B Garg2011B He2011 He2011 Kim2010 Magro2017 Nozue2012 Park2013 Sinning2013 Valgimigil2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Ch ^a = 2 Tast for overall effect; 2 1.7.5 Repeated Revas Garg2011A Garg2011B Girasis2011 He2011 Park2013 Sinning2013 Valgimigil2007 Valgimigil2007 Subtotal (95% CI) Total events Heterogeneity: Ch ^a = 1 Test for overall effect; 2 1.7.6 Stent Thrombos Garg2011A	$\begin{array}{c} 65\\ 132\\ 65\\ 12\\ 118\\ 18\\ 50\\ 3\\ 202\\ 94\\ 11\\ 71\\ 20.05, df=11 (P=2\\ 2-15.07 (P<0.0\\ 32\\ 90\\ 42\\ 9\\ 14\\ 150\\ 48\\ 5\\ 92\\ 14\\ 150\\ 48\\ 5\\ 92\\ 14\\ 150\\ 48\\ 5\\ 92\\ 14\\ 150\\ 48\\ 5\\ 92\\ 14\\ 150\\ 16\\ 16\\ 16\\ 16\\ 16\\ 16\\ 16\\ 16\\ 16\\ 16$	659 268 67 331 116 219 6 1656 1556 1553 93 461 4291 0.0(4); l² = 4(0001) 2662 659 268 67 219 1656 153 93 461 3838 0,21); l² = 267 0001) 262	59 37 1 151 23 1 68 122 3 36 466 5% 11 35 28 11 5 55 58 0 194 %	608 % 293 711 849 435 2090 26 1608 52 103 341 209 26 103 444 5119 209 1608 52 103 341 209 1608 52 103 3809 3809	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 1.8% 0.7.0% 3.6% 37.7% 1.8% 0.1% 0.5% 5.7% 1.2% 0.5% 5.2% 19.9%	2.37 (7.8. 3.16) 1.92 (13.3. 2.78) 1.272 (1.70, 95.14) 2.00 (1.63, 2.46) 2.01 (1.63, 2.46) 2.07 (1.31, 3.27) 2.00 (1.62, 1.04, 25) 2.86 (1.60, 4.44) 4.06 (1.17, 1.4, 11) 1.99 (1.36, 2.90) 2.34 (2.09, 2.61) 3.45 (1.78, 6.71) 2.72 (1.87, 397) 1.64 (1.05, 2.57) 2.65 (1.60, 4.44) 3.45 (1.78, 6.71) 2.72 (1.87, 397) 1.64 (1.05, 2.57) 2.65 (1.96, 3.68) 2.65 (1.96, 3.68) 2.64 (1.03, 4.02) 2.37 (2.02, 2.78] 8.31 (1.91, 36.23)	
Garg2011A Garg2011B Garg2011B He2011 He2011 Kim2010 Magr02011 Nozue2012 Park2013 Sinning2013 Valgimigl/2007 Wykrzykowska2010 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = 1.7.5 Repeated Revas Garg2011A Garg2011A Garg2011 He2011 Magr02013 Valgimigl/2007 Wykrzykowska2010 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = Test for overall effect: 1.7.6 Stent Thrombos Garg2011A Garg2011A Garg2013	$\begin{array}{c} 65\\ 132\\ 65\\ 12\\ 05\\ 12\\ 118\\ 18\\ 50\\ 3\\ 202\\ 94\\ 11\\ 71\\ 2005, df = 11 (P = 2\\ 2 = 15.07 (P < 0.0)\\ 48\\ 99\\ 42\\ 9\\ 14\\ 150\\ 48\\ 5\\ 92\\ 14\\ 150\\ 48\\ 5\\ 14\\ 150\\ 16\\ 15\\ 11\\ 11\\ 11\\ 11\\ 11\\ 11\\ 12\\ 10\\ 10\\ 10\\ 10\\ 10\\ 10\\ 10\\ 10\\ 10\\ 10$	659 268 67 331 116 219 6 1556 153 93 461 4291 0.04); I ² = 4{ 0001) 262 659 268 67 219 1656 67 219 1656 153 93 461 3838 0.21); I ² = 260 0001)	59 37 1 151 23 1 68 12 3 36 466 5% 11 35 28 1 55 55 8 0 51 194 %	608 8293 711 8499 435 2099 2096 229 52 101 52 10100 52 100 50 100	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 2.2% 1.8% 0.7% 3.6% 37.7% 4.1% 0.1% 0.1% 0.1% 0.0% 5.2% 19.9%	$\begin{array}{c} 2.3^{*} (7.8, 3.16) \\ 1.92 (13.3, 2.78) \\ 1.272 (17.0, 95.14) \\ 2.00 (1.63, 2.46) \\ 2.01 (1.63, 2.46) \\ 2.01 (1.31, 2.37) \\ 2.01 (1.52, 10.425) \\ 2.86 (1.60, 4.44) \\ 4.06 (1.7, 1.41, 1.4) \\ 1.96 (1.36, 2.47) \\ 2.34 [2.09, 2.61] \\ 2.37 [2.02, 2.78] \\ 2.37 [2.02, 2.78] \\ 2.37 [2.02, 2.78] \\ 2.37 [2.02, 2.78] \\ 2.31 [1.91, 36.23] \\ 1.94 [0.72, 5.22] \\ 2.52 [2.02] \\ 2.$	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magro2017 Kim2010 Magro2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = <i>j</i> Test for overall effect: <i>j</i> 1.7.5 Repeated Revas Garg2011A Girasis2011 He2011 Magro2013 Park2013 Subtotal (95% CI) Total events Heterogeneity: Chi ² = <i>j</i> Test for overall effect: <i>j</i> 1.7.6 Stent Thrombos Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A Garg2011A	$\begin{array}{c} 65\\ 132\\ 65\\ 12\\ 118\\ 18\\ 50\\ 3\\ 202\\ 94\\ 11\\ 11\\ 71\\ 20.05, df=11 (P=2\\ 15.07 (P<0.0\\ cularization\\ 32\\ 2 = 15.07 (P<0.0\\ 39\\ 42\\ 2 = 15.07 (P<0.0\\ 39\\ 14\\ 150\\ 48\\ 5\\ 92\\ 14\\ 150\\ 48\\ 5\\ 92\\ 14\\ 150\\ 150\\ 14\\ 11\\ 11\\ 11\\ 11\\ 11\\ 11\\ 11\\ 11\\ 11$	659 268 67 331 116 219 6 1656 153 93 461 4291 0.04); I ² = 4 0001) 262 268 67 219 1656 67 219 1656 153 93 461 3838 0.21); I ² = 26 ² 0001) 262 659 268 67 219 163 263 268 67 659 268 67 219 268 659 268 67 219 268 659 268 67 219 268 659 268 67 2001)	59 37 1 151 23 466 5% 11 35 28 11 35 28 135 55 55 50 194 % 2 6 7	608 % 2933 711 8499 262 2090 262 1608 522 1003 4454 5119 3111 2090 1608 522 1003 711 2090 1608 522 523 454 3809 3111 668 3293	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 3.4% 3.6% 3.4% 3.3.6% 3.3.7% 0.1% 5.7% 0.1% 5.7% 1.2% 0.5% 5.2% 19.9%	2.37 (7.8. 3.16) 1.92 (13.3. 2.78) 1.272 (1.70, 95.14) 2.00 (1.63, 2.46) 2.01 (1.31, 2.27) 2.00 (1.63, 2.46) 2.06 (1.60, 4.44) 4.06 (1.17, 14.11) 1.99 (1.36, 2.90) 2.34 (2.09, 2.61) 3.45 (1.76, 6.71) 2.72 (1.87, 397) 1.64 (1.05, 2.57) 2.65 (1.66, 3.58) 2.04 (1.03, 4.02) 2.65 (1.66, 3.58) 2.04 (1.03, 4.02) 12.17 (0.68, 2.17, 15) 1.82 (1.32, 2.49) 2.37 (2.02, 2.78) 8.31 (1.91, 36.23) 1.94 (0.72, 5.22) 1.72 (0.68, 4.37)	
Garg2011A Garg2011B Garg32011B He2011 He2011 Kim2010 Magr02011 Nozue2012 Park2013 Sinning2013 Valgimgil2007 Wykrzykowska2010 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = <i>z</i> Test for overall effect: <i>1</i> <i>1.7.5</i> Repeated Revast Garg2011A Garg2011B Garg32011 Park2013 Valgimgil2007 Wykrzykowska2010 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = <i>z</i> Test for overall effect: <i>1</i> <i>1.7.5</i> Stent Thrombos Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B	$\begin{array}{c} 65\\ 65\\ 132\\ 65\\ 12\\ 118\\ 18\\ 50\\ 3\\ 202\\ 94\\ 11\\ 71\\ 20.05, df = 11 (P = 2\\ 2 = 15.07 (P < 0.0)\\ 62\\ 90\\ 42\\ 9\\ 14\\ 150\\ 42\\ 9\\ 14\\ 150\\ 48\\ 22\\ 10.85, df = 8 (P = (2 + 2))\\ 48\\ 150\\ 62\\ 14\\ 150\\ 14\\ 150\\ 12\\ 2 = 10.59 (P < 0.0)\\ 14\\ 12\\ 22\\ 14\\ 15\\ 12\\ 22\\ 10.59 (P < 0.0)\\ 14\\ 11\\ 12\\ 22\\ 22\\ 22\\ 14\\ 15\\ 15\\ 15\\ 15\\ 15\\ 15\\ 15\\ 15\\ 15\\ 15$	659 268 67 331 116 219 6 1556 153 93 461 4291 0.04); l ² = 4{ 0001) 262 659 268 67 219 1656 153 93 461 3638 0.21); l ² = 260 0001) 262 659 268 1656	59 37 1 151 23 466 5% 11 35 28 0 51 194 % 2 6 7 3	6688 2933 71 435 2099 26 25 2103 26 25 25 1033 464 464 55 2933 2039 2009 2009 2009 2009 2009 2009	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.0% 3.6% 3.7.7% 3.6% 3.7.7% 3.6% 5.7% 0.1% 5.7% 0.5% 5.2% 0.5% 5.2% 0.6% 0.6% 0.6% 0.7%	$\begin{array}{c} 2.3^{*} (7.8, 3.16) \\ 1.92 (13.3, 2.78) \\ 1.27 (217, 0.95, 14) \\ 2.00 (1.63, 2.46) \\ 2.00 (1.63, 2.46) \\ 2.01 (1.63, 2.46) \\ 2.01 (1.31, 2.27) \\ 2.01 (1.52, 10.4, 25) $	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Valgimigil2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = <i>2</i> Test for overall effect: <i>2</i> 1.7.5 Repeated Revas Garg2011A Garg2011B Girasis2011 Magro2013 Subtotal (95% CI) Total events Heterogeneity: Chi ² = <i>1</i> Test for overall effect: <i>2</i> 1.7.6 Stent Thrombos Garg2011A Garg2011B Garga2013 Subtotal (95% CI) Total events Heterogeneity: Chi ² = <i>1</i> Test for overall effect: <i>2</i> 1.7.6 Stent Thrombos Garg2011A Garg2011B Girasis2011 Park2013	$\begin{array}{c} 65\\ 132\\ 65\\ 12\\ 118\\ 18\\ 50\\ 3\\ 202\\ 94\\ 11\\ 20.05, df = 11 (P = 2\\ 15.07 (P < 0.0\\ cularization\\ 32\\ 2 = 15.07 (P < 0.0\\ cularization\\ 42\\ 2 = 15.07 (P < 0.0\\ 32\\ 2 = 15.07 (P < 0.0\\ 32\\ 2 = 15.07 (P < 0.0\\ 32\\ 2 = 10.59 (P < 0.0\\ 32\\ 2 = 10.59 (P < 0.0\\ 15\\ 32\\ 2 = 10.59 (P < 0.0\\ 15\\ 32\\ 2 = 10.59 (P < 0.0\\ 10\\ 10\\ 12\\ 2 = 28\\ 10\\ 11\\ 11\\ 22\\ 28\\ 10\\ 10\\ 12\\ 28\\ 10\\ 10\\ 10\\ 10\\ 10\\ 10\\ 10\\ 10\\ 10\\ 10$	659 268 67 331 116 219 6155 153 93 461 4291 0.04); l² = 4(0001) 2659 268 67 219 1556 155 155 155 155 165 165 165 165 16	59 37 1 151 23 1 68 12 3 36 466 55 5 5 5 5 5 5 5 5 5 5 5 5	608 8293 711 8499 721 714 8499 726 721 714 725 7209 726 725 721 720 726 725 721 720 720 721 720 720 721 720 720 720 720 720 720 720 720 720 720	5.8% 3.6% 0.1% 8.6% 2.4% 0.2% 7.0% 3.4% 3.6% 3.7.7% 9.3% 0.3% 3.6% 3.7.7% 9.2% 0.2% 0.0% 0.6% 0.6% 0.7% 0.3%	2.37 (7.8. 3.16) 1.92 (13.3. 2.78) 1.272 (1.70, 95.14) 2.00 (1.63, 2.46) 2.01 (1.31, 2.37) 2.04 (2.11, 3.12) 2.05 (1.60, 4.44) 4.06 (1.17, 1.41.11) 1.99 (1.36, 2.90) 2.34 (2.09, 2.61) 2.34 (2.09, 2.61) 2.34 (2.09, 2.61) 2.34 (2.09, 2.61) 2.34 (2.09, 2.61) 2.34 (2.09, 2.61) 2.34 (2.09, 2.61) 2.35 (1.76, 6.71) 2.72 (1.87, 3.97) 1.64 (1.05, 2.57) 2.65 (1.96, 3.58) 2.04 (1.03, 4.02) 2.65 (1.96, 3.58) 2.04 (1.03, 4.02) 2.65 (1.96, 3.58) 2.04 (1.03, 4.02) 2.57 (2.02, 2.78) 3.194 (0.72, 5.22) 1.72 (0.68, 3.37) 7.12 (2.14, 2.374)	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magr02011 Nozue2012 Park2013 Sinning2013 Valgimgil2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = <i>z</i> Test for overall effect: <i>z</i> 1.7.5 Repeated Revast Garg2011A Garg2011B Garasis2011 Park2013 Sunbita1 (95% CI) Total events Heterogeneity: Chi ² = <i>z</i> Test for overall effect: <i>z</i> Test for overall effect: <i>z</i> 1.7.6 Stent Thrombost Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A	$\begin{array}{c} 65\\ 65\\ 132\\ 65\\ 12\\ 118\\ 18\\ 50\\ 3\\ 202\\ 94\\ 11\\ 71\\ 20.05, df = 11 (P = 2\\ 2 = 15.07 (P < 0.0)\\ 62\\ 90\\ 42\\ 9\\ 14\\ 150\\ 42\\ 9\\ 14\\ 150\\ 48\\ 22\\ 10.85, df = 8 (P = (2 + 2))\\ 48\\ 150\\ 62\\ 14\\ 150\\ 14\\ 150\\ 12\\ 2 = 10.59 (P < 0.0)\\ 14\\ 12\\ 22\\ 14\\ 15\\ 12\\ 22\\ 10.59 (P < 0.0)\\ 14\\ 11\\ 12\\ 22\\ 22\\ 22\\ 14\\ 15\\ 15\\ 15\\ 15\\ 15\\ 15\\ 15\\ 15\\ 15\\ 15$	$\begin{array}{c} 659\\ 268\\ 67\\ 331\\ 116\\ 219\\ 6\\ 1556\\ 153\\ 93\\ 461\\ 4291\\ 0.04); l^2 = 4(\\ 0001)\\ \end{array}$	59 37 1 151 23 466 5% 11 35 28 0 51 194 % 2 6 7 3	6688 2933 711 435 2090 2020 1608 2033 711 6688 2933 711 2035 119 1608 2933 711 2035 1033 464 454 3809 3111 6688 464 464 2233 3111 6698 464 464 2233 512 215 215 215 215 215 215 215 215 215	5.8% 3.6% 3.6% 2.2% 2.2% 2.2% 2.4% 0.3% 3.7.7% 3.7.7% 3.3.6% 3.3.6% 3.7.7% 0.1% 0.5% 5.2% 19.9%	$\begin{array}{c} 2.3^{*} (7.8, 3.16) \\ 1.92 (1.33, 2.78) \\ 1.27 (217, 0.95, 1.4) \\ 2.00 (1.63, 2.46) \\ 2.00 (1.63, 2.46) \\ 2.01 (1.63, 2.46) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16) \\ 2.01 (1.32,$	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magro2012 Park2013 Sinning2017 Valgimgil2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = <i>j</i> Test for overall effect: <i>j</i> 1.7.5 Repeated Revas Garg2011A Garg2011A Garg2011A Garg2011A Park2013 Sinning2013 Valgimgil2007 Wykrzykowska2010 Yubitotal (95% CI) Total events Heterogeneity: Chi ² = <i>j</i> 1.7.6 Stent Thrombos Garg2011A Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2012B Garg2011B Garg2012B Garg202B Garg202B Garg202B Garg202B Garg202B Garg202B Garg202B Gar	$\begin{array}{c} 65\\ 132\\ 65\\ 12\\ 65\\ 12\\ 118\\ 18\\ 50\\ 3\\ 202\\ 94\\ 11\\ 71\\ 202, 6f=11(P=2\\ 2=15.07(P<0.0\\ 62\\ 92\\ 14\\ 150\\ 48\\ 92\\ 14\\ 150\\ 48\\ 5\\ 92\\ 14\\ 150\\ 48\\ 5\\ 92\\ 14\\ 150\\ 48\\ 5\\ 14\\ 11\\ 12\\ 28\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\ 5\\$	659 268 67 331 116 219 6155 153 93 461 4291 0.04); l² = 4(0001) 2659 268 67 219 1556 155 155 155 155 165 165 165 165 16	59 37 1 151 23 466 5% 11 35 28 135 28 135 55 55 55 55 55 55 55 8 0 51 194 %	608 8293 711 8499 721 714 8499 726 721 714 725 7209 726 725 721 720 726 725 721 7209 726 725 721 7209 7209 721 7209 721 7209 7209 7200 7200 7200 7200 7200 7200	5.8% 3.6% 0.1% 8.6% 2.4% 0.2% 7.0% 3.4% 3.6% 3.7.7% 9.3% 0.3% 3.6% 3.7.7% 9.2% 0.2% 0.0% 0.6% 0.6% 0.5%	2.37 (7.8. 3.16) 1.92 (13.3. 2.78) 1.272 (1.70, 95.14) 2.00 (1.63, 2.46) 2.01 (1.31, 2.37) 2.04 (2.11, 3.12) 2.05 (1.60, 4.44) 4.06 (1.17, 1.41.11) 1.99 (1.36, 2.90) 2.34 (2.09, 2.61) 2.34 (2.09, 2.61) 2.34 (2.09, 2.61) 2.34 (2.09, 2.61) 2.34 (2.09, 2.61) 2.34 (2.09, 2.61) 2.34 (2.09, 2.61) 2.35 (1.76, 6.71) 2.72 (1.87, 3.97) 1.64 (1.05, 2.57) 2.65 (1.96, 3.58) 2.04 (1.03, 4.02) 2.65 (1.96, 3.58) 2.04 (1.03, 4.02) 2.65 (1.96, 3.58) 2.04 (1.03, 4.02) 2.57 (2.02, 2.78) 3.194 (0.72, 5.22) 1.72 (0.68, 3.37) 7.12 (2.14, 2.374)	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Valgimigli2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1 Test for overall effect: ; 1.7.5 Repeated Revas Garg2011A Garg2011B Garasis2011 He2011 Magro2011 Park2013 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1 Test for overall effect: ; 1.7.6 Stent Thrombos Garg2011A Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011B Garg2011A Garg2011B Garg2012B Garg2011B Garg2011B Garg2011B Garg2012B Garg2011B Garg2012B Garg2011B Garg2012B Garg2	$\begin{array}{c} 65\\ 132\\ 65\\ 12\\ 18\\ 18\\ 50\\ 3\\ 202\\ 94\\ 11\\ 20.05, df = 11 (P = 2\\ 2 = 15.07 (P < 0.0\\ 42\\ 9\\ 14\\ 150\\ 42\\ 9\\ 14\\ 150\\ 42\\ 9\\ 14\\ 150\\ 42\\ 9\\ 14\\ 150\\ 42\\ 5\\ 92\\ 14\\ 150\\ 42\\ 5\\ 92\\ 14\\ 150\\ 14\\ 15\\ 5\\ 92\\ 14\\ 15\\ 5\\ 92\\ 14\\ 15\\ 5\\ 92\\ 14\\ 15\\ 5\\ 92\\ 14\\ 15\\ 5\\ 92\\ 14\\ 15\\ 5\\ 92\\ 14\\ 15\\ 5\\ 92\\ 14\\ 15\\ 5\\ 92\\ 14\\ 15\\ 5\\ 92\\ 14\\ 11\\ 22\\ 28\\ 5\\ 5\\ 91\\ 11\\ 12\\ 28\\ 5\\ 5\\ 91\\ 11\\ 11\\ 22\\ 28\\ 5\\ 5\\ 91\\ 11\\ 11\\ 22\\ 28\\ 5\\ 91\\ 11\\ 11\\ 22\\ 28\\ 5\\ 5\\ 91\\ 11\\ 11\\ 22\\ 28\\ 5\\ 91\\ 11\\ 11\\ 22\\ 11\\ 11\\ 22\\ 28\\ 5\\ 91\\ 11\\ 11\\ 22\\ 11\\ 11\\ 22\\ 11\\ 11\\ 22\\ 11\\ 11$	659 268 67 331 116 219 6 1656 1553 93 461 4291 0.0(4); l ² = 4; 0001) 2662 659 268 67 219 1656 153 93 461 3838 0,21); l ² = 267 0001) 262 659 268 67 219 165 659 268 67 219 165 659 268 67 219 165 65 268 67 65 219 268 67 17 219 65 268 67 17 219 268 67 17 219 268 67 17 219 268 67 17 219 268 67 17 219 268 67 17 219 268 67 17 219 268 67 17 219 268 67 17 219 268 67 17 219 268 67 17 219 268 67 17 219 268 67 17 219 268 67 17 219 268 67 17 219 268 67 17 219 268 67 20 268 67 219 268 67 20 268 67 20 268 67 20 268 67 20 268 67 20 268 67 20 268 67 20 268 67 20 268 67 20 268 67 20 268 67 20 268 67 20 268 67 20 268 67 20 268 67 20 268 67 20 268 67 20 268 67 20 269 268 67 20 268 659 268 268 659 268 268 269 268 268 268 268 268 269 268 268 268 268 268 269 268 268 268 268 269 268 268 268 268 268 268 268 268 268 268	59 37 1 151 23 466 5% 466 5% 11 3 36 466 55 58 01 194 % 2 6 7 3 5 5 5 5 8 0 1 1 5 5 5 5 8 0 1 1 5 8 1 1 5 8 1 1 5 1 5 1 5 1 5 1 5 1 5 5 5 5 5 5 5 5 5 5 5 5 5	6688 2933 711 435 2090 2020 1608 2033 711 6688 2933 711 2035 119 1608 2933 711 2035 1033 464 454 3809 3111 6688 464 464 2233 3111 6698 464 464 2233 512 215 215 215 215 215 215 215 215 215	5.8% 3.6% 3.6% 2.2% 2.2% 2.2% 2.4% 0.3% 3.7.7% 3.7.7% 3.3.6% 3.3.6% 3.7.7% 0.1% 0.5% 5.2% 19.9%	$\begin{array}{c} 2.3^{*} (7.8, 3.16) \\ 1.92 (1.33, 2.78) \\ 1.27 (217, 0.95, 1.4) \\ 2.00 (1.63, 2.46) \\ 2.00 (1.63, 2.46) \\ 2.01 (1.63, 2.46) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16) \\ 2.01 (1.32,$	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magro2011 Nozue2012 Park2013 Sinning2013 Sinning2013 Sinning2013 Subto14 (95% CI) Total events Heterogeneity: Chi ² = <i>z</i> Test for overall effect: <i>z</i> 1.7.5 Repeated Revas Garg2011A Garg2011A Garg2011A Garg2011A Park2013 Sinning2013 Valgimigil2007 Wykrzykowska2010 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = <i>z</i> test for overall effect: <i>z</i> 1.7.6 Stent Thrombos Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2011B Garg2012B Garg2012B Garg2012B Garg2013 Wykrzykowska2010 Wykrzykowska2010 Wykrzykowska2010 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = <i>z</i>	65 132 65 12 118 18 50 3 202 94 11 77 205, df = 11 (P = 2 = 15.07 (P < 0.0 48 2 = 15.07 (P < 0.0 48 48 9 2 = 10.59 (P < 0.0 is 11 11 11 22 28 5 5 91 0.75, df = 5 (P = 0.	659 268 67 331 116 219 6 1556 153 93 461 4291 0.04); l² = 4{ 0001) 262 659 268 67 219 153 93 461 3838 0.21); l² = 262 0001) 262 262 659 268 1656 153 93 461 3838 0.21); l² = 262 0001) 262 262 659 268 164 163 370	59 37 1 151 23 466 5% 466 5% 11 3 36 466 55 58 01 194 % 2 6 7 3 5 5 5 5 8 0 1 1 5 5 5 5 8 0 1 1 5 8 1 1 5 8 1 1 5 1 5 1 5 1 5 1 5 1 5 5 5 5 5 5 5 5 5 5 5 5 5	6688 2933 711 435 2090 2020 1608 2033 711 6688 2933 711 2035 119 1608 2933 711 2035 1033 464 454 3809 3111 6688 464 464 2233 3111 6698 464 464 2233 512 215 215 215 215 215 215 215 215 215	5.8% 3.6% 3.6% 2.2% 2.2% 2.2% 2.4% 0.3% 3.7.7% 3.7.7% 3.3.6% 3.3.6% 3.7.7% 0.1% 0.5% 5.2% 19.9%	$\begin{array}{c} 2.3^{*} (7.8, 3.16) \\ 1.92 (1.33, 2.78) \\ 1.27 (217, 0.95, 1.4) \\ 2.00 (1.63, 2.46) \\ 2.00 (1.63, 2.46) \\ 2.01 (1.63, 2.46) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16) \\ 2.01 (1.32,$	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magr02011 Nozue2012 Park2013 Sinning2013 Valgimgil2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = <i>z</i> Test for overall effect: <i>z</i> 1.7.5 Repeated Revast Garg2011A Garg2011B Garasis2011 Park2013 Sunbita1 (95% CI) Total events Heterogeneity: Chi ² = <i>z</i> Test for overall effect: <i>z</i> Test for overall effect: <i>z</i> 1.7.6 Stent Thrombost Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A Garg2011B Garg2011A	65 132 65 12 118 18 50 3 202 94 11 77 205, df = 11 (P = 2 = 15.07 (P < 0.0 48 2 = 15.07 (P < 0.0 48 48 9 2 = 10.59 (P < 0.0 is 11 11 11 22 28 5 5 91 0.75, df = 5 (P = 0.	659 268 67 331 116 219 6 1556 153 93 461 4291 0.04); l² = 4{ 0001) 262 659 268 67 219 153 93 461 3838 0.21); l² = 262 0001) 262 262 659 268 1656 153 93 461 3838 0.21); l² = 262 0001) 262 262 659 268 164 163 370	59 37 1 151 23 466 5% 466 5% 11 3 36 466 55 58 01 194 % 2 6 7 3 5 5 5 5 8 0 1 1 5 5 5 5 8 0 1 1 5 8 1 1 5 8 1 1 5 1 5 1 5 1 5 1 5 1 5 5 5 5 5 5 5 5 5 5 5 5 5	668 8233 711 8499 7455 2099 761 1608 752 7519 7511900000000000000000000000000000000000	5.8% 3.6% 3.6% 2.2% 2.2% 2.2% 2.4% 0.3% 3.7.7% 3.7.7% 3.3.6% 3.3.6% 3.7.7% 0.1% 0.5% 5.2% 19.9%	$\begin{array}{c} 2.3^{*} (7.8, 3.16) \\ 1.92 (1.33, 2.78) \\ 1.27 (217, 0.95, 1.4) \\ 2.00 (1.63, 2.46) \\ 2.00 (1.63, 2.46) \\ 2.01 (1.63, 2.46) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16, 2.16) \\ 2.01 (1.32, 0.16) \\ 2.01 (1.32,$	
Garg2011A Garg2011B Grasis2011 He2011 Kim2010 Magr02011 Nozue2012 Park2013 Sinning2013 Valgimigl/2007 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.7.5 Repeated Revas Garg2011A Garg2011A Garg2011A Garg2011 Park2013 Sinning2013 Valgimigl/2007 Wykrzykowska2010 Wykrzykowska2010 Subtotal (95% CI) Total events Heterogeneity: Chi ² = Test for overall effect: 1.7.6 Stent Thrombos Garg2011A Garg2013 Valgimigl/2007 Wykrzykowska2010 Wykrzykowska2010 Wykrzykowska2010 Wykrzykowska2010 Wykrzykowska2010 Total events Heterogeneity: Chi ² = Subtotal (95% CI) Total events	65 132 65 12 118 18 50 3 202 94 11 77 205, df = 11 (P = 2 = 15.07 (P < 0.0 48 2 = 15.07 (P < 0.0 48 48 9 2 = 10.59 (P < 0.0 is 11 11 11 22 28 5 5 91 0.75, df = 5 (P = 0.	659 268 67 331 116 219 6 1556 153 93 461 4291 0.04); l² = 44 0001) 262 659 268 67 219 1556 153 93 461 3838 0.21); l² = 262 0001) 262 659 268 1656 1653 93 461 3370 12); l² = 43% 001)	59 37 1 151 23 466 5% 466 5% 11 3 36 466 55 58 01 194 % 2 6 7 3 5 5 5 5 8 0 1 1 5 5 5 5 8 0 1 1 5 8 1 1 5 8 1 1 5 1 5 1 5 1 5 1 5 1 5 5 5 5 5 5 5 5 5 5 5 5 5	668 8233 711 8499 7455 2099 761 1608 752 7519 7511900000000000000000000000000000000000	5.8% 3.6% 0.1% 8.6% 2.2% 2.4% 0.3% 3.6% 0.3% 3.7.7% 1.0% 3.4% 2.7% 0.3% 3.7.7% 1.0% 5.2% 19.9% 0.2% 0.6% 0.7% 0.5% 0.1% 5.2% 19.9%	$\begin{array}{c} 2.3^{*} (7.8, 3.16) \\ 1.92 (13.3, 2.78) \\ 1.272 (17.0, 95.14) \\ 2.00 (1.63, 2.46) \\ 2.01 (1.63, 2.46) \\ 2.01 (1.31, 2.37) \\ 2.01 (1.62, 1.04, 25) \\ 2.01 (1.62, 1.04, 25) \\ 2.01 (1.62, 1.04, 25) \\ 2.01 (1.7, 1.41, 1) \\ 1.99 (1.36, 2.16) \\ 2.34 [2.09, 2.61] \\ 2.34 [2.09, 2.61] \\ 2.34 [2.09, 2.61] \\ 2.34 [2.09, 2.61] \\ 2.34 [2.09, 2.61] \\ 2.34 [2.09, 2.61] \\ 2.34 [2.09, 2.61] \\ 2.34 [2.09, 2.61] \\ 2.34 [2.09, 2.61] \\ 2.34 [2.09, 2.61] \\ 2.34 [2.09, 2.61] \\ 2.34 [2.09, 2.61] \\ 2.34 [2.09, 2.61] \\ 2.37 [2.02, 2.78] \\ 2.37 [2.02, 2.78] \\ 2.37 [2.02, 2.78] \\ 2.37 [2.02, 2.78] \\ 2.37 [2.02, 2.78] \\ 3.31 [1.91, 3.623] \\ 1.94 [0.72, 5.22] \\ 1.72 [0.68, 4.37] \\ 1.94 [0.72, 5.22] \\ 1.72 [0.68, 4.37] \\ 1.94 [2.2, 1.447] \\ 5.04 [2.2, 1.447] \\ 5.04 [2.2, 1.447] \\ 5.04 [2.2, 1.447] \\ 5.04 [2.2, 1.447] \\ 5.04 [2.2, 1.447] \\ 5.04 [2.2, 1.477] \\ 5.07 [2.67, 1.63] \\ 4.09 [2.67, 6.27] \end{array}$	

Figure 11. Postinterventional adverse cardiovascular outcomes which were observed between a low versus a high (tertile III) SYNTAX score.

revascularization by PCI, and who were treated with clopidogrel after this invasive procedure, showed higher platelet reactivity to be independently associated with an increased risk of MACEs only in patients with a high SYNTAX score. This association was not visible in patients with lower SYNTAX scores.

In addition, a recently published meta-analysis also showed a positive aspect of the SYNTAX score in predicting all-cause mortality in patients who were treated by PCI, indicating its importance in Interventional cardiology.^[35] However, in this same analysis, the authors stated that the SYNTAX score often overestimated the risk of MACEs. However, in this current analysis, MACEs, which are among the vital clinical endpoints in Interventional cardiology,^[36] were not overestimated.


Nevertheless, it should be noted that this current analysis has almost all the features that are required to be considered a wellcarried out meta-analysis in terms of the total number of studies


	High SYNTA)	(Score	Low SYNTAX	Score		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
1.1.1 Mortality							
Akgun2014	381	2174	73	819	44.3%	1.97 [1.55, 2.49]	■
Garg2011A	34	496	10	311	5.1%	2.13 [1.07, 4.25]	
Magro2011	63	460	18	209	10.3%	1.59 [0.97, 2.62]	
Subtotal (95% CI)		3130		1339	59.8%	1.92 [1.56, 2.35]	•
Total events	478		101				
Heterogeneity: Chi ² =	0.68, df = 2 (P =	0.71); l ² =	0%				
Test for overall effect:	Z = 6.23 (P < 0.0	00001)					
1.1.2 Myocardial Infa	rction						
Akgun2014	211	2174	60	819	36.4%	1.32 [1.01, 1.74]	
Garg2011A	22	496	4	311	2.1%	3.45 [1.20, 9.91]	
Magro2011	12	460	3	209	1.7%	1.82 [0.52, 6.37]	
Subtotal (95% CI)		3130		1339	40.2%	1.45 [1.12, 1.88]	◆
Total events	245		67				
Heterogeneity: Chi ² =	3.13, df = 2 (P =	0.21); l ² =	36%				
Test for overall effect:	Z = 2.83 (P = 0.0	005)					
Total (95% CI)		6260		2678	100.0%	1.73 [1.47, 2.03]	•
Total events	723		168				
Heterogeneity: Chi ² =	6.84, df = 5 (P =	0.23); l ² =	27%				
Test for overall effect:							0.01 0.1 1 10 100
Test for subaroup diffe	•	,	$(P = 0.10)$ $l^2 =$	62.6%			Favours [high SS] Favours [low SS]

Figure 12. Postinterventional adverse cardiovascular outcomes which were observed between a low versus a higher (tertile II+III) SYNTAX score in patients with STEMI. STEMI. STEMI. STEMI. STEMI.

	High SYNTAX	Score	Low SYNTAX			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI
1.1.1 Major adverse ca	ardiac events						
Akgun2014	1007	2174	279	819	43.1%	1.36 [1.22, 1.51]	
Garg2011A	96	496	24	311	28.6%	2.51 [1.64, 3.83]	
Magro2011	87	460	23	209	28.3%	1.72 [1.12, 2.64]	
Subtotal (95% CI)		3130		1339	100.0%	1.73 [1.18, 2.53]	•
Total events	1190		326				
Heterogeneity: Tau ² = 0	.08; Chi ² = 8.5 ²	1, df = 2 (F	P = 0.01); I ² = 7	6%			
Test for overall effect: Z	2 = 2.84 (P = 0.0	005)					
Total (95% CI)		3130		1339	100.0%	1.73 [1.18, 2.53]	•
Total events	1190		326				
Heterogeneity: Tau ² = 0	0.08; Chi ² = 8.5 ²	1, df = 2 (F	P = 0.01); I ² = 7	6%			0.01 0.1 1 10 10
	2 = 2.84 (P = 0.0	0.05					0.01 0.1 1 10 10

Figure 13. Postinterventional major adverse cardiac events which were observed between a low versus a higher (tertile II+III) SYNTAX score in patients with STEMI. STEMI. STEMI = ST-segment elevation myocardial infarction.





and participants, low bias risks across the studies, low levels of heterogeneity in almost all the subgroups, and well-presented robust results. Therefore, the SYNTAX score should be expected to at least be integrated in Interventional cardiology, despite emerging newer clinical tools,^[37–39] which should but might take longer to find a place in Interventional cardiology.

4.1. Novelty

New features in this analysis include the following:

- 1. A new idea in Interventional cardiology.
- 2. An important potential tool has been studied.
- 3. This meta-analysis might be among the first analyses demonstrating the use of this new tool in Interventional cardiology.
- 4. A large number of participants who underwent revascularization by PCI were included.
- 5. Low SYNTAX score was compared with higher (tertiles II and III) SYNTAX score.
- 6. Low SYNTAX score was compared with intermediate (tertile II) SYNTAX score.
- 7. Low SYNTAX score was compared with high (tertile III) SYNTAX score.
- 8. Different range limits of SYNTAX score were also compared.
- 9. Randomized trials were also separately analyzed.
- 10. Several adverse cardiovascular outcomes were analyzed.
- Patients who suffered from STEMI were also separately analyzed to show a result specifically for this particular subgroup of patients.

4.2. Limitations

The limitations of this study were as follows:

- 1. Different studies reported different follow-up periods which might have influenced the result. However, most of the studies reported a follow-up period of 1 year only.
- 2. Several types of patients with CAD were analyzed together. However, when patients with STEMI were separately analyzed, the same results were obtained.
- 3. Data obtained from observational studies and randomized trials were combined and analyzed. However, even when randomized trials were separately analyzed, a similar result was obtained, partly solving this limitation.
- 4. The range limit of the scores was not exactly the same; small variations might have been responsible for the moderate level of heterogeneity observed in certain subgroups.

5. Conclusions

This analysis is a confirmatory piece of evidence to show that the application of the SYNTAX score in Interventional cardiology is apparently relevant. A low SYNTAX score was associated with significantly better cardiovascular outcomes in comparison with a higher SYNTAX score. Therefore, the SYNTAX score is an angiographic tool which might possibly be of some importance and should be applied in clinical practice.

References

- Lüscher TF. Update on interventional cardiology: outcome according to stent type and implantation technique. Eur Heart J 2016;37:3359–61.
- [2] Jiménez-Quevedo P, Serrador A, Pérez de Prado A, et al. Spanish Cardiac Catheterization and Coronary Intervention Registry. 25th Official

Report of the Spanish Society of Cardiology Working Group on Cardiac Catheterization and Interventional Cardiology (1990-2015). Rev Esp Cardiol (Engl Ed) 2016;69:1180–9.

- [3] Mehta RM, Agarwal M, Ifedili I, et al. Procedural variations in performing primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. Curr Probl Cardiol 2017;42:46–60.
- [4] Faxon DP, Williams DO. Interventional cardiology: current status and future directions in coronary disease and valvular heart disease. Circulation 2016;133:2697–711.
- [5] Bundhun PK, Soogund MZ, Huang WQ. Same day discharge versus overnight stay in the hospital following percutaneous coronary intervention in patients with stable coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. PLoS One 2017;12:e0169807.
- [6] Wang L, Zhou Y, Qian C, et al. Clinical characteristics and improvement of the guideline-based management of acute myocardial infarction in China: a national retrospective analysis. Oncotarget 2017;doi: 10.18632/oncotarget.14890 [Epub ahead of print].
- [7] Bates ER, Tamis-Holland JE, Bittl JA, et al. PCI strategies in patients with ST-segment elevation myocardial infarction and multivessel coronary artery disease. J Am Coll Cardiol 2016;68:1066–81.
- [8] Hyun DY, Jeong MH, Sim DS, et al. Two-year clinical outcomes in stable angina and acute coronary syndrome after percutaneous coronary intervention of left main coronary artery disease. Korean J Intern Med 2016;31:1084–92.
- [9] Upadhaya S, Baniya R, Madala S, et al. Drug-eluting stent placement versus coronary artery bypass surgery for unprotected left main coronary artery disease: a meta-analysis of randomized controlled trials. J Card Surg 2017;32:70–9.
- [10] Franzone A, Taniwaki M, Rigamonti F, et al. Angiographic complexity of coronary artery disease according to SYNTAX score and clinical outcomes after revascularisation with newer-generation drug-eluting stents: a substudy of the BIOSCIENCE trial. EuroIntervention 2016;12: e595–604.
- [11] Amsterdam EA, Wenger NK, Brindis RG, et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. Am Assoc Clin Chem 2014;64:e139–228.
- [12] Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
- [13] Akgun T, Oduncu V, Bitigen A, et al. Baseline SYNTAX score and longterm outcome in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Clin Appl Thromb Hemost 2015;21:712–9.
- [14] Capodanno D, Capranzano P, Di Salvo ME, et al. Usefulness of SYNTAX score to select patients with left main coronary artery disease to be treated with coronary artery bypass graft. JACC Cardiovasc Interv 2009;2:731–8.
- [15] Capodanno D, Di Salvo ME, Cincotta G, et al. Usefulness of the SYNTAX score for predicting clinical outcome after percutaneous coronary intervention of unprotected left main coronary artery disease. Circ Cardiovasc Interv 2009;2:302–8.
- [16] Garg S, Sarno G, Serruys PW, et al. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in AcuteMyocardial Infarction Study) trials. JACC Cardiovasc Interv 2011;4:66–75.
- [17] Garg S, Serruys PW, Silber S, et al. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial. JACC Cardiovasc Interv 2011;4:432–41.
- [18] Girasis C, Garg S, Räber L, et al. SYNTAX score and clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of SIRolimus-eluting stent compared with pacliTAXel-eluting stent for coronary revascularization (SIRTAX) trial. Eur Heart J 2011;32: 3115–27.
- [19] He JQ, Gao YC, Yu XP, et al. Syntax score predicts clinical outcome in patients with three-vessel coronary artery disease undergoing percutaneous coronary intervention. Chin Med J (Engl) 2011;124:704–9.
- [20] Ikeno F, Brooks MM, Nakagawa K, et al. SYNTAX score and long-term outcomes: the BARI-2D trial. J Am Coll Cardiol 2017;69:395–403.

- [21] Kim YH, Park DW, Kim WJ, et al. Validation of SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score for prediction of outcomes after unprotected left main coronary revascularization. JACC Cardiovasc Interv 2010;3:612–23.
- [22] Magro M, Nauta S, Simsek C, et al. Value of the SYNTAX score in patients treated by primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: the MI SYNTAX score study. Am Heart J 2011;161:771–81.
- [23] Nozue T, Kamijima R, Iwaki T, et al. Impact of SYNTAX score on 1-year clinical outcomes in patients undergoing percutaneous coronary intervention for unprotected left main coronary artery. Am J Cardiovasc Dis 2012;2:216–22.
- [24] Park KW, Kang J, Kang SH, et al. Usefulness of the SYNTAX and clinical SYNTAX scores in predicting clinical outcome after unrestricted use of sirolimus- and everolimus-eluting stents. Circ J 2013;77:2912–21.
- [25] Sinning JM, Asdonk T, Erlhöfer C, et al. Combination of angiographic and clinical characteristics for the prediction of clinical outcomes in elderly patients undergoing multivessel PCI. Clin Res Cardiol 2013;102:865–73.
- [26] Valgimigli M, Serruys PW, Tsuchida K, et al. Cyphering the complexity of coronary artery disease using the syntax score to predict clinical outcome in patients with three-vessel lumen obstruction undergoing percutaneous coronary intervention. Am J Cardiol 2007;99:1072–81.
- [27] Wykrzykowska JJ, Garg S, Girasis C, et al. Value of the SYNTAX score for risk assessment in the all-comers population of the randomized multicenter LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial. J Am Coll Cardiol 2010;56:272–7.
- [28] Yadav M, Généreux P, Palmerini T, et al. SYNTAX score and the risk of stent thrombosis after percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: an ACUITY trial substudy. Catheter Cardiovasc Interv 2015;85:1–0.
- [29] Cutlip DE, Nakazawa G, Krucoff MW, et al. Autopsy validation study of the Academic Research Consortium stent thrombosis definition. JACC Cardiovasc Interv 2011;4:554–9.
- [30] Higgins JP, et al. Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions 2008;Wiley, 187–241.

- [31] Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in metaanalyses. Available at: http://www.ohri.ca/programs/clinical_epidemiol ogy/oxford.htm. Accessed October 19, 2009.
- [32] Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in metaanalysis. BMJ 2001;323:101–5.
- [33] Minamisawa M, Miura T, Motoki H, et al. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with prior heart failure undergoing percutaneous coronary intervention: sub-analysis of the SHINANO registry. Heart Vessels 2017;32:399–407.
- [34] Palmerini T, Calabrò P, Piscione F, et al. Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study. JACC Cardiovasc Interv 2014;7:1117–27.
- [35] Chen J, Tang B, Lin Y, et al. Validation of the ability of SYNTAX and clinical SYNTAX scores to predict adverse cardiovascular events after stent implantation: a systematic review and meta-analysis. Angiology 2016;67:820–8.
- [36] Waliszewski M, Rittger H. Surrogate and clinical endpoints in interventional cardiology: are statistics the brakes? Ther Adv Cardiovasc Dis 2016;10:314–26.
- [37] Chen SL, Chen JP, Mintz G, et al. Comparison between the NERS (New Risk Stratification) score and the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score in outcome prediction for unprotected left main stenting. JACC Cardiovasc Interv 2010;3:632–41.
- [38] Salvatore A, Boukhris M, Giubilato S, et al. Usefulness of SYNTAX score II in complex percutaneous coronary interventions in the setting of acute coronary syndrome. J Saudi Heart Assoc 2016; 28:63–72.
- [39] Madeira S, Raposo L, Brito J, et al. Potential utility of the SYNTAX score 2 in patients undergoing left main angioplasty. Arq Bras Cardiol 2016;106:270–8.